

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/161325/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Kennedy, Natasha, Win, Tint Lwin, Bandyopadhyay, Amrita, Kennedy, Jonathan, Rowe, Benjamin, McNerney, Cynthia, Evans, Julie, Hughes, Karen, Bellis, Mark A, Jones, Angela, Harrington, Karen, Moore, Simon and Brophy, Sinead 2023. Insights from linking police domestic abuse data and health data in South Wales, UK: a linked routine data analysis using decision tree classification. *The Lancet Public Health* 8 (8) , e629-e638. 10.1016/S2468-2667(23)00126-3 file

Publishers page: [http://dx.doi.org/10.1016/S2468-2667\(23\)00126-3](http://dx.doi.org/10.1016/S2468-2667(23)00126-3)

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Insights from linking police domestic abuse data and health data in South Wales, UK: a linked routine data analysis using decision tree classification



Natasha Kennedy, Tint Lwin Win, Amrita Bandyopadhyay, Jonathan Kennedy, Benjamin Rowe, Cynthia Mc Nerney, Julie Evans, Karen Hughes, Mark A Bellis, Angela Jones, Karen Harrington, Simon Moore, Sinead Brophy



Summary

Background Exposure to domestic abuse can lead to long-term negative impacts on the victim's physical and psychological wellbeing. The 1998 Crime and Disorder Act requires agencies to collaborate on crime reduction strategies, including data sharing. Although data sharing is feasible for individuals, rarely are whole-agency data linked. This study aimed to examine the knowledge obtained by integrating information from police and health-care datasets through data linkage and analyse associated risk factor clusters.

Methods This retrospective cohort study analyses data from residents of South Wales who were victims of domestic abuse resulting in a Public Protection Notification (PPN) submission between Aug 12, 2015 and March 31, 2020. The study links these data with the victims' health records, collated within the Secure Anonymised Information Linkage databank, to examine factors associated with the outcome of an Emergency Department attendance, emergency hospital admission, or death within 12 months of the PPN submission. To assess the time to outcome for domestic abuse victims after the index PPN submission, we used Kaplan-Meier survival analysis. We used multivariable Cox regression models to identify which factors contributed the highest risk of experiencing an outcome after the index PPN submission. Finally, we created decision trees to describe specific groups of individuals who are at risk of experiencing a domestic abuse incident and subsequent outcome.

Findings After excluding individuals with multiple PPN records, duplicates, and records with a poor matching score or missing fields, the resulting clean dataset consisted of 8709 domestic abuse victims, of whom 6257 (71.8%) were female. Within a year of a domestic abuse incident, 3650 (41.9%) individuals had an outcome. Factors associated with experiencing an outcome within 12 months of the PPN included younger victim age (hazard ratio 1.183 [95% CI 1.053–1.329], $p=0.0048$), further PPN submissions after the initial referral (1.383 [1.295–1.476]; $p<0.0001$), injury at the scene (1.484 [1.368–1.609]; $p<0.0001$), assessed high risk (1.600 [1.444–1.773]; $p<0.0001$), referral to other agencies (1.518 [1.358–1.697]; $p<0.0001$), history of violence (1.229 [1.134–1.333]; $p<0.0001$), attempted strangulation (1.311 [1.148–1.497]; $p<0.0001$), and pregnancy (1.372 [1.142–1.648]; $p=0.0007$). Health-care data before the index PPN established that previous Emergency Department and hospital admissions, smoking, smoking cessation advice, obstetric codes, and prescription of antidepressants and antibiotics were associated with having a future outcome following a domestic abuse incident.

Interpretation The results indicate that vulnerable individuals are detectable in multiple datasets before and after involvement of the police. Operationalising these findings could reduce police callouts and future Emergency Department or hospital admissions, and improve outcomes for those who are vulnerable. Strategies include querying previous Emergency Department and hospital admissions, giving a high-risk assessment for a pregnant victim, and facilitating data linkage to identify vulnerable individuals.

Funding National Institute for Health Research.

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Attending police officers issue a Public Protection Notification (PPN) to document the vulnerabilities of individuals who are victims of domestic abuse.¹ Once issued, the documented information is forwarded to the Force Public Protection Unit for a comprehensive risk assessment and subsequent determination of necessary action.¹ Although individuals have a right to privacy, a PPN enables information specific to the risk of serious

harm to be shared with partner agencies when multi-agency management provides the appropriate response to those risks. Indeed, the 1998 Crime and Disorder Act requires agencies to collaborate on crime reduction strategies, including data sharing. The Domestic Abuse, Stalking, and Harassment (DASH) questionnaire is a standardised risk assessment tool adopted by the police and other agencies to identify and evaluate the potential risk of harm to victims of domestic abuse, stalking, or

Lancet Public Health 2023;
8: e629–38

See [Comment](#) page e580

National Centre for Population Health and Wellbeing Research (N Kennedy PhD, A Bandyopadhyay MSc, J Kennedy EngD, K Harrington MSc, Prof S Brophy PhD), Health Data Research UK (Prof S Brophy), Administrative Data Research Wales (N Kennedy, C Mc Nerney BBus, Prof S Brophy), and SAIL Databank (C Mc Nerney), Swansea University Medical School (T Lwin MSc), Swansea, UK; Data Lab, National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Swansea, UK (J Kennedy); South Wales Police, South Wales Police Head Quarters Cowbridge Road, Bridgend, UK (B Rowe BSc); Public Health Wales, Cardiff, UK (J Evans MSc, Prof K Hughes PhD, A Jones MPH); WHO Collaborating Centre for Violence Prevention, Liverpool John Moores University, Liverpool, UK (Prof M A Bellis DSc); Security, Crime & Intelligence Innovation Institute and Violence Research Group, School of Dentistry, Cardiff University, Heath Park, Cardiff, UK (Prof S Moore PhD)

Correspondence to:
Dr Natasha Kennedy, National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Swansea SA2 8PP, UK
n.l.kennedy@swansea.ac.uk

Research in context

Evidence before this study

PubMed and Web of Science were searched for studies published in any language between April 17, 2013 and April 17, 2023, that investigated health-care use by victims of domestic abuse. Using the terms (“domestic violence” or “domestic abuse” or “intimate partner violence”) and (“emergency medical attendance” or “emergency department visits” or “ED attendance” or “hospitalisation”) and (“police”), the search yielded 198 results. The results were further filtered to include papers with the full text available and limited to research involving a human cohort. We manually searched the reference lists of the resulting studies for appropriate papers and highlighted key authors for relevant further studies. Numerous studies report the prevalence of domestic abuse victims and the negative health consequences that are endured. Consequently, these adverse health outcomes result in increased interactions with health-care services. However, knowledge is not communicated between agencies on a national level, preventing the implementation of safeguarding measures. Only four studies have investigated the value of linking data from police and health-care records on domestic abuse, with studies set in the USA and Canada. The findings of these studies suggested several risk factors for adverse outcomes, including increased Emergency Department usage, subsequent injuries when the incident involved physical violence, and the perpetrator having a history of domestic

abuse. Furthermore, the studies showed that victims of domestic abuse often experience mental health disorders.

Added value of this study

In this study, we describe the value of unifying sensitive data, such as police and health-care data. This present study shows that highly vulnerable individuals frequently interact with health-care services but remain unknown to the police until a critical incident, underscoring the value in establishing data linkages across different agencies. Moreover, the study provides a use case that illustrates results that can be derived from linking whole data systems to identify points of early intervention for individuals at risk of domestic abuse, thus enabling proactive, upstream efforts to protect families.

Implications of all the available evidence

The evidence presented in this study demonstrates the preventive opportunities for stakeholders across multiple sectors, which can be facilitated when agencies communicate and link data. Future research should examine whether early identification of these vulnerable groups by the police or the health-care sector could lead to improved outcomes, in addition to examining the outcomes stratified by demographic profiles. This research can guide the development of targeted interventions that might mitigate the escalation of domestic abuse and related health outcomes.

harassment.^{1,2} The DASH questionnaire comprises a series of methodically constructed questions that capture vital aspects of the situation, such as the perpetrator’s behaviour, the victim’s response, and the level of threat to the victim’s safety. The collected data are analysed to determine the risk of further harm, and the results are used to implement effective interventions to safeguard the victim.²

Domestic abuse—defined here to include domestic violence and intimate partner violence, as per the DASH questionnaire—encompasses a range of incidents characterised by coercive, controlling, and abusive behaviours directed towards another individual.³ These behaviours manifest in various forms, such as coercive control and emotional, financial, physical, psychological, or sexual violence or threats.^{3,4} A lifetime incidence of domestic abuse has been estimated to affect 27% of women globally,⁵ with a former intimate partner or spouse as the predominant perpetrator.⁴

Studies have indicated that exposure to domestic abuse results in long-term negative impacts on the victim’s physical and psychological wellbeing.^{6–8} Research into the long-term consequences of repeated victimisation is minimal; however, about two-thirds of female domestic abuse victims are revictimised.⁴ When a cycle of revictimisation is present, it exacerbates the consequences of domestic abuse, such as affecting new

relationships, introducing negative health behaviours in the form of addictions, and developing mental health disorders, including post-traumatic stress disorder.^{4,7–10} This cycle of revictimisation also increases the use of health-care services. Domestic abuse victims interact more frequently with Emergency Departments than people from the general population.^{4,11,12}

Although domestic abuse victims attend Emergency Departments frequently, these visits rarely result in the disclosure of abuse to staff or reports to the police.^{11,12} Research into the identification of domestic abuse by Emergency Department staff indicated that, of 259 visits in 1999–2001 in a semi-rural county in the USA, physicians were more likely to document the violence (83% documented by the physician) than triage nurses (62%) or treatment nurses (44%).¹¹ In the context of emergency care, it is expected that clinical personnel proactively identify and address vulnerabilities that extend beyond the initial presenting symptoms. In addition to patients’ disclosure, clinicians routinely assess their medical history using available data. Consequently, clinicians can enact safeguarding measures, including referring patients to an Independent Domestic Violence Advocate, if they perceive that the patient is at risk, even in cases where disclosure is absent. Further studies have indicated that domestic abuse victims frequently present to the Emergency Department

for non-injury-related complaints. Additionally, they also have an increased likelihood of having accompanying medical records documenting mental health and substance abuse issues.^{11,13–15} Consequently, the Emergency Department and hospital setting offers a crucial opportunity for intervention and prevention, prioritising the health and wellbeing of domestic abuse victims. However, it is necessary to establish a robust infrastructure to gather additional information to effectively address the victims' needs.

This study aimed to examine knowledge obtained by integrating information from police PPN records and health-care datasets through data linkage. The study was conducted by investigating associations with information from numerous datasets, and examining the clustering patterns of related factors, as well as their association with Emergency Department attendance, emergency hospital admission, or death within 12 months of the index PPN submission, thereby identifying opportunities to improve ascertainment of individuals at high risk of domestic abuse without disclosure.

Methods

Study design and setting

We conducted a retrospective cohort study to ascertain the risk factors associated with victims who will experience an outcome (ie, Emergency Department admission, emergency admission to hospital, or death) in the 12 months following a PPN submission for domestic abuse. The cohort was composed of residents in the South Wales Police Force Region who were domestic abuse victims resulting in a PPN submission between Aug 12, 2015 and March 31, 2020. The cohort was based on the PPN dataset that also comprises records formed from the DASH risk identification and assessment model.² Data of anonymised identified persons were linked on the individual level to health record data within the Secure Anonymised Information Linkage (SAIL) databank.^{16–18} The SAIL databank is a data repository containing over 10 billion anonymised records, with a population coverage of 100% for hospital and general practitioner (GP) data for this South Wales dataset, thus enabling person-based data linkage across numerous datasets. Each individual is assigned an encrypted anonymised linking field; this field is used to link anonymised individuals across datasets, thus facilitating longitudinal analysis of the individual's progression through the different datasets.¹⁷ The linked data includes the primary care Wales Longitudinal General Practice dataset to identify reasons for contact with health-care professionals in general practice; data collected by GPs are captured via Read Codes, version 2, which relate to diagnosis, medication, and process-of-care codes. Hospital inpatient and outpatient data are collated in the Patient Episode Database for Wales, which encompasses clinical information pertaining to patients' hospital admissions, diagnoses, operations, and discharges using

the International Classification of Diseases, 10th revision (ICD-10) clinical classification system. The Emergency Department Dataset for Wales uses three-digit alphanumeric codes to capture data regarding activity and information from Emergency Department and Minor Injury Units. The Office of National Statistics mortality dataset held within the Annual District Death Extract dataset contains demographic data, place of death, and underlying cause of death as ICD-10 codes. The Welsh Demographic Service dataset was used to identify all patients registered with a GP practice and to flag when people move in and out of Wales.

Variables

The outcomes for all analyses were Emergency Department attendance, emergency hospital admission, and death due to any cause within 12 months of the index PPN submission; where the time to event is reported, it is the time to the first event for cases where an individual had multiple events (ie, emergency admission followed by death). An Emergency Department admission includes Emergency Department attendance or emergency admission to hospital. For women, we ensured that the hospital admissions and Emergency Department attendances were non-obstetric. Emergency Department, hospital, and GP data were examined for up to 1 and 3 years before receiving the index PPN submission to highlight early risk factors of experiencing an outcome following a domestic abuse incident (appendix 1 p 1).

In terms of exposures and confounders, all variables recorded at the index PPN from the DASH questionnaire² were included: attempted strangulation, conflict over a child (ie, conflict regarding contact with the child), hurt other people, history of further violence, injury, multi-agency risk assessment conference (MARAC) referral, pregnant, and past pregnancy. Subsequent PPN visits following the initial index PPN were also included as an explanatory variable. Additionally, for the decision tree analysis, information from Emergency Department and GP (ie, diagnoses, medications, procedures, and referrals) and hospital admissions (ie, cause of admission and date) were included in the analysis up to 1 and 3 years before the index PPN. Specific codes included are in the code list in appendix 2; these were filtered to include codes that possessed a frequency of greater than or equal to 250 within the cohort. The majority of the variables from the dataset were presented in a binary form, with 1 representing the presence of a concept and 0 representing its absence. The age of individuals was presented in 10-year brackets to understand the difference between different age groups while maintaining a suitable population size for analysis.

Data access

The data used in this study are available in the SAIL databank¹⁸ at Swansea University (Swansea, UK). All data

For the **Emergency Department Dataset for Wales** see <https://web.www.healthdatagateway.org/dataset/75c4dcb8-33bf-43f4-b2bb-db51b6621b2c>

For the **Annual District Death Extract dataset** see <https://web.www.healthdatagateway.org/dataset/15cf4241-abad-4dcc-95b0-8cd7c02be999>

For the **Welsh Demographic Service dataset** see <https://web.www.healthdatagateway.org/dataset/8a8a5e90-b0c6-4839-bcd2-c69e6e8dca6d>

See Online for appendix 1

For the **Wales Longitudinal General Practice dataset** see <https://web.www.healthdatagateway.org/dataset/33fc3ffd-aa4c-4a16-a32f-0c900aaea3d2>

For more on **Read Codes** see <https://digital.nhs.uk/services/terminology-and-classifications/read-codes>

For the **Patient Episode Database for Wales** see <https://web.www.healthdatagateway.org/dataset/4c33a5d2-164c-41d7-9797-dc2b008cc852>

See Online for appendix 2




Figure 1: Study profile
PPN=Public Protection Notification.

held in the SAIL databank are anonymised; therefore, ethical approval is not mandatory in accordance with the Health Research Authority guidance and there is no legal requirement for explicit consent to participate under the Data Protection Act and UK General Data Protection Regulation. Furthermore, permission has been obtained from the relevant Caldicott Guardian or Data Protection Officer for all data contained in SAIL. In addition, proposals using SAIL data are subject to review by an Information Governance Review Panel (IGRP) to secure approval. The IGRP approval number for this study is 0916.

Statistical analysis

After the exclusion of multiple PPN records and records with missing fields or duplicates, missing values were visualised; individuals with 25% or more of missing data were removed. The missing values for the remaining individuals were replaced with a new category, NR (no response). Any categorical variables were altered to factors for analysis.

Descriptive statistics were generated to assess the rates of experiencing an outcome, stratified by both gender and age for the domestic abuse victims who were the subject of a PPN submission. We used Kaplan-Meier survival analysis to examine the time to outcome for the domestic abuse victim after the index PPN submission, censoring individuals who moved out of Wales. We used multivariable Cox proportional-hazard models, adjusted

for confounders, to identify which factors contributed to the highest risk of experiencing an outcome after the index PPN submission. The hazard ratios (HRs) were reported with 95% CIs and a significance level accepted at $p < 0.05$. The reference groups were No for most factors; otherwise, the reference group was Male for gender, Standard Risk for the risk assessment factor, and the age group 20–29 years for age comparisons.

We created decision trees to identify specific groups of individuals who are at risk of experiencing a domestic abuse incident and subsequent outcome. The decision trees were not used to develop a predictive model, they were utilised in the context of descriptive epidemiology to investigate the clustering of risk factors within individuals (ie, everything represented by codes in the code list [appendix 2]). This approach facilitated the identification of the relevant nodes that could be used to classify an individual considering their risk factor clusters. The data handling and preparation were performed in SQL, using Eclipse 2020-03 (version 4.15). Final data preparation was performed in R Studio, version 4.1.3, whereas the decision trees were conducted in IBM SPSS, version 28.0.0.0.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

The PPN dataset contained 26 762 records; of these, 15 189 individuals had multiple PPN records. The exclusion of multiple PPN records resulted in a dataset comprising only the index PPN record, generating a cohort of 11 573 domestic abuse victims. We also excluded records with a poor matching score ($n=344$; appendix 1 p 1), duplicates ($n=424$), missing gender ($n=60$), and an empty PPN record ($n=27$). Individuals with 25% or more of missing data were removed ($n=2009$), resulting in a 3% decrease of male victims, disproportionate to female victims, in the 20–39-year age range.

The resulting cohort comprised 8709 individuals (figure 1), of whom 6257 (71.8%) were female (table 1). The age groups of 20–29 years (30.0%) and 30–39 years (26.4%) contributed the highest proportion of domestic abuse victims; conversely, the age groups 0–9 (0.6%) and 80 years or older (0.7%) contributed the lowest proportion of domestic abuse victims.

3650 (41.9%) individuals had an outcome within a year of a domestic abuse incident; 2661 (72.9%) were female and 989 (27.1%) were male (table 1). 3544 individuals attended an Emergency Department, of whom 1085 individuals were then transferred to hospital. Overall, 1182 had an emergency hospital admission.

The age distribution of the outcome cohort indicates that more women than men had an outcome in the age range 20–39 years, which comprises the largest

proportion of domestic abuse victims. The total Emergency Department attendance rate was 572 (95% CI 554–591) per 1000 person-years and the hospitalisation rate was 185 (175–197) per 1000 person-years.

In comparison with the base age group of 20–29 years, those aged 10–19 years had an increased risk of experiencing an outcome (HR 1.183 [95% CI 1.053–1.329], $p=0.0048$; table 2; appendix 1 pp 1–4). Conversely, individuals aged 30–69 years had a decreased risk of experiencing an outcome (30–39 years: 0.882 [0.808–0.962], $p=0.0045$; 40–49 years: 0.801 [0.724–0.887], $p<0.0001$; 50–59 years: 0.772 [0.681–0.874], $p<0.0001$; 60–69 years: 0.728 [0.602–0.879], $p=0.0010$).

Cases involving attempted strangulation of the victim were associated with a higher risk of a future outcome (HR 1.311 [95% CI 1.148–1.497]; $p<0.0001$) than cases for which attempted strangulation was not present. Furthermore, victims had a higher risk of experiencing an outcome in the year proceeding a domestic abuse incident when the incident resulted in an injury (1.484 [1.368–1.609]; $p<0.0001$) than when it did not. Cases involving a pregnant household member had an increased risk of a future non-obstetric outcome (1.372 [1.142–1.648]; $p=0.0007$). Incidences where the perpetrator has hurt other people (1.218 [1.028–1.444]; $p=0.023$) or has a history of further violence (1.229 [1.134–1.333]; $p<0.0001$) resulted in an increased risk of the victim undergoing an outcome. Similarly, households that were subject to a MARAC referral (1.518 [1.358–1.697]; $p<0.0001$) or received multiple subsequent police visits after the index PPN (1.383 [1.295–1.476]; $p<0.0001$) have an increased risk of experiencing an outcome. Cases assessed as high risk, medium risk, or receiving no response from the responding police officer (high risk: 1.600 [1.444–1.773]; $p<0.0001$; medium risk: 1.117 [1.034–1.206]; $p=0.0051$; no response: 1.188 [1.075–1.312]; $p=0.0007$) were associated with a higher risk of experiencing an outcome than cases assessed as standard risk. Incidents involving conflict over a child had a lower risk of undergoing an outcome (0.856 [0.774–0.947]; $p=0.0026$) than those that did not. Furthermore, if a household member has had a child in the 18 months before the domestic abuse incident (past pregnancy), then the risk of an outcome is lowered (0.812 [0.722–0.913]; $p=0.0005$).

A decision tree combining knowledge gathered from GP and Emergency Department admissions up to a year before the domestic abuse incident, as well as information obtained by the police during the PPN submission, indicated that any Emergency Department admission before the domestic abuse incident is the most significant risk factor of experiencing an outcome (figure 2). Those with an Emergency Department admission 1 year before the event were further classified with the quantity (PPN count) and severity (MARAC referral) of their interactions with the police. Those who are known to the health-care

	Male	Female	Total
Demographics			
Total cohort	n=2452	n=6257	n=8709
Age category, years			
0–9	29 (1.2%)	22 (0.4%)	51 (0.6%)
10–19	263 (10.7%)	521 (8.3%)	784 (9.0%)
20–29	649 (26.5%)	1962 (31.4%)	2611 (30.0%)
30–39	595 (24.3%)	1700 (27.2%)	2295 (26.4%)
40–49	423 (17.3%)	1085 (17.3%)	1508 (17.3%)
50–59	275 (11.2%)	617 (9.9%)	892 (10.2%)
60–69	137 (5.6%)	211 (3.4%)	348 (4.0%)
70–79	57 (2.3%)	104 (1.7%)	161 (1.8%)
≥80	24 (1.0%)	35 (0.6%)	59 (0.7%)
Outcomes			
Overall	n=989	n=2661	n=3650
Type of outcome			
Any admission	985 (99.6%)	2656 (99.8%)	3641 (99.8%)
Emergency Department attendance	960 (97.1%)	2584 (97.1%)	3544 (97.1%)
Emergency hospital admission	266 (26.9%)	916 (34.4%)	1182 (32.4%)
Death	23 (2.3%)	25 (0.9%)	48 (1.3%)
Outcomes by age category, years			
0–9	16 (1.6%)	9 (0.3%)	25 (0.7%)
10–19	110 (11.1%)	286 (10.7%)	396 (10.8%)
20–29	294 (29.7%)	876 (32.9%)	1170 (32.1%)
30–39	227 (23.0%)	701 (26.3%)	928 (25.4%)
40–49	167 (16.9%)	411 (15.4%)	578 (15.8%)
50–59	99 (10.0%)	228 (8.6%)	327 (9.0%)
60–69	43 (4.3%)	78 (2.9%)	121 (3.3%)
70–79	21 (2.1%)	55 (2.1%)	76 (2.1%)
≥80	12 (1.2%)	17 (0.6%)	29 (0.8%)

Table 1: Descriptive statistics of the cohort split by gender

system and go on to have further contact with the police were the most at risk of having an outcome after the domestic abuse incident.

Individuals with up to one Emergency Department admission and who had subsequent interactions with the police were further split by the prescription of CNS drugs; those who were prescribed these drugs were more likely to experience an outcome. These drugs were mostly prescribed for anxiety, depression, and sleep disorders. Individuals who were not prescribed CNS drugs were split on age; the extreme age groups, 10–19 years and 80 years and older, were classified as being at greater risk of undergoing an outcome after a domestic abuse incident than those in other age groups.

For individuals who had minimal interactions with the health-care and police systems, the question about history of further violence was important as it is asked when there is an injury at the scene. Therefore, in scenarios where this question was asked, the risk of a future outcome was higher than scenarios where this question was not asked and marked as NA (ie, not applicable).

	Hazard ratio (95% CI)	p value
Age group, years		
20–29	Ref	
0–9	1.400 (0.938–2.092)	0.10
10–19	1.183 (1.053–1.329)	0.0048
30–39	0.882 (0.808–0.962)	0.0045
40–49	0.801 (0.724–0.887)	<0.0001
50–59	0.772 (0.681–0.874)	<0.0001
60–69	0.728 (0.602–0.879)	0.0010
70–79	1.087 (0.860–1.374)	0.48
≥80	1.110 (0.767–1.607)	0.58
Attempted strangulation		
No	Ref	
No response	0.970 (0.602–1.562)	0.90
Yes	1.311 (1.148–1.497)	<0.0001
Conflict over a child		
No	Ref	
No response	1.060 (0.709–1.584)	0.78
Yes	0.856 (0.774–0.947)	0.0026
Hurt other people		
No	Ref	
No response	0.570 (0.285–1.140)	0.11
Yes	1.218 (1.028–1.444)	0.023
History of further violence		
No	Ref	
No response	0.905 (0.649–1.263)	0.56
Yes	1.229 (1.134–1.333)	<0.0001
Gender		
Male	Ref	
Female	1.071 (0.996–1.152)	0.066

(Table 2 continues in next column)

	Hazard ratio (95% CI)	p value
(Continued from previous column)		
Injury		
No	Ref	
No response	1.143 (0.571–2.288)	0.71
Yes	1.484 (1.368–1.609)	<0.0001
MARAC referral		
No	Ref	
No response	1.024 (0.956–1.097)	0.51
Yes	1.518 (1.358–1.697)	<0.0001
Multiple police visits (PPNs)		
No	Ref	
Yes	1.383 (1.295–1.476)	<0.0001
Past pregnancy		
No	Ref	
No response	0.784 (0.516–1.193)	0.26
Yes	0.812 (0.722–0.913)	0.0005
Pregnant		
No	Ref	
No response	0.929 (0.514–1.679)	0.81
Yes	1.372 (1.142–1.648)	0.0007
Risk assessment		
Standard	Ref	
No response	1.188 (1.075–1.312)	0.0007
Medium	1.117 (1.034–1.206)	0.0051
High	1.600 (1.444–1.773)	<0.0001

MARAC=multi-agency risk assessment conference. PPN=Public Protection Notification.

Table 2: Hazard ratios and CIs for each factor for predicting an emergency attendance following a PPN, adjusted for confounders

The smoking status of the victim was indicated as an important factor for those for whom NA was the answer to history of further injury; the presence of smoking behaviour related to an increased risk of experiencing an outcome.

Incorporating additional information provided by the health-care system up to 3 years preceding the index PPN submission further indicated that multiple Emergency Department admissions before the domestic abuse incident was significantly associated with experiencing an outcome (figure 3). The individuals who were most at risk of undergoing an outcome after the domestic abuse incident were those who had more than seven Emergency Department admissions in the 3 years before and who received smoking cessation advice from their GP. Individuals who had more than three Emergency Department admissions but less than seven admissions, and have had more than two PPN submissions, are also at high risk; those who were classified as a cigarette smoker by their GP had a greater risk of experiencing an outcome than those who were not. Individuals with less than three Emergency Department admissions were split

by future PPN count; overall, those with a PPN count of less than one were at the lowest risk of having an outcome compared with the entire cohort. However, those individuals who were not known to the health-care or police systems but had been prescribed CNS drugs by their GP and who were in the extreme age group categories of 0–29 years and 70–79 years were at risk of undergoing an outcome.

Discussion

This study shows how communication between separate services can be utilised to identify points of early intervention for victims of domestic abuse up to 3 years before a potential police PPN submission. The findings demonstrate several risk factors that reflect vulnerability; when the perpetrator exhibited a pre-existing predisposition for violence, either in hurting others or with a history of violence, the domestic abuse victims were found to have an increased vulnerability for future outcomes. Furthermore, pregnant victims showed heightened vulnerability and had poorer outcomes; research has indicated that domestic abuse has been independently associated with the birth of a low-birthweight baby.¹⁹




Figure 2: Decision tree to examine clustering of those who experience an outcome using data from other sources up to 1 year before the index PPN submission date

GP=general practitioner. MARAC=multi-agency risk assessment conference. NA=not applicable. PPN=Public Protection Notification.

Additionally, victims were shown to be known to Emergency Departments before the police are involved. Highly vulnerable individuals might interact frequently with Emergency Department health-care services but remain unknown to the police until a domestic abuse incident that requires an intervention;^{4,11-13} the most vulnerable individuals have been identified as those who had more than seven Emergency Department admissions up to 3 years before the index PPN submission.

The decision tree analysis highlighted several risk profiles with differing clusters of risk factors that might reflect different pathways through police contact, health care, and individual contexts. Our findings corroborated previous observations that the highest risk group of people experiencing domestic abuse are those well known to Emergency Department health-care services.¹¹ In our decision tree analysis, we found that an additional indicator for high risk was having had interactions with their GP, either for smoking cessation advice or by being identified as a cigarette smoker. This observation is in line with research that indicated that domestic abuse is associated with adverse health behaviours, such as substance abuse and addiction.^{4,7-9,11,13} Smoking could be indicative of an addiction behaviour that might serve as a

coping mechanism.²⁰ Furthermore, smoking behaviour has been shown to be more prevalent in individuals from an economically deprived background,²¹⁻²³ which has been found to be associated with domestic abuse within the household.⁶

A further set of factors suggested a subset of victims that are at high risk for a major health outcome. These individuals are repeatedly in contact with police after the index PPN submission and before the subsequent outcome event. Both decision trees indicated that those at the highest risk are split by the presence of more than two police visits. Individuals with less than two police visits but with a MARAC referral were also considered to be at high risk. This finding might indicate a progressively worsening home situation. These findings are similar to what has been found in victims of intimate partner violence; a study in the USA observed that Emergency Department use was associated with an increased number of police calls,¹³ whereas another study in Canada found it was associated with more violent abuse than for those who do not use the Emergency Department.⁴ These findings indicate that the manifestation of domestic abuse, specifically intimate partner violence in these studies, has shifted from a situation of coercive control to physical violence.




Figure 3: Decision tree to examine clustering of those who experience an outcome using data from other sources up to 3 years before the index PPN submission date

GP=general practitioner. NA=not applicable. PPN=Public Protection Notification.

In contrast another group comprised individuals who were less often in contact with Emergency Department health-care services. This group consists of people who have had more than one police visit after the domestic abuse incident, with less than three Emergency Department admissions up to 3 years before, or less than one Emergency Department admission up to 1 year before the domestic abuse incident. Obstetric codes recorded by the victim’s GP up to 3 years before were indicative of those at highest risk within this group: mothers with young children. Several studies have observed that victims of intimate partner violence, which is included in the definition of domestic abuse by the DASH questionnaire, are more likely to be in their childbearing years;^{11,24–26} those who suffer abuse during pregnancy reported that it worsened throughout the duration, whereas for some who previously suffered abuse, they indicated that it was a protective period.²⁵ Research has indicated that having a child can increase economic pressures;²⁷ economic hardship increases stress on relationships, which has been shown to escalate the incidence of abuse.²⁷ The survival analysis also highlighted that victims who are pregnant at the time of PPN submission were more likely to have an outcome in the following year. Conversely, cases characterised by conflict over child contact had a decreased risk of experiencing a future outcome, which might be interpreted that a co-parent and potential perpetrator no longer cohabits

within the same household, which could decrease exposure to abusive behaviour.

Finally, we identified a group that was relatively unknown to both Emergency Department health-care services and police, but who nonetheless could be considered vulnerable individuals from the presence of GP codes. Those who had less than one police visit after the PPN submission were more likely to experience an outcome if they have been prescribed CNS drugs and were in the extreme age groups of 0–29 years or 70–79 years, compared with those who have not been prescribed these drugs or who are in different age groups. Furthermore, victims who were questioned by the police about the perpetrator’s violent tendencies at the incident and were prescribed both CNS drugs and drugs used in infections are more likely to experience the outcome compared to those who are not prescribed such drugs. These codes could suggest a stressful home environment, which is associated with adverse mental health symptoms. The presence of infection codes might indicate that these people have injuries or poor living conditions.

Our findings suggest that people who are attended to by the police for cases of abuse in the household have previously been in contact with various service providers, including GPs and Emergency Department health care. The linking of data from different organisations might enhance the efficiency and effectiveness of these

organisations' response systems. By using anonymised data sharing and linkage across multiple agencies we could identify warning signs, such as frequent visits to an Emergency Department. It could also help refine the DASH questionnaire adding additional risk factors that have been identified from linked data research, such as questions regarding previous Emergency Department admissions and the prescription of antidepressants or antibiotics from their GP. The use of an anonymised linkage system with a trusted third party enables research and system learning while preserving confidentiality and anonymity of the individuals. However, the implementation of cross-organisational data linkage at the national level for long-term purposes beyond research to identify individuals requires consultation with the public and consensus on the appropriate data types, linkage objectives, and purpose for linkage. Consensus is necessary to ensure that data sharing between organisations does not prevent individuals seeking help from Emergency Departments or similar services due to fear of being identified by the police, as such awareness has potential to deter help-seeking behaviours. The results of this study underscore the importance of providing training for Emergency Department personnel to recognise and address potential cases of abuse.

There are several limitations to this study. The PPN dataset comprises records spanning 2015–20 as PPN records were not available before 2015. Consequently, left-censoring arose in this study. In addition, the inclusion criteria required that the victim first has a PPN submission before experiencing a domestic abuse-related outcome. As such, those individuals who are experiencing domestic abuse without engaging with the police are excluded from this analysis. Furthermore, the index PPN submission within this study might not be the actual first PPN submission; thus, the actual time to event might be different to the calculated time to event between the index PPN and the outcome event. Moreover, this study is predominantly descriptive; therefore factors identified cannot be used to establish cause and effect and residual confounding might operate. Finally, restricting the analysis to non-obstetric Emergency Department admissions for women might have resulted in an underestimation of the influence of household abuse in pregnancy. Notably, some events, such as pre-term delivery, which could be triggered by abuse, would have been excluded.

Highly vulnerable individuals frequently interact with health-care services but remain unknown to the police before an incident that requires an intervention. This finding underscores the potential value of linking data across different agencies to facilitate targeted prevention measures instead of reactive ones. Moreover, identifying individuals at high risk following a police interaction could enable the establishment of protective measures. The data generated by this study have the potential to identify risk without relying on disclosure, forming a

foundation for enhanced integration. Further research is needed to validate these findings and examine whether early identification of these groups by the police or in the health-care setting could lead to improved outcomes, in addition to examining the outcomes stratified by demographic profiles.

Contributors

MAB, AJ, KHa, SM, and SB conceptualised the study. AB and SM designed the study. SB secured funding, contributed to the methodology, and undertook the role of project principal investigator. NK, TLW, and CM collected the data, with NK and TLW directly accessing and verifying the underlying data. NK, TLW, AB, and JK undertook the data analysis. NK, JK, and SB interpreted the data. NK and JK generated the figures. NK drafted the report. BR, CM, JE, KHu, MAB, AJ, SM, and SB all undertook project supervisory and advisory roles for their specialities. KHa acted as a patient and public involvement advisor. All authors contributed to revisions, approved the final version, and were responsible for the decision to submit the manuscript for publication.

Declaration of interests

We declare no competing interests.

Data sharing

The data that support the findings of this study are available from the Secure Anonymised Information Linkage (SAIL) databank,¹⁵ but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. Interested individuals can apply to the SAIL databank for access, and once approved, can apply to the corresponding author.

Acknowledgments

This research was funded by the National Institute for Health Research, Public Health Research Board (reference number NIHR133680: Unlocking Data to Inform Public Health Policy and Practice). The study was also supported by Health Care Research Wales through the National Centre for Population Health and Wellbeing Research, supported by ESRC through Administrative Data Research Wales, and received infrastructure support through Health Data Research UK. This study makes use of anonymised data held in the SAIL databank.¹⁵ We would like to acknowledge all the data providers who make anonymised data available for research.

References

- 1 His Majesty's Inspectorate of Constabulary and Fire & Rescue Services. Police effectiveness 2015 (vulnerability). Dec 15, 2015. <https://www.justiceinspectors.gov.uk/hmicfrs/publications/police-effectiveness-vulnerability-2015-south-wales/> (accessed April 17, 2023).
- 2 Richards L. Domestic Abuse, Stalking and Harassment and Honour Based Violence (DASH, 2009) risk identification and assessment and management. 2009. <https://proceduresonline.com/trixcms/media/6627/dash-risk-assessment.pdf> (accessed April 17, 2023).
- 3 UK Parliament. Domestic Abuse Act. 2021. <https://www.legislation.gov.uk/ukpga/2021/17/part/1/enacted> (accessed April 17, 2023).
- 4 Nesca M, Au W, Turnbull L, Brownell M, Brownridge DA, Urquia ML. Intentional injury and violent death after intimate partner violence. A retrospective matched-cohort study. *Prev Med* 2021; **149**: 106616.
- 5 Sardinha L, Maheu-Giroux M, Stöckl H, Meyer SR, García-Moreno C. Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018. *Lancet* 2022; **399**: 803–13.
- 6 Nettet MB, Gudde CB, Mentzoni GE, Palmstierna T. Intimate partner violence during COVID-19 lockdown in Norway: the increase of police reports. *BMC Public Health* 2021; **21**: 2292.
- 7 Bacchus LJ, Ranganathan M, Watts C, Devries K. Recent intimate partner violence against women and health: a systematic review and meta-analysis of cohort studies. *BMJ Open* 2018; **8**: e019995.
- 8 Chandan JS, Thomas T, Bradbury-Jones C, et al. Female survivors of intimate partner violence and risk of depression, anxiety and serious mental illness. *Br J Psychiatry* 2020; **217**: 562–67.
- 9 Hegadoren KM, Lasiuk GC, Coupland NJ. Posttraumatic stress disorder part III: health effects of interpersonal violence among women. *Perspect Psychiatr Care* 2006; **42**: 163–73.

- 10 Alejo K. Long-term physical and mental health effects of domestic violence. May 1, 2014. <https://scholarworks.sjsu.edu/thesis/vol2/iss1/5> (accessed Feb 28, 2022).
- 11 Kothari CL, Rhodes KV. Missed opportunities: emergency department visits by police-identified victims of intimate partner violence. *Ann Emerg Med* 2006; **47**: 190–99.
- 12 Kothari CL, Rhodes KV, Wiley JA, et al. Protection orders protect against assault and injury: a longitudinal study of police-involved women victims of intimate partner violence. *J Interpers Violence* 2012; **27**: 2845–68.
- 13 Rhodes KV, Kothari CL, Dichter M, Cerulli C, Wiley J, Marcus S. Intimate partner violence identification and response: time for a change in strategy. *J Gen Intern Med* 2011; **26**: 894–99.
- 14 Coker AL, Smith PH, Bethea L, King MR, McKeown RE. Physical health consequences of physical and psychological intimate partner violence. *Arch Fam Med* 2000; **9**: 451–57.
- 15 Campbell JC. Health consequences of intimate partner violence. *Lancet* 2002; **359**: 1331–36.
- 16 Lyons RA, Ford DV, Moore L, Rodgers SE. Use of data linkage to measure the population health effect of non-health-care interventions. *Lancet* 2014; **383**: 1517–19.
- 17 Jones KH, Ford DV, Thompson S, Lyons RA. A profile of the SAIL databank on the UK Secure Research Platform. *Int J Popul Data Sci* 2019; **4**: 1134.
- 18 Ford DV, Jones KH, Verplancke JP, et al. The SAIL databank: building a national architecture for e-health research and evaluation. *BMC Health Serv Res* 2009; **9**: 157.
- 19 Bandyopadhyay A, Jones H, Parker M, et al. Weighting of risk factors for low birth weight: a linked routine data cohort study in Wales, UK. *BMJ Open* 2023; **13**: e063836.
- 20 Sullivan TP, Flanagan JC, Dudley DN, Holt LJ, Mazure CM, McKee SA. Correlates of smoking status among women experiencing intimate partner violence: substance use, posttraumatic stress, and coping. *Am J Addict* 2015; **24**: 546–53.
- 21 Martire KA, Clare P, Courtney RJ, et al. Smoking and finances: baseline characteristics of low income daily smokers in the FISCALS cohort. *Int J Equity Health* 2017; **16**: 157.
- 22 Guillaumier A, Twyman L, Paul C, Siahpush M, Palazzi K, Bonevski B. Financial stress and smoking within a large sample of socially disadvantaged Australians. *Int J Environ Res Public Health* 2017; **14**: 231.
- 23 Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol* 2017; **186**: 1026–34.
- 24 Ribeiro MRC, Batista RFL, Schraiber LB, et al. Recurrent violence, violence with complications, and intimate partner violence against pregnant women and breastfeeding duration. *J Womens Health (Larchmt)* 2021; **30**: 979–89.
- 25 Alhusen JL, Ray E, Sharps P, Bullock L. Intimate partner violence during pregnancy: maternal and neonatal outcomes. *J Womens Health (Larchmt)* 2015; **24**: 100–06.
- 26 MacMillan HL, Wathen CN. Children's exposure to intimate partner violence. *Child Adolesc Psychiatr Clin N Am* 2014; **23**: 295–308, viii–ix.
- 27 Friedline T, Chen Z, Morrow S. Families' financial stress & well-being: the importance of the economy and economic environments. *J Fam Econ Issues* 2021; **42** (suppl 1): 34–51.
- 28 Spooner M. Does eligibility for protection orders prevent repeat abuse of domestic abuse victims in Caribbean states? *J Fam Violence* 2009; **24**: 377–87.

THE LANCET

Public Health


Supplementary appendix 1

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Kennedy N, Win TL, Bandyopadhyay A, et al. Insights from linking police domestic abuse data and health data in South Wales, UK: a linked routine data analysis using decision tree classification. *Lancet Public Health* 2023; **8**: e629–38.

Appendix


Appendix A. Dataset date span diagram.



Appendix B. Poor Matching Scores.


A reliable intermediary assigns a unique anonymous identifier, known as an ALF, to each individual in a received dataset following a rigorous matching process.¹⁷ The matching algorithm was collaboratively designed and assessed by the trustworthy third party and SAIL. The algorithm compares numerous personal identifiers between the received dataset and the Welsh Demographic Service dataset. It starts with NHS numbers and then moves on to first name, surname, date of birth, and postcode. The algorithm's development ensures a high matching accuracy, with specific thresholds for match accuracy reported to SAIL within the anonymised dataset. A poor matching score indicates incomplete or inaccurate personal information provided by an individual or a lack of registration on the NHS database.¹⁷

Appendix C. Survival plot of those experiencing an outcome after the PPN visit.




Appendix D. Survival plots split by different factors from the DASH Report.


App D.a Time to outcome after a PPN by age.




App D.b Time to outcome after a PPN by incidence of attempted strangulation.




App D.c Time to outcome after a PPN by incidence of conflict over a child.




App D.d Time to outcome after a PPN by incidence of hurting other people.




App D.e Time to outcome after a PPN by incidence of history of further violence.




App D.f Time to outcome after a PPN by incidence of injury.




App D.g Time to outcome after a PPN by incidence of MARAC referral.




App D.h Time to outcome after a PPN by incidence of multiple police visits (PPNs).




App D.i Time to outcome after a PPN by incidence of past pregnancies within the household.



App D.j Time to outcome after a PPN by incidence of whether a member of the household is pregnant.



App D.k Time to outcome after a PPN by incidence of assessed risk.



Appendix E. Percentage drop of the population at 0 days, indicating the amount of PPN's which resulted in an attendance.

Factor	Outcome	Percentage attending ED on day of PPN (%)*
Overall Survival		6.96
Age Group	0-9	< 20.00
	10-19	8.08
	20-29	6.50
	30-39	7.00
	40-49	6.92
	50-59	7.34
	60-69	7.44
	70-79	< 6.58
	80+	< 17.24
Attempted Strangulation	NR	< 29.41
	N	6.32
	Y	15.88
Conflict over a Child	NR	< 20.83
	N	7.47
	Y	3.04
Hurt Other People	NR	< 62.5
	N	7.13
	Y	< 3.62
History of Further Violence	NR	0.00
	N	4.95
	Y	15.03
Gender	M	6.77
	F	7.03
Injury	N	2.09
	Y	26.58
MARAC Referral	NR	5.74
	N	4.19
	Y	25.27
Multiple Police Visits (PPNs)	N	7.08
	Y	6.81
Past Pregnancy	NR	< 19.23
	N	6.91
	Y	7.12
Pregnant	NR	< 45.45
	N	6.73
	Y	12.71
Risk Assessment	NR	7.23
	Standard	2.47
	Medium	6.70
	High	22.25

*Percentages have been censored to <5 individuals when the real value has been considered disclosive.

LOCATION	CODE	DESC
PEDW	A	Cholera
PEDW	B	Herpesviral [herpes simplex] infections
PEDW	C	Malignant neoplasm of lip
PEDW	D	Carcinoma in situ of oral cavity, oesophagus and stomach
PEDW	E	Congenital iodine-deficiency syndrome
PEDW	F	Dementia in Alzheimer's disease
PEDW	G	Bacterial meningitis, not elsewhere classified
PEDW	H	Hordeolum and chalazion
PEDW	I	Rheumatic fever without mention of heart involvement
PEDW	J	Acute nasopharyngitis [common cold]
PEDW	K	Disorders of tooth development and eruption
PEDW	L	Staphylococcal scalded skin syndrome
PEDW	M	Pyogenic arthritis
PEDW	N	Acute nephritic syndrome
PEDW	O	Ectopic pregnancy
PEDW	Q	Anencephaly and similar malformations
PEDW	R	Abnormalities of heart beat
PEDW	S	Superficial injury of head
PEDW	T	Superficial injuries involving multiple body regions
PEDW	V	Pedestrian injured in collision with pedal cycle
PEDW	W	Fall on same level involving ice and snow
PEDW	X	Exposure to uncontrolled fire in building or structure
PEDW	Y	Assault by blunt object
PEDW	Z	General examination and investigation of persons without complaint and reported diagnosis
PEDW	A0	Cholera
PEDW	B3	Viral conjunctivitis
PEDW	B9	Sequelae of tuberculosis
PEDW	D2	Benign neoplasm of soft tissue of retroperitoneum and peritoneum
PEDW	D6	Acquired pure red cell aplasia [erythroblastopenia]
PEDW	E0	Congenital iodine-deficiency syndrome
PEDW	E1	Type 1 diabetes mellitus
PEDW	E7	Disorders of aromatic amino-acid metabolism

PEDW	F1	Mental and behavioural disorders due to use of alcohol
PEDW	F3	Manic episode
PEDW	F4	Phobic anxiety disorders
PEDW	G4	Epilepsy
PEDW	G5	Disorders of trigeminal nerve
PEDW	H5	Other strabismus
PEDW	H6	Otitis externa
PEDW	I1	Essential (primary) hypertension
PEDW	I2	Angina pectoris
PEDW	I4	Acute myocarditis
PEDW	I8	Phlebitis and thrombophlebitis
PEDW	J0	Acute nasopharyngitis [common cold]
PEDW	J1	Influenza due to other identified influenza virus
PEDW	J2	Acute bronchitis
PEDW	J3	Vasomotor and allergic rhinitis
PEDW	J4	Bronchitis, not specified as acute or chronic
PEDW	K0	Disorders of tooth development and eruption
PEDW	K2	Oesophagitis
PEDW	K3	Functional dyspepsia
PEDW	K4	Inguinal hernia
PEDW	K5	Crohn disease [regional enteritis]
PEDW	K6	Fissure and fistula of anal and rectal regions
PEDW	K8	Cholelithiasis
PEDW	K9	Intestinal malabsorption
PEDW	L0	Staphylococcal scalded skin syndrome
PEDW	M1	Gout
PEDW	M2	Acquired deformities of fingers and toes
PEDW	M5	Cervical disc disorders
PEDW	M7	Soft tissue disorders related to use, overuse and pressure
PEDW	M8	Osteoporosis with pathological fracture
PEDW	N1	Acute tubulo-interstitial nephritis
PEDW	N3	Cystitis
PEDW	N7	Salpingitis and oophoritis

PEDW	N8	Endometriosis
PEDW	N9	Other noninflammatory disorders of vulva and perineum
PEDW	O0	Ectopic pregnancy
PEDW	O1	Pre-existing hypertension complicating pregnancy, childbirth and the puerperium
PEDW	O2	Haemorrhage in early pregnancy
PEDW	O3	Multiple gestation
PEDW	O4	Polyhydramnios
PEDW	O6	Preterm labour and delivery
PEDW	O7	Perineal laceration during delivery
PEDW	O8	Single spontaneous delivery
PEDW	O9	Complications of the puerperium, not elsewhere classified
PEDW	R0	Abnormalities of heart beat
PEDW	R1	Abdominal and pelvic pain
PEDW	R2	Disturbances of skin sensation
PEDW	R3	Pain associated with micturition
PEDW	R4	Somnolence, stupor and coma
PEDW	R5	Fever of unknown origin
PEDW	R6	Oedema, not elsewhere classified
PEDW	S0	Superficial injury of head
PEDW	S5	Superficial injury of forearm
PEDW	S6	Superficial injury of wrist and hand
PEDW	S8	Superficial injury of lower leg
PEDW	T3	Burn and corrosion, body region unspecified
PEDW	T4	Poisoning by narcotics and psychodysleptics [hallucinogens]
PEDW	T5	Poisoning by diuretics and other and unspecified drugs, medicaments and biological substances
PEDW	T8	Complications following infusion, transfusion and therapeutic injection
PEDW	W0	Fall on same level involving ice and snow
PEDW	W1	Fall on and from stairs and steps
PEDW	W2	Struck by thrown, projected or falling object
PEDW	X4	Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	X5	Overexertion and strenuous or repetitive movements

PEDW	X6	Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	Y0	Assault by blunt object
PEDW	Y8	Physical medicine devices associated with adverse incidents
PEDW	Z0	General examination and investigation of persons without complaint and reported diagnosis
PEDW	Z3	Contraceptive management
PEDW	Z4	Prophylactic surgery
PEDW	Z5	Care involving use of rehabilitation procedures
PEDW	Z7	Counselling related to sexual attitude, behaviour and orientation
PEDW	Z8	Family history of malignant neoplasm
PEDW	Z9	Acquired absence of organs, not elsewhere classified
PEDW	B34	Viral infection of unspecified site
PEDW	B95	Streptococcus and staphylococcus as the cause of diseases classified to other chapters
PEDW	B96	Other bacterial agents as the cause of diseases classified to other chapters
PEDW	D64	Other anaemias
PEDW	E11	Non-insulin-dependent diabetes mellitus
PEDW	E78	Disorders of lipoprotein metabolism and other lipidaemias
PEDW	F10	Mental and behavioural disorders due to use of alcohol
PEDW	F17	Mental and behavioural disorders due to use of tobacco
PEDW	F32	Depressive episode
PEDW	F41	Other anxiety disorders
PEDW	G40	Epilepsy
PEDW	I10	Essential (primary) hypertension
PEDW	I25	Chronic ischaemic heart disease
PEDW	I84	Haemorrhoids
PEDW	J03	Acute tonsillitis
PEDW	J06	Acute upper respiratory infections of multiple and unspecified sites
PEDW	J18	Pneumonia, organism unspecified
PEDW	J22	Unspecified acute lower respiratory infection
PEDW	J44	Other chronic obstructive pulmonary disease
PEDW	J45	Asthma
PEDW	K02	Dental caries

PEDW	K21	Gastro-oesophageal reflux disease
PEDW	K29	Gastritis and duodenitis
PEDW	K44	Diaphragmatic hernia
PEDW	K52	Other noninfective gastroenteritis and colitis
PEDW	K59	Other functional intestinal disorders
PEDW	K62	Other diseases of anus and rectum
PEDW	K80	Cholelithiasis
PEDW	K92	Other diseases of digestive system
PEDW	M25	Other joint disorders, not elsewhere classified
PEDW	M54	Dorsalgia
PEDW	M79	Other soft tissue disorders, not elsewhere classified
PEDW	N39	Other disorders of urinary system
PEDW	N73	Other female pelvic inflammatory diseases
PEDW	N83	Noninflammatory disorders of ovary, fallopian tube and broad ligament
PEDW	N92	Excessive, frequent and irregular menstruation
PEDW	N93	Other abnormal uterine and vaginal bleeding
PEDW	O02	Other abnormal products of conception
PEDW	O20	Haemorrhage in early pregnancy
PEDW	O21	Excessive vomiting in pregnancy
PEDW	O23	Infections of genitourinary tract in pregnancy
PEDW	O26	Maternal care for other conditions predominantly related to pregnancy
PEDW	O32	Maternal care for known or suspected malpresentation of fetus
PEDW	O34	Maternal care for known or suspected abnormality of pelvic organs
PEDW	O36	Maternal care for other known or suspected fetal problems
PEDW	O42	Premature rupture of membranes
PEDW	O46	Antepartum haemorrhage, not elsewhere classified
PEDW	O47	False labour
PEDW	O48	Prolonged pregnancy
PEDW	O60	Preterm labour and delivery
PEDW	O63	Long labour
PEDW	O68	Labour and delivery complicated by fetal stress [distress]
PEDW	O70	Perineal laceration during delivery
PEDW	O72	Postpartum haemorrhage

PEDW	O75	Other complications of labour and delivery, not elsewhere classified
PEDW	O80	Single spontaneous delivery
		Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium
PEDW	O99	
PEDW	R00	Abnormalities of heart beat
PEDW	R06	Abnormalities of breathing
PEDW	R07	Pain in throat and chest
PEDW	R10	Abdominal and pelvic pain
PEDW	R11	Nausea and vomiting
PEDW	R31	Unspecified haematuria
PEDW	R51	Headache
PEDW	R55	Syncope and collapse
PEDW	R56	Convulsions, not elsewhere classified
PEDW	S02	Fracture of skull and facial bones
PEDW	S09	Other and unspecified injuries of head
PEDW	S52	Fracture of forearm
PEDW	S61	Open wound of wrist and hand
PEDW	S82	Fracture of lower leg, including ankle
PEDW	T39	Poisoning by nonopioid analgesics, antipyretics and antirheumatics
PEDW	T40	Poisoning by narcotics and psychodysleptics [hallucinogens]
PEDW	T42	Poisoning by antiepileptic, sedative-hypnotic and antiparkinsonism drugs
PEDW	T43	Poisoning by psychotropic drugs, not elsewhere classified
PEDW	T51	Toxic effect of alcohol
PEDW	T81	Complications of procedures, not elsewhere classified
PEDW	W19	Unspecified fall
PEDW	X40	Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	X41	Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified
PEDW	X60	Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	X61	Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified

PEDW	X65	Intentional self-poisoning by and exposure to alcohol
PEDW	Y04	Assault by bodily force
PEDW	Y83	Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
PEDW	Z03	Medical observation and evaluation for suspected diseases and conditions
PEDW	Z30	Contraceptive management
PEDW	Z33	Pregnant state, incidental
PEDW	Z34	Supervision of normal pregnancy
PEDW	Z37	Outcome of delivery
PEDW	Z51	Other medical care
PEDW	Z53	Persons encountering health services for specific procedures, not carried out
PEDW	Z72	Problems related to lifestyle
PEDW	Z86	Personal history of certain other diseases
PEDW	Z87	Personal history of other diseases and conditions
PEDW	Z88	Personal history of allergy to drugs, medicaments and biological substances
PEDW	Z91	Personal history of risk-factors, not elsewhere classified
PEDW	Z92	Personal history of medical treatment
PEDW	B349	Viral infection, unspecified
PEDW	B962	Escherichia coli [E. coli] as the cause of diseases classified to other chapters
PEDW	E119	Type 2 diabetes mellitus
PEDW	E780	Pure hypercholesterolaemia
PEDW	F100	Mental and behavioural disorders due to use of alcohol
PEDW	F101	Mental and behavioural disorders due to use of alcohol
PEDW	F171	Mental and behavioural disorders due to use of tobacco
PEDW	F329	Depressive episode, unspecified
PEDW	F419	Anxiety disorder, unspecified
PEDW	I10X	Essential (primary) hypertension
PEDW	J039	Acute tonsillitis, unspecified
PEDW	J069	Acute upper respiratory infection, unspecified
PEDW	J22X	Unspecified acute lower respiratory infection
PEDW	J459	Asthma, unspecified
PEDW	K029	Dental caries, unspecified

PEDW	K219	Gastro-oesophageal reflux disease without oesophagitis
PEDW	K297	Gastritis, unspecified
PEDW	K449	Diaphragmatic hernia without obstruction or gangrene
PEDW	K529	Noninfective gastroenteritis and colitis, unspecified
PEDW	K590	Constipation
PEDW	M549	Dorsalgia, unspecified
PEDW	M796	Pain in limb
PEDW	N390	Urinary tract infection, site not specified
PEDW	N832	Other and unspecified ovarian cysts
PEDW	N920	Excessive and frequent menstruation with regular cycle
PEDW	N939	Abnormal uterine and vaginal bleeding, unspecified
PEDW	O021	Missed abortion
PEDW	O209	Haemorrhage in early pregnancy, unspecified
PEDW	O234	Unspecified infection of urinary tract in pregnancy
PEDW	O268	Other specified pregnancy-related conditions
PEDW	O342	Maternal care due to uterine scar from previous surgery
PEDW	O365	Maternal care for poor fetal growth
PEDW	O368	Maternal care for other specified fetal problems
PEDW	O429	Premature rupture of membranes, unspecified
PEDW	O469	Antepartum haemorrhage, unspecified
PEDW	O470	False labour before 37 completed weeks of gestation
PEDW	O471	False labour at or after 37 completed weeks of gestation
PEDW	O48X	Prolonged pregnancy
PEDW	O60X	Preterm delivery
PEDW	O631	Prolonged second stage (of labour)
PEDW	O680	Labour and delivery complicated by fetal heart rate anomaly
PEDW	O689	Labour and delivery complicated by fetal stress, unspecified
PEDW	O700	First degree perineal laceration during delivery
PEDW	O701	Second degree perineal laceration during delivery
PEDW	O709	Perineal laceration during delivery, unspecified
PEDW	O800	Spontaneous vertex delivery
PEDW	R073	Other chest pain
PEDW	R074	Chest pain, unspecified

PEDW	R101	Pain localized to upper abdomen
PEDW	R102	Pelvic and perineal pain
PEDW	R103	Pain localized to other parts of lower abdomen
PEDW	R104	Other and unspecified abdominal pain
PEDW	R11X	Nausea and vomiting
PEDW	R31X	Unspecified haematuria
PEDW	R51X	Headache
PEDW	R55X	Syncope and collapse
PEDW	S099	Unspecified injury of head
PEDW	T391	Poisoning: 4-Aminophenol derivatives
PEDW	T424	Poisoning: Benzodiazepines
PEDW	T432	Poisoning: Other and unspecified antidepressants
PEDW	T510	Toxic effect: Ethanol
PEDW	X409	Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	X419	Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified
PEDW	X600	Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	X609	Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW	X619	Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified
PEDW	Z301	Insertion of (intrauterine) contraceptive device
PEDW	Z302	Sterilization
PEDW	Z33X	Pregnant state, incidental
PEDW	Z349	Supervision of normal pregnancy, unspecified
PEDW	Z370	Single live birth
PEDW	Z512	Other chemotherapy
PEDW	Z538	Procedure not carried out for other reasons
PEDW	Z720	Tobacco use
PEDW	Z864	Personal history of psychoactive substance abuse
PEDW	Z867	Personal history of diseases of the circulatory system

PEDW	Z880	Personal history of allergy to penicillin
PEDW	Z915	Personal history of self-harm
WLGP	0	Occupations
WLGP	2	Examination / Signs
WLGP	3	Diagnostic procedures
WLGP	4	Laboratory procedures
WLGP	5	Radiology/physics in medicine
WLGP	6	Preventive procedures
WLGP	7	Operations, procedures, sites
WLGP	8	Other therapeutic procedures
WLGP	a	GASTRO-INTESTINAL DRUGS
WLGP	A	Infectious and parasitic diseases
WLGP	b	CARDIOVASCULAR DRUGS
WLGP	B	Neoplasms
WLGP	C	Endocrine, nutritional, metabolic and immunity disorders
WLGP	c	RESPIRATORY DRUGS
WLGP	d	CENTRAL NERVOUS SYSTEM DRUGS
WLGP	D	Diseases of blood and blood-forming organs
WLGP	e	DRUGS USED IN INFECTIONS
WLGP	E	Mental disorders
WLGP	f	ENDOCRINE DRUGS
WLGP	F	Nervous system and sense organ diseases
WLGP	G	Circulatory system diseases
WLGP	g	OBS/GYNAE/UTI DRUGS
WLGP	h	CHEMOTHERAPY/IMMUNOSUPPRESSANT DRUGS
WLGP	H	Respiratory system diseases
WLGP	i	HAEMATOLOGY/DIETETIC DRUGS
WLGP	J	Digestive system diseases
WLGP	j	MUSCULOSKELETAL DRUGS
WLGP	k	EYE DRUGS
WLGP	K	Genitourinary system diseases
WLGP	L	Complications of pregnancy, childbirth and the puerperium
WLGP	I	ENT DRUGS

WLGP	M	Skin and subcutaneous tissue diseases
WLGP	m	SKIN DRUGS
WLGP	n	IMMUNOLOGY DRUGS AND VACCINES
WLGP	N	Musculoskeletal and connective tissue diseases
WLGP	o	ANAESTHETIC DRUGS
WLGP	p	APPLIANCES & REAGENTS ETC
WLGP	P	Congenital anomalies
WLGP	R	[D]Symptoms, signs and ill-defined conditions
WLGP	S	Injury and poisoning
WLGP	T	Causes of injury and poisoning
WLGP	U	[X]External causes of morbidity and mortality
WLGP	Z	Unspecified conditions
WLGP	0	Occupations
WLGP	1	History / symptoms
WLGP	2	Examination / Signs
WLGP	3	Education/welfare/health prof.
WLGP	4	Laboratory procedures
WLGP	5	Radiology/physics in medicine
WLGP	11	Depth of history
WLGP	12	Family history
WLGP	13	Social/personal history
WLGP	14	Past medical history
WLGP	15	Gynaecological history
WLGP	16	General symptoms
WLGP	17	Respiratory symptoms
WLGP	18	Cardiovascular symptoms
WLGP	19	Gastrointestinal symptoms
WLGP	21	Depth of examination
WLGP	22	General examination of patient
WLGP	23	Examn. of respiratory system
WLGP	24	Exam. of cardiovascular system
WLGP	25	Exam. of digestive system
WLGP	26	Exam. of genitourinary system

WLGP	27	Obstetric examination
WLGP	29	Motor/sensory systems exam.
WLGP	31	Special diagnostic procedures
WLGP	32	Electrocardiography
WLGP	33	Physiological function tests
WLGP	36	Endoscopy / administration
WLGP	38	Misc. diagnostic procedures
WLGP	41	Laboratory procedures -general
WLGP	42	Haematology
WLGP	43	Immunology
WLGP	44	Blood chemistry
WLGP	45	Chemical function tests
WLGP	46	Urine examination
WLGP	47	Examination of faeces
WLGP	51	Radiology/physics - general
WLGP	52	Plain radiography
WLGP	53	Soft tissue imaging - plain
WLGP	54	Contrast radiography excl.CVS
WLGP	56	Other X-ray diagn. procedures
WLGP	61	Contraception
WLGP	62	Patient pregnant
WLGP	63	Birth details
WLGP	64	Child health care
WLGP	65	Infectious dis:prevent/control
WLGP	66	Chronic disease monitoring
WLGP	67	Counselling/health education
WLGP	68	Screening
WLGP	69	Special examinations
WLGP	70	Nervous system operations
WLGP	72	Eye operations
WLGP	73	Ear operations
WLGP	74	Respiratory tract operations
WLGP	75	Mouth operations

WLGP	76	Upper digestive tract operations
WLGP	77	Lower digestive tract operations
WLGP	78	Other abdominal organ operations
WLGP	81	Removal of unwanted material
WLGP	85	Other mechanical procedures
WLGP	87	Respiratory procedures
WLGP	89	Pre/post-operative procedures
WLGP	1A	Genitourinary symptoms
WLGP	1B	Nervous system symptoms
WLGP	1C	Ear/nose/throat symptoms
WLGP	1D	General symptom description
WLGP	1F	Dietary history
WLGP	1J	Suspected condition
WLGP	1M	Pain
WLGP	1P	Behaviours and observations relating to behaviour
WLGP	1T	History of substance misuse
WLGP	2B	Central nervous system exam.
WLGP	2C	Haemopoietic system exam.
WLGP	2D	Ear, nose + throat examination
WLGP	2E	Examination of fever
WLGP	2F	Examination of skin
WLGP	2G	Examination of the extremities
WLGP	2H	Orthopaedic examination
WLGP	2I	General sign qualifications
WLGP	2J	General clinical states
WLGP	4I	Miscellaneous samples
WLGP	4J	Microbiology
WLGP	4K	General pathology
WLGP	4Q	Generic biochemistry levels
WLGP	6A	Patient reviewed
WLGP	7B	Urinary operations
WLGP	7C	Male genital organ operations
WLGP	7D	Lower female genital tract operations

WLGP	7E	Upper female genital tract operations
WLGP	7F	Obstetric operations
WLGP	7G	Skin operations
WLGP	7H	Soft tissue operations
WLGP	7K	Other bone and joint operations
WLGP	7L	Miscellaneous operations
WLGP	7M	Subsidiary classification of methods of operation
WLGP	7N	Subsidiary classification of laterality and operation sites
WLGP	7P	Diagnostic imaging, testing and rehabilitation
WLGP	8A	Monitoring of patient
WLGP	8B	Other therapy
WLGP	8C	Other care
WLGP	8E	Physiotherapy/remedial therapy
WLGP	8G	Psychotherapy/sociotherapy
WLGP	8H	Referral for further care
WLGP	8I	Procedure not carried out
WLGP	8M	Patient requested procedure
WLGP	8P	Removal of surgical material and sutures
WLGP	9H	Mental health administration
WLGP	A0	Intestinal infectious diseases
WLGP	a2	COMPOUND ANTACIDS
WLGP	A3	Other bacterial diseases
WLGP	a4	ANTISPASMODICS/GASTRO-INTESTIN TRACT MOTILITY ALTERING DRUGS
WLGP	A5	Viral diseases with exanthem
WLGP	a6	ULCER-HEALING DRUGS
WLGP	A7	Other viral and chlamydial diseases
WLGP	a8	ANTIDIARRHOEAL-MOTILITY REDUCTION
WLGP	ab	BULK FORMING DRUGS [GASTRO-INTESTINAL USE]
WLGP	AB	Mycoses
WLGP	AC	Helminthiases
WLGP	ac	STIMULANT LAXATIVES
WLGP	AD	Other infectious and parasitic diseases
WLGP	ae	OSMOTIC LAXATIVES

WLGP	af	RECTALLY GIVEN LAXATIVES
WLGP	ah	RECTAL SOOTHING AGENTS
WLGP	aj	RECTAL COMPOUNDS WITH STEROIDS
WLGP	aw	PERIPHERALLY ACTING ANTI-OBESITY DRUGS
WLGP	b2	THIAZIDE DIURETICS
WLGP	b3	LOOP DIURETICS
WLGP	B7	Benign neoplasms
WLGP	BB	[M]Morphology of neoplasms
WLGP	bd	BETA-ADRENOCEPTOR BLOCKERS
WLGP	bi	ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
WLGP	bl	VASODILATORS USED IN ANGINA PECTORIS
WLGP	bu	ANTIPLATELET DRUGS
WLGP	bw	ANTIFIBRINOLYTICS/HAEMOSTATICS
WLGP	bx	LIPID-LOWERING DRUGS
WLGP	C0	Disorders of thyroid gland
WLGP	C1	Other endocrine gland diseases
WLGP	c1	SELECTIVE BETA-ADRENOCEPTOR STIMULANT
WLGP	c3	ANTICHOLINERGIC BRONCHODILATORS
WLGP	C3	Other metabolic and immunity disorders
WLGP	c6	CORTICOSTEROIDS [RESPIRATORY USE]
WLGP	c8	ANTIHISTAMINES
WLGP	cg	COUGH SUPPRESSANTS
WLGP	ch	EXPECTORANTS/COUGH COMPOUNDS
WLGP	ci	SYSTEMIC NASAL DECONGESTANTS
WLGP	D0	Deficiency anaemias
WLGP	d1	HYPNOTICS
WLGP	d2	ANXIOLYTICS
WLGP	d4	ANTIPSYCHOTIC DRUGS
WLGP	d7	TRICYCLIC ANTIDEPRESSANTS
WLGP	da	OTHER ANTIDEPRESSANT DRUGS
WLGP	dh	NAUSEA AND VERTIGO DRUGS
WLGP	di	NON-NARCOTIC ANALGESICS
WLGP	dj	NARCOTIC ANALGESICS

WLGP	dl	ACUTE MIGRAINE TREATMENT
WLGP	dm	PROPHYLAXIS OF MIGRAINE
WLGP	dn	CONTROL OF EPILEPSY
WLGP	du	ALCOHOL/DRUG DEPENDENCY DRUGS
WLGP	E1	Non-organic psychoses
WLGP	e1	PENICILLINASE SENS PENICILLINS
WLGP	E2	Neurotic, personality and other nonpsychotic disorders
WLGP	e2	PENICILLINASE-RESISTANT PENICILLINS
WLGP	e3	BROAD SPECTRUM PENICILLINS
WLGP	e6	CEPHALOSPORINS & CEPHAMYCINS
WLGP	e7	TETRACYCLINES [SYSTEMIC]
WLGP	e9	MACROLIDES
WLGP	ec	SULPHONAMIDES & TRIMETHOPRIM
WLGP	ef	METRONIDAZOLE & TINIDAZOLE
WLGP	eg	URINARY ANTIMICROBIAL DRUGS
WLGP	eh	ANTIFUNGAL DRUGS
WLGP	ei	ANTIVIRAL DRUGS
WLGP	EM	NA
WLGP	eq	DRUGS FOR THREADWORMS
WLGP	Eu	[X]Mental and behavioural disorders
WLGP	F2	Other central nervous system disorders
WLGP	F3	Peripheral nervous system disorders
WLGP	f4	BIGUANIDES
WLGP	F4	Disorders of eye and adnexa
WLGP	F5	Diseases of the ear and mastoid process
WLGP	f9	THYROID HORMONES
WLGP	fe	CORTICOSTEROID CLINICAL USE
WLGP	ff	OESTROGENS
WLGP	fg	PROGESTOGENS
WLGP	fh	COMBINED OESTROGEN + PROGESTOGEN PREPARATIONS
WLGP	G2	Hypertensive disease
WLGP	g4	GENITAL ANTIMICROBIAL PREPARATIONS
WLGP	G5	Other forms of heart disease

WLGP	g5	VAGINAL ANTIBACTERIAL PREPARATIONS
WLGP	g8	COMBINED ORAL CONTRACEPTIVE - ETHINYLOESTRADIOL
WLGP	G8	Vein, lymphatic and circulatory diseases NOS
WLGP	ga	PROGESTOGEN ONLY CONTRACEPTIVE
WLGP	gd	ENURESIS FREQUENCY INCONTINENCE
WLGP	H0	Acute respiratory infections
WLGP	H1	Other upper respiratory tract diseases
WLGP	H2	Pneumonia and influenza
WLGP	H3	Chronic obstructive pulmonary disease
WLGP	H5	Other respiratory system diseases
WLGP	hc	PROGESTOGENS IN MALIGNANCY
WLGP	i1	IRON DEFICIENCY - ORAL IRON
WLGP	i3	MEGALOBLASTIC ANAEMIAS
WLGP	i8	ELECTROLYTES-ORAL-SODIUM
WLGP	ie	SUPPLEMENT & COMPLETE FEEDS
WLGP	in	VITAMIN B GROUP
WLGP	ip	VITAMIN D
WLGP	is	MULTIVITAMIN PREPARATIONS
WLGP	J0	Oral cavity, salivary glands and jaw diseases
WLGP	j1	ASPIRIN AND THE SALICYLATES
WLGP	J1	Oesophageal, stomach and duodenal diseases
WLGP	j2	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
WLGP	J3	Hernia of abdominal cavity
WLGP	j4	LOCAL CORTICOSTEROID INJECTIONS
WLGP	J4	Noninfective enteritis and colitis
WLGP	J5	Other diseases of the intestines and peritoneum
WLGP	J6	Liver, biliary, pancreas + gastrointestinal diseases NEC
WLGP	ja	RUBEFACIENTS + TOPICAL ANTIRHEUMATICS
WLGP	K1	Other urinary system diseases
WLGP	K2	Male genital organ diseases
WLGP	K3	Disorders of breast
WLGP	k3	TOPICAL PREPARATIONS [EYE]
WLGP	K4	Female pelvic inflammatory diseases

WLGP	K5	Other female genital tract disorders
WLGP	k6	CORTICOSTER + ANTI-INFL [EYE]
WLGP	ka	TEAR DEFICIENCY PREPARATIONS
WLGP	L0	Pregnancy with abortive outcome
WLGP	L1	Pregnancy complications
WLGP	L2	Risk factors in pregnancy
WLGP	I3	AURAL ANTI-INFECTIVE PREPARATIONS
WLGP	L3	Complications occurring during labour and delivery
WLGP	I4	AURAL ANTI-INFECTIVE COMPOUNDS
WLGP	I7	REMOVAL OF EAR WAX
WLGP	I8	NASAL ALLERGY DRUGS
WLGP	I9	TOPICAL NASAL DECONGESTANTS
WLGP	Ia	ANTI-INFECTIVE NASAL PREPS.
WLGP	Ib	APHTHOUS MOUTH ULCER DRUGS
WLGP	Ic	OROPHARYNGEAL ANTI-INFECTIVES
WLGP	Ie	MOUTH-WASHES/GARGLES/DENTIFRICES
WLGP	M0	Skin and subcutaneous tissue infections
WLGP	M1	Other skin and subcutaneous tissue inflammatory conditions
WLGP	m1	VEHICLES AND DILUENTS
WLGP	m2	EMOLLIENTS + BARRIER PREPARATIONS
WLGP	M2	Other skin and subcutaneous tissue disorders
WLGP	m3	LOCAL ANAESTHETIC/ANTIPRURITIC
WLGP	m4	TOPICAL CORTICOSTEROIDS
WLGP	m5	PSORIASIS AND ECZEMA PREPARATIONS
WLGP	m6	ACNE - TOPICAL PREPARATIONS
WLGP	m8	WARTS AND CALLUSES
WLGP	mb	SCALP PREPARATIONS
WLGP	mc	ANTIBACTERIAL TOPICAL PREPARATIONS
WLGP	md	ANTIBACT. - SYSTEMIC USE ALSO
WLGP	me	ANTIFUNGAL PREPARATIONS
WLGP	mf	ANTIVIRAL PREPARATIONS
WLGP	mg	PARASITICIDAL PREPARATIONS
WLGP	mi	DISINFECTING/CLEANSING AGENTS

WLGP	N0	Arthropathies and related disorders
WLGP	N1	Vertebral column syndromes
WLGP	N2	Rheumatism, excluding the back
WLGP	N3	Osteopathies, chondropathies and acquired musculoskeletal deformities
WLGP	n4	VACCINES AND ANTISERA
WLGP	oa	LOCAL ANAESTHESIA
WLGP	p1	ABSORB COTTONS LINTS DRESSINGS
WLGP	p4	RESPIRATORY APPLIANCES
WLGP	p5	BANDAGES & SURGICAL TAPES
WLGP	ph	HYPODERMIC NEEDLES & SYRINGES
WLGP	ps	STOCKINETTES
WLGP	pu	REAGENTS & ANALYSIS SETS
WLGP	R0	[D]Symptoms
WLGP	R1	[D]Nonspecific abnormal findings
WLGP	S0	Fracture of skull
WLGP	S2	Fracture of upper limb
WLGP	S3	Fracture of lower limb
WLGP	S4	Dislocations and subluxations
WLGP	S5	Sprains and strains of joints and adjacent muscles
WLGP	S6	Intracranial injury excluding those with skull fracture
WLGP	S8	Open wound of head, neck and trunk
WLGP	S9	Open wound of upper limb
WLGP	SD	Superficial injury
WLGP	SE	Contusion (bruise) with intact skin
WLGP	SH	Burns
WLGP	SK	Traumatic complications and unspecified injuries
WLGP	SL	Poisoning
WLGP	SN	Other and unspecified external effect causes
WLGP	SP	Surgical and medical care complications NEC
WLGP	T1	Motor vehicle traffic accidents (MVTA)
WLGP	TC	Accidental falls
WLGP	TE	Accidents due to natural and environmental factors
WLGP	TJ	Drugs, medicines and biological substances causing adverse effects in therapeutic use

WLGP	TK	Suicide and selfinflicted injury
WLGP	U2	[X]Intentional self-harm
WLGP	U3	[X]Assault
WLGP	ZV	[V]Factors influencing health status and contact with health services
WLGP	7E0	Uterus operations
WLGP	12	Family history
WLGP	14	Past medical history
WLGP	15	Gynaecological history
WLGP	16	General symptoms
WLGP	23	Examn. of respiratory system
WLGP	24	Exam. of cardiovascular system
WLGP	26	Exam. of genitourinary system
WLGP	32	Electrocardiography
WLGP	41	Laboratory procedures -general
WLGP	42	Haematology
WLGP	46	Urine examination
WLGP	52	Plain radiography
WLGP	61	Contraception
WLGP	62	Patient pregnant
WLGP	63	Birth details
WLGP	64	Child health care
WLGP	65	Infectious dis:prevent/control
WLGP	67	Counselling/health education
WLGP	68	Screening
WLGP	7E1	Fallopian tube operations
WLGP	115	No significant medical history
WLGP	122	No relevant family history
WLGP	124	FH: Neoplasm - *
WLGP	125	FH: Endocrine disorders
WLGP	128	FH: Mental disorder
WLGP	129	FH: CNS disorder
WLGP	133	Personal status
WLGP	136	Alcohol consumption

WLGP	137	Tobacco consumption
WLGP	138	Exercise grading
WLGP	141	H/O: infectious disease
WLGP	146	H/O: psychiatric disorder
WLGP	147	H/O: CNS disorder
WLGP	151	Menstrual data
WLGP	152	Parity status
WLGP	156	Contraceptive history
WLGP	157	H/O: menstrual disorder
WLGP	158	H/O: abnormal uterine bleeding
WLGP	159	H/O:gynaecological problem NOS
WLGP	162	Weight symptom
WLGP	165	Temperature symptoms
WLGP	166	Sweating symptom
WLGP	168	Tiredness symptom
WLGP	171	Cough
WLGP	173	Breathlessness
WLGP	176	C/O - catarrh
WLGP	181	Palpitations
WLGP	182	Chest pain
WLGP	183	Oedema
WLGP	191	Tooth symptoms
WLGP	192	Mouth symptoms
WLGP	195	Indigestion symptoms
WLGP	196	Type of GIT pain
WLGP	197	Site of GIT pain
WLGP	198	Nausea
WLGP	199	Vomiting
WLGP	2E2	O/E - method fever registered
WLGP	212	Patient examined
WLGP	222	O/E - general observations
WLGP	225	O/E - state of mind
WLGP	229	O/E - height

WLGP	231	Depth of resp. system examn.
WLGP	235	O/E - rate of respiration
WLGP	242	O/E - pulse rate
WLGP	243	O/E - pulse rhythm
WLGP	246	O/E - blood pressure reading
WLGP	251	Depth of GIT examination
WLGP	268	O/E - bi-manual vaginal exam.
WLGP	269	O/E - vaginal speculum exam.
WLGP	271	O/E - gravid uterus size
WLGP	277	O/E - VE for pelvic assessment
WLGP	311	Neurological diagnostic proced
WLGP	312	Visual testing
WLGP	321	ECG - general
WLGP	332	Tuberculin test - mantoux
WLGP	338	Lung volume testing
WLGP	339	Respiratory flow rates
WLGP	361	Endoscopy: general admin
WLGP	387	Procedures related to diagn.
WLGP	388	Miscellaneous scales
WLGP	413	Laboratory test requested
WLGP	414	Sample sent to lab. for test
WLGP	421	Haematology - general
WLGP	423	Haemoglobin estimation
WLGP	424	Full blood count - FBC
WLGP	425	Haematocrit - PCV
WLGP	426	Red blood cell (RBC) count
WLGP	428	Mean corpusc. haemoglobin(MCH)
WLGP	429	Mean corpusc. Hb. conc. (MCHC)
WLGP	439	Rubella antibody titre
WLGP	442	Thyroid hormone tests
WLGP	443	Gonadotrophin levels
WLGP	445	Serum pregnancy test (B-HCG)
WLGP	446	Female sex hormones - serum

WLGP	447	Male sex hormones - serum
WLGP	451	Renal function tests
WLGP	461	Urine exam. - general
WLGP	465	Urine pregnancy test
WLGP	466	Urine test for glucose
WLGP	467	Urine protein test
WLGP	468	Urine ketone test
WLGP	469	Urine blood test
WLGP	511	Radiology - general
WLGP	525	Plain X-ray spine
WLGP	527	Plain X-ray pelvis
WLGP	528	Plain X-ray shoulder/arm
WLGP	529	Plain X-ray hand
WLGP	535	Standard chest X-ray
WLGP	537	Soft tissue X-ray breast
WLGP	567	Computerised axial tomography
WLGP	569	Nuclear magnetic resonance
WLGP	585	Other diagnostic ultrasound
WLGP	588	Physics - other measurements
WLGP	611	General contraceptive advice
WLGP	614	Oral contraceptive
WLGP	615	Intra-uterine contr. device
WLGP	621	Patient currently pregnant
WLGP	633	Outcome of delivery
WLGP	634	Sex of baby
WLGP	635	Maturity of baby
WLGP	652	Typhoid vaccination
WLGP	653	Tuberculosis (BCG) vaccination
WLGP	654	Diphtheria vaccination
WLGP	655	Pertussis vaccination
WLGP	656	Tetanus vaccination
WLGP	657	Other bacterial vaccinations
WLGP	658	Polio vaccination

WLGP	661	Chronic disease - general
WLGP	662	Cardiac disease monitoring
WLGP	663	Respiratory disease monitoring
WLGP	665	Psych. disorder monitoring
WLGP	671	Counselling - general
WLGP	677	Medical counselling
WLGP	678	Health education - general
WLGP	679	Health education - subject
WLGP	681	Screening - general
WLGP	685	Cervical neoplasia screening
WLGP	686	Other neoplasm screening
WLGP	689	Mental/dev. handicap screen
WLGP	7E2	Ovary and broad ligament operations
WLGP	730	External ear and external auditory canal operations
WLGP	731	Mastoid and middle ear operations
WLGP	740	Nose operations
WLGP	745	Lung and mediastinum operations
WLGP	751	Tooth and gingiva operations
WLGP	753	Tonsil and other parts of mouth operations
WLGP	761	Stomach and pylorus operations
WLGP	770	Appendix operations
WLGP	771	Colon operations and sigmoidoscopy of rectum
WLGP	781	Gall bladder operations
WLGP	879	Other respiratory procedures
WLGP	892	Informed consent for procedure
WLGP	2E3	O/E - level of fever
WLGP	0..	Occupations
WLGP	1..	History / symptoms
WLGP	12C	FH: Cardiovascular disease
WLGP	12D	FH: Respiratory disease
WLGP	13A	Diet - patient initiated
WLGP	13c	Drug user
WLGP	13H	Personal milestones

WLGP	13I	Family milestones
WLGP	13J	Employment milestones
WLGP	13M	Family bereavement
WLGP	13O	Sickness/invalidity benefit
WLGP	13W	Family circumstance NOS
WLGP	13Z	Social/personal history NOS
WLGP	14a	History of road traffic accident
WLGP	14B	H/O: respiratory disease
WLGP	14F	H/O: skin disorder
WLGP	14G	H/O: musculoskeletal disease
WLGP	14J	H/O: injury
WLGP	14L	H/O: drug allergy
WLGP	14M	H/O: non-drug allergy
WLGP	14O	H/O: risk factor
WLGP	14Q	H/O: regular medication
WLGP	14X	History of abuse
WLGP	15D	Dyspareunia
WLGP	16A	Stiff neck symptom
WLGP	16C	Backache symptom
WLGP	16E	Feels unwell
WLGP	16J	Swelling
WLGP	16Z	General symptom NOS
WLGP	19B	Flatulence/wind
WLGP	19C	Constipation
WLGP	19E	Faeces/motions - symptoms
WLGP	19F	Diarrhoea symptoms
WLGP	19G	Diarrhoea and vomiting
WLGP	1A.	Genitourinary symptoms
WLGP	1A1	Micturition frequency
WLGP	1A2	Micturition control
WLGP	1A5	Genitourinary pain
WLGP	1A7	Vaginal discharge symptom
WLGP	1A8	Breast lump symptom

WLGP	1AZ	Genitourinary symptoms NOS
WLGP	1B1	General nervous symptoms
WLGP	1B4	Sensory symptoms
WLGP	1B5	Incoordination symptom
WLGP	1B6	Disturbance of consciousness
WLGP	1B8	Eye symptoms
WLGP	1BA	Headache site
WLGP	1BD	Harmful thoughts
WLGP	1BO	Mood swings
WLGP	1BT	Depressed mood
WLGP	1C.	Ear/nose/throat symptoms
WLGP	1C1	Hearing symptoms
WLGP	1C3	Earache symptoms
WLGP	1C6	Nose bleed symptom
WLGP	1C8	Nasal symptoms OS
WLGP	1C9	Sore throat symptom
WLGP	1D1	C/O: a general symptom
WLGP	1D2	Symptom distribution
WLGP	1FA	Diet good
WLGP	1J.	Suspected condition
WLGP	1J4	Suspected UTI
WLGP	1M.	Pain
WLGP	1M0	Pain in upper limb
WLGP	1M1	Pain in lower limb
WLGP	2..	Examination / Signs
WLGP	22A	O/E - weight
WLGP	22K	Body Mass Index
WLGP	22N	Circumference measurements
WLGP	24E	O/E - peripheral pulses R.-leg
WLGP	24F	O/E - peripheral pulses L.leg
WLGP	26A	O/E - vaginal discharge
WLGP	26B	O/E - general breast exam.
WLGP	29B	O/E - tactile sensation

WLGP	2B6	O/E - visual acuity R-eye
WLGP	2B7	O/E - visual acuity L-eye
WLGP	2C3	O/E - lymphadenopathy
WLGP	2D.	Ear, nose + throat examination
WLGP	2D1	ENT examination - general
WLGP	2D7	O/E - painful ear
WLGP	2D8	O/E - auditory canal
WLGP	2F1	O/E - general skin exam.
WLGP	2FD	O/E - skin cyst
WLGP	2G5	O/E - foot
WLGP	2I1	O/E - general sign
WLGP	38C	Health assessment
WLGP	38D	Further miscellaneous scales
WLGP	38G	Additional miscellaneous scales
WLGP	4..	Laboratory procedures
WLGP	41B	Laboratory test due
WLGP	41C	Patient informed - test result
WLGP	41D	Sample obtained
WLGP	42A	Mean corpuscular volume (MCV)
WLGP	42B	Plasma viscosity
WLGP	42d	Blood haematinic levels
WLGP	42g	Haematology test
WLGP	42h	Haematology screening test
WLGP	42H	Total white cell count
WLGP	42J	Neutrophil count
WLGP	42j	Other coagulation/bleeding tests
WLGP	42K	Eosinophil count
WLGP	42L	Basophil count
WLGP	42M	Lymphocyte count
WLGP	42N	Monocyte count
WLGP	42P	Platelet count
WLGP	42Q	Coagulation/bleeding tests
WLGP	42R	Serum iron tests

WLGP	42T	Serum vitamin B12
WLGP	42U	Blood folate
WLGP	42W	Hb. A1C - diabetic control
WLGP	42Y	Other haematology test
WLGP	42Z	Haematology NOS
WLGP	43A	Infectious mononucleosis test
WLGP	43a	Other autoantibody titre
WLGP	43c	Immunology screening test
WLGP	43d	Viral antibody level
WLGP	43F	Rheumatoid factor
WLGP	43G	Autoantibody titres
WLGP	43J	Immunoglobulins
WLGP	43j	Nucleic acid detection
WLGP	43U	Chlamydia antigen test
WLGP	43W	Specific antibody level
WLGP	43Z	Immunology NOS
WLGP	44a	Tumour marker levels
WLGP	44C	Enzymes/specific proteins
WLGP	44D	Liver function tests - general
WLGP	44E	Serum bilirubin level
WLGP	44F	Serum alkaline phosphatase
WLGP	44f	Serum glucose level
WLGP	44G	Liver enzymes
WLGP	44g	Plasma glucose level
WLGP	44h	Blood electrolyte levels
WLGP	44H	Cardiac enzymes
WLGP	44I	Serum electrolytes
WLGP	44J	Blood urea/renal function
WLGP	44K	Blood urate
WLGP	44I	Biochemical ratio
WLGP	44L	Blood trace elements/vitamins
WLGP	44M	Serum / plasma proteins
WLGP	44O	Serum lipids

WLGP	44p	Biochemical test
WLGP	44P	Serum cholesterol
WLGP	44q	Biochemical screening test
WLGP	44Q	Serum triglycerides
WLGP	44T	Blood glucose method
WLGP	44U	Blood glucose result
WLGP	44Y	Blood gases
WLGP	44Z	Blood chemistry NOS
WLGP	46A	Urine pH test
WLGP	46M	Urine electrolytes
WLGP	46N	Urine protein
WLGP	46Q	Urine drug levels
WLGP	46T	Urine levels NOS
WLGP	46U	Urine culture
WLGP	46W	Urine microalbumin
WLGP	46X	Urine nitrite
WLGP	47D	Faeces examination - organisms
WLGP	4I1	Sample examination - general
WLGP	4I2	Type of sample
WLGP	4J.	Microbiology
WLGP	4J1	Sample - microbiological exam
WLGP	4J3	Sample: virology - general
WLGP	4JF	E.N.T. swab taken
WLGP	4JJ	Urine sample for organism
WLGP	4JK	GUT sample taken for organism
WLGP	4JR	Microbiology screening test
WLGP	4K.	General pathology
WLGP	4K1	Histology
WLGP	4K2	Cervical smear result
WLGP	4K3	Cervical smear - inflam.change
WLGP	4K5	Cytology - general
WLGP	4Q7	Trace element level
WLGP	5..	Radiology/physics in medicine

WLGP	52A	Plain X-ray hip/leg
WLGP	52B	Plain X-ray foot
WLGP	58D	Ultrasound scan
WLGP	61A	Post-coital contraception
WLGP	61B	Depot contraceptive
WLGP	61K	Subcutaneous contraceptive
WLGP	61M	Emergency contraception
WLGP	62B	Delivery booking place
WLGP	62G	Antenatal ultrasound scan
WLGP	62N	Antenatal examinations
WLGP	62P	Infant feeding method
WLGP	62R	Postnatal visits
WLGP	62S	Maternal P/N 6 week exam.
WLGP	64B	Child exam. - birth
WLGP	64D	Child 6 week exam.
WLGP	64E	Child 8-9 month examination
WLGP	64F	Child 18 month exam.
WLGP	64L	Child exam.: general/head
WLGP	64M	Child exam.: special senses
WLGP	64N	Child exam.: trunk/limbs
		Diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated
WLGP	65a	polio vaccination
WLGP	65A	Measles vaccination
WLGP	65B	Rubella vaccination
WLGP	65E	Influenza vaccination
WLGP	65F	Other viral vaccinations
WLGP	65H	Triple - DTP - vaccination
WLGP	65I	DTP (triple)+polio vaccination
WLGP	65J	Double - DT - vaccination
WLGP	65K	DT (double)+polio vaccination
WLGP	65M	Other combined vaccinations
WLGP	65P	Communicable disease contact
WLGP	66A	Diabetic monitoring

WLGP	66C	Obesity monitoring
WLGP	66R	Repeat prescription monitoring
WLGP	66U	Menopause monitoring
WLGP	66Y	Other respiratory disease monitoring
WLGP	67A	Pregnancy advice
WLGP	67E	Foreign travel advice
WLGP	67H	Lifestyle counselling
WLGP	67I	Advice
WLGP	68A	Neurolog./special sense screen
WLGP	68N	Immunisation status screen
WLGP	68P	Adult screening
WLGP	68R	New patient screen
WLGP	69D	Health exam. of sub-groups
WLGP	6A.	Patient reviewed
WLGP	6A1	Patient reviewed at hospital
WLGP	6A6	Mental health review
WLGP	7B2	Bladder operations
WLGP	7D1	Vagina operations
WLGP	7F1	Induction and delivery operations
WLGP	7G0	Removal of skin or subcutaneous tissue
WLGP	7G2	Other skin,subcutaneous tissue and wound procedures
WLGP	7H2	Peritoneum operations
WLGP	7K1	Bone operations
WLGP	7K6	Other joint operations
WLGP	7L1	Other miscellaneous operations
WLGP	7N8	[SO]Soft tissue
WLGP	7NA	[SO]Other bones and joints
WLGP	7NB	[SO]Other operation sites and laterality
WLGP	7P0	Diagnostic imaging
WLGP	81H	Dressing of wound
WLGP	85D	Injection given
WLGP	8A4	Respiratory monitoring
WLGP	8B1	Emergency treatment

WLGP	8B2	Therapeutic prescription
WLGP	8B3	Drug therapy
WLGP	8B4	Previous treatment continue
WLGP	8B6	Prophylactic drug therapy
WLGP	8BA	Other misc. therapy
WLGP	8BI	Other medication review
WLGP	8BM	Other medication management
WLGP	8C1	Nursing care
WLGP	8C9	Reassurance given
WLGP	8CA	Patient given advice
WLGP	8CB	Had a chat to patient
WLGP	8CE	Self-help advice leaflet given
WLGP	8CM	Care plan
WLGP	8E.	Physiotherapy/remedial therapy
WLGP	8GA	Psychological nursing
WLGP	8H.	Referral for further care
WLGP	8H2	Emergency hospital admission
WLGP	8H3	Non-urgent hospital admission
WLGP	8H4	Referral to physician
WLGP	8H5	Referral to surgeon
WLGP	8H6	Referral to other doctor
WLGP	8H7	Other referral
WLGP	8H8	Follow-up arranged
WLGP	8H9	Planned telephone contact
WLGP	8HA	No follow-up arranged
WLGP	8Hc	Referral to mental health team
WLGP	8Hd	Admission to hospital
WLGP	8HE	Discharged from hospital
WLGP	8HH	Referred - other care
WLGP	8HJ	Self-referral to hospital
WLGP	8Hk	Referred to service
WLGP	8HM	Listed for admission to hosp.
WLGP	8HQ	Refer for imaging

WLGP	8HR	Refer for physiology investign
WLGP	8HT	Referral to clinic
WLGP	8I2	Procedure contraindicated
WLGP	8I3	Procedure refused
WLGP	8I6	Treatment not indicated
WLGP	8IA	Procedure declined
WLGP	8IE	Procedure declined - additional
WLGP	8M6	Requests pregnancy termination
WLGP	9H9	Mental health annual physical examination done
WLGP	A07	Intestinal infection due to other organisms
WLGP	A08	Ill-defined intestinal tract infections
WLGP	a23	COMPOUND PROPRIETARY ANTACIDS D-L
WLGP	a24	COMPOUND PROPRIETARY ANTACIDS M-Z
WLGP	a47	HYOSCINE BUTYLBROMIDE
WLGP	a4d	ALVERINE CITRATE
WLGP	a4e	MEBEVERINE HYDROCHLORIDE
WLGP	a4f	PEPPERMINT OIL
WLGP	A52	Chickenpox - varicella
WLGP	A53	Herpes zoster
WLGP	A54	Herpes simplex
WLGP	A57	Other viral exanthemata
WLGP	a62	RANITIDINE
WLGP	a6b	OMEPRAZOLE
WLGP	a6c	LANSOPRAZOLE
WLGP	A78	Other viral or chlamydial diseases
WLGP	A79	Specific viral infections
WLGP	a81	CODEINE PHOSPHATE [GASTRO-INTESTINAL TRACT USE]
WLGP	a83	LOPERAMIDE HYDROCHLORIDE
WLGP	AB0	Dermatophytosis including tinea or ringworm
WLGP	AB1	Dermatophytosis other and unspecified
WLGP	AB2	Candidiasis
WLGP	ab2	ISPAGHULA HUSK [GASTRO-INTESTINAL BULK LAXATIVE]
WLGP	AC7	Other intestinal helminthiasis

WLGP	ac7	SENNA
WLGP	AD2	Pediculosis and phthirus infections
WLGP	AD3	Acariasis
WLGP	ae1	LACTULOSE
WLGP	ae4	POLYETHYLENE GLYCOL ELECTROLYTE
WLGP	af1	RECTAL LAXATIVES A-Z
WLGP	ah1	RECTAL SOOTHER A-Z
WLGP	aj1	RECTAL COMPOUNDS+STEROIDS A-Z
WLGP	aw1	ORLISTAT
WLGP	b21	BENDROFLUMETHIAZIDE
WLGP	b31	FUROSEMIDE
WLGP	B76	Benign neoplasm of skin
WLGP	bd1	PROPRANOLOL HYDROCHLORIDE
WLGP	bi6	RAMIPRIL
WLGP	blb	AMLODIPINE
WLGP	bu2	ASPIRIN [ANTIPLATELET]
WLGP	bw3	TRANEXAMIC ACID
WLGP	bx d	SIMVASTATIN
WLGP	bx i	ATORVASTATIN
WLGP	C04	Acquired hypothyroidism
WLGP	C10	Diabetes mellitus
WLGP	c11	SALBUTAMOL [ORAL PREPARATIONS]
WLGP	c13	SALBUTAMOL [INHALATION PREPARATIONS]
WLGP	c14	TERBUTALINE SULPHATE [RESPIRATORY USE]
WLGP	c19	SALMETEROL XINAFOATE
WLGP	c1D	SALMETEROL+FLUTICASONE PROPIONATE
WLGP	c1E	SALBUTAMOL [INHALATION PREPARATIONS 2]
WLGP	C32	Disorders of lipid metabolism
WLGP	C38	Obesity and other hyperalimentation
WLGP	c61	BECLOMETASONE DIPROPIONATE [RESPIRATORY USE]
WLGP	c66	BECLOMETASONE DIPROPIONATE [RESPIRATORY USE 2]
WLGP	c67	BUDESONIDE+FORMOTEROL
WLGP	c84	CHLORPHENAMINE MALEATE

WLGP	c8i	PROMETHAZINE HYDROCHLORIDE [ANTIHISTAMINE]
WLGP	c8n	CETIRIZINE DIHYDROCHLORIDE
WLGP	c8o	LORATADINE
WLGP	c8p	FEXOFENADINE
WLGP	c8r	DES Loratadine
WLGP	cg1	CODEINE PHOSPHATE
WLGP	cg7	PHOLCODINE
WLGP	ch1	GENERIC EXPECTORANTS/COUGH COMPOUND PREPARATIONS
WLGP	ci1	EPHEDRINE SYSTEMIC DECONGESTANTS
WLGP	D00	Iron deficiency anaemias
WLGP	d1a	TEMAZEPAM [HYPNOTIC]
WLGP	d1d	ZOPICLONE
WLGP	d21	DIAZEPAM [ANXIOLYTIC]
WLGP	d4s	QUETIAPINE
WLGP	d71	AMITRIPTYLINE HYDROCHLORIDE [ANTIDEPRESSANT]
WLGP	d75	DOSULEPIN HYDROCHLORIDE
WLGP	d79	LOFEPRAMINE
WLGP	d7e	TRAZODONE HYDROCHLORIDE
WLGP	da4	FLUOXETINE HYDROCHLORIDE
WLGP	da5	SERTRALINE HYDROCHLORIDE
WLGP	da6	PAROXETINE HYDROCHLORIDE
WLGP	da7	VENLAFAXINE
WLGP	da9	CITALOPRAM
WLGP	daB	MIRTAZAPINE
WLGP	daC	ESCITALOPRAM
WLGP	dh1	BETAHISTINE HYDROCHLORIDE
WLGP	dh4	CYCLIZINE
WLGP	dh7	DOMPERIDONE (NAUSEA)
WLGP	dhb	METOCLOPRAMIDE HYDROCHLORIDE
WLGP	dhe	PROCHLORPERAZINE [NAUSEA]
WLGP	di2	PARACETAMOL
WLGP	dia	COMPOUND ANALGESICS A-L
WLGP	dib	COMPOUND ANALGESICS M-Z

WLGP	dic	COMPOUND ANALGESICS[1]
WLGP	dj1	MORPHINE SALTS(1) [CENTRAL NERVOUS SYSTEM USE]
WLGP	dj4	CODEINE PHOSPHATE [ANALGESIC]
WLGP	dj8	DIHYDROCODEINE TARTRATE
WLGP	dji	TRAMADOL
WLGP	dl1	ANALGESICS WITH ANTI-EMETICS
WLGP	dl5	SUMATRIPTAN SUCCINATE
WLGP	dm3	PIZOTIFEN
WLGP	dnj	GABAPENTIN
WLGP	dnp	PREGABALIN
WLGP	du3	NICOTINE
WLGP	du7	NICOTINE 2
WLGP	du8	VARENICLINE
WLGP	E11	Affective psychoses
WLGP	e15	PHENOXYMETHYLPENICILLIN
WLGP	E20	Neurotic disorders
WLGP	e22	FLUCLOXACILLIN
WLGP	E22	Sexual deviations or disorders
WLGP	E23	Alcohol dependence syndrome
WLGP	E24	Drug dependence
WLGP	E25	Nondependent abuse of drugs
WLGP	E27	Psychogenic syndromes NEC
WLGP	E29	Adjustment reaction
WLGP	E2B	Depressive disorder NEC
WLGP	E2C	Disturbance of conduct NEC
WLGP	e31	AMOXICILLIN
WLGP	e32	AMPICILLIN
WLGP	e33	AMPICILLIN + PENICILLINASE-RESISTANT PENICILLIN
WLGP	e3z	AMOXICILLIN [GENERIC ADDITIONS]
WLGP	e61	CEFACLOR
WLGP	e69	CEFALEXIN
WLGP	e75	DOXYCYCLINE
WLGP	e76	LYMECYCLINE

WLGP	e78	OXYTETRACYCLINE
WLGP	e91	ERYTHROMYCIN
WLGP	e92	CLARITHROMYCIN
WLGP	e93	AZITHROMYCIN DIHYDRATE
WLGP	ecc	TRIMETHOPRIM
WLGP	ef1	METRONIDAZOLE
WLGP	eg1	NITROFURANTOIN
WLGP	eg6	CIPROFLOXACIN
WLGP	eh7	NYSTATIN [SYSTEMIC]
WLGP	eh8	FLUCONAZOLE
WLGP	eha	TERBINAFINE HYDROCHLORIDE [1]
WLGP	ei1	ACICLOVIR [SYSTEMIC]
WLGP	EMI	NA
WLGP	eq1	MEBENDAZOLE
WLGP	Eu3	[X]Mood - affective disorders
WLGP	Eu4	[X]Neurotic, stress - related and somoform disorders
WLGP	F25	Epilepsy
WLGP	F26	Migraine
WLGP	F34	Mononeuritis of upper limb and mononeuritis multiplex
WLGP	f41	METFORMIN HYDROCHLORIDE
WLGP	F4C	Disorders of conjunctiva
WLGP	F4D	Inflammation of eyelids
WLGP	F4J	Strabismus and other disorders of binocular eye movements
WLGP	F50	Disorders of external ear
WLGP	F51	Nonsuppurative otitis media + eustachian tube disorders
WLGP	F52	Suppurative and unspecified otitis media
WLGP	F56	Vertiginous syndromes and other disorders of vestibular system
WLGP	F58	Other ear disorders
WLGP	F59	Hearing loss
WLGP	f92	LEVOTHYROXINE SODIUM
WLGP	fe6	PREDNISOLONE [ENDOCRINE]
WLGP	fg5	NORETHISTERONE [ENDOCRINE]
WLGP	fh1	MENSTRUAL SYMPTOMS - COMBINED PREPARATIONS

WLGP	G2.	Hypertensive disease
WLGP	G20	Essential hypertension
WLGP	g42	CLOTTRIMAZOLE
WLGP	g81	DESOGESTREL
WLGP	g83	LEVONORGESTREL [COMBINED ORAL CONTRACEPTIVE]
WLGP	G83	Varicose veins of the legs
WLGP	G84	Haemorrhoids
WLGP	g87	NORETHISTERONE ACETATE [COMBINED ORAL CONTRACEPTIVE]
WLGP	g88	GESTODENE [COMBINED ORAL CONTRACEPTIVE]
WLGP	g89	NORGESTIMATE [COMBINED OC]
WLGP	g8A	DROSPIRENONE
WLGP	ga2	LEVONORGESTREL [PROGESTOGEN CONTRACEPTIVE]
WLGP	ga3	MEDROXYPROGESTERONE ACETATE [PROGESTOGEN ORAL CONTRACEPTIVE]
WLGP	ga5	NORETHISTERONE [PROGESTOGEN ORAL CONTRACEPTIVE]
WLGP	ga7	ETONOGESTREL
WLGP	ga8	DESOGESTREL [PROGESTOGEN ONLY CONTRACEPTIVE]
WLGP	gdd	SOLIFENACIN
WLGP	gde	DULOXETINE
WLGP	H00	Acute nasopharyngitis
WLGP	H01	Acute sinusitis
WLGP	H02	Acute pharyngitis
WLGP	H03	Acute tonsillitis
WLGP	H04	Acute laryngitis and tracheitis
WLGP	H05	Other acute upper respiratory infections
WLGP	H06	Acute bronchitis and bronchiolitis
WLGP	H12	Chronic pharyngitis and nasopharyngitis
WLGP	H17	Allergic rhinitis
WLGP	H27	Influenza
WLGP	H33	Asthma
WLGP	hc2	MEDROXYPROGEST AC [MALIGNANCY]
WLGP	i11	FERROUS FUMARATE
WLGP	i15	FERROUS SULPHATE
WLGP	i16	IRON & FOLIC ACID

WLGP	i33	FOLIC ACID
WLGP	i81	SODIUM SALTS
WLGP	in4	THIAMINE HYDROCHLORIDE
WLGP	in7	VITAMIN B COMPLEX
WLGP	ip3	CHOLECALCIFEROL OR ERGOCALCIFEROL
WLGP	is1	MULTIVITAMINS
WLGP	J02	Pulp and periapical tissue disease
WLGP	J08	Oral soft tissue disease
WLGP	J10	Diseases of oesophagus
WLGP	j11	ASPIRIN [MUSCULOSKELETAL USE]
WLGP	J15	Gastritis and duodenitis
WLGP	J16	Disorders of stomach function
WLGP	j22	DICLOFENAC SODIUM
WLGP	j28	IBUPROFEN [MUSCULOSKELETAL USE]
WLGP	j2b	MEFENAMIC ACID [MUSCULOSKELETAL USE]
WLGP	j2c	NAPROXEN
WLGP	j43	METHYLPREDNIS. ACETATE [MUSCULOSKELETAL USE]
WLGP	J43	Other non-infective inflammatory gastroenteritis and colitis
WLGP	J52	Functional gastrointestinal tract disorders NEC
WLGP	J57	Other disorders of intestine
WLGP	J64	Cholelithiasis
WLGP	ja1	TOPICAL ANTI-INFLAMMATORY PREP[1]
WLGP	ja2	TOPICAL ANTI-INFLAMMATORY PREP[2]
WLGP	ja3	TOPICAL ANTI-INFLAMMATORY PREP[3]
WLGP	K15	Cystitis
WLGP	K19	Other urethral and urinary tract disorders
WLGP	K28	Other male genital organ disorders
WLGP	K31	Other breast disorders
WLGP	k32	CHLORAMPHENICOL [EYE]
WLGP	k3g	FUSIDIC ACID [EYE]
WLGP	K40	Ovarian, fallopian tube and pelvic inflammatory diseases
WLGP	K42	Cervical, vaginal and vulval inflammatory diseases
WLGP	K58	Female genital organ symptoms

WLGP	K59	Menstruation disorders
WLGP	K5A	Menopausal and postmenopausal disorders
WLGP	k69	SODIUM CROMOGLICATE [EYE]
WLGP	ka8	CARBOMERS
WLGP	L04	Spontaneous abortion
WLGP	L10	Haemorrhage in early pregnancy
WLGP	L13	Excessive pregnancy vomiting
WLGP	L20	Normal delivery in a completely normal case
WLGP	l32	CLIOQUINOL
WLGP	l35	GENTAMICIN [EAR]
WLGP	L39	Other complications of labour and delivery NEC
WLGP	l41	AURAL ANTI-INFECTIVE COMPOUNDS
WLGP	l71	REMOVAL OF EAR WAX
WLGP	l81	BECLOMETASONE DIPROPIONATE [NOSE]
WLGP	l88	FLUTICASONE [NOSE]
WLGP	l8D	MOMETASONE FUROATE MONOHYDRATE [NOSE]
WLGP	l94	XYLOMETAZOLINE HYDROCHLORIDE
WLGP	la1	ANTI-INFECTIVE NASAL PREPS.
WLGP	lb1	BENZYDAMINE HYDROCHLORIDE
WLGP	lb4	CORTICOSTEROIDS FOR OROPHARYNX
WLGP	lc4	MICONAZOLE [OROPHARYNGEAL]
WLGP	le2	CHLORHEXIDINE GLUCONATE
WLGP	M0.	Skin and subcutaneous tissue infections
WLGP	M01	Furuncle - boil
WLGP	M02	Cellulitis and abscess of finger and toe
WLGP	M03	Other cellulitis and abscess
WLGP	M05	Impetigo
WLGP	M07	Other local infections of skin and subcutaneous tissue
WLGP	M0z	Skin and subcut tissue infection NOS
WLGP	M10	Erythematousquamous dermatosis
WLGP	M11	Atopic dermatitis and related conditions
WLGP	m11	VEHICLES + DILUENTS : CREAMS
WLGP	M12	Contact dermatitis and other eczemas

WLGP	m12	VEHICLES+DILUENTS : OINTMENTS
WLGP	M15	Erythematous conditions
WLGP	M16	Psoriasis and similar disorders
WLGP	M18	Pruritus and related conditions
WLGP	m21	EMOLLIENTS/BARRIER CREAMS: A-E
WLGP	M21	Other atrophic and hypertrophic conditions of skin
WLGP	m22	EMOLLIENTS/BARRIER CREAMS: F-O
WLGP	M22	Other dermatoses
WLGP	M23	Diseases of nail
WLGP	m23	EMOLLIENTS/BARRIER CREAMS: P-Z
WLGP	M24	Hair and hair follicle diseases
WLGP	M25	Disorders of sweat glands
WLGP	m25	EMOLLIENT BATH ADDITIVES
WLGP	M26	Sebaceous gland diseases
WLGP	m27	ANTISEPTIC EMOLLIENTS
WLGP	m28	EMOLLIENTS/BARRIER CREAMS:A-E (1)
WLGP	M28	Urticaria
WLGP	M2y	Other specified diseases of skin or subcutaneous tissue
WLGP	m31	CALAMINE
WLGP	m32	CROTAMITON [ANTIPRURITIC]
WLGP	m41	HYDROCORTISONE CREAMS
WLGP	m42	HYDROCORTISONE OINTMENTS
WLGP	m45	HYDROCORTISONE+ANTIMICROBIALS
WLGP	m48	BETAMETHASONE ESTERS
WLGP	m49	BETAMETHASONE + ANTIMICROBIALS
WLGP	m4a	CLOBETASOL PROPIONATE
WLGP	m4b	CLOBETASONE BUTYRATE [SKIN]
WLGP	m4q	MOMETASONE FUROATE [TOPICAL]
WLGP	m59	CALCIPOTRIOL
WLGP	m67	ERYTHROMYCIN [SKIN]
WLGP	m68	CLINDAMYCIN [SKIN]
WLGP	m6D	ADAPALENE
WLGP	m6z	BENZOYL PEROXIDE [GENERIC ADDITIONS]

WLGP	m81	SALICYLIC ACID [CALLOSITY]
WLGP	mb1	SHAMPOOS
WLGP	mb2	SCALP APPLICATIONS
WLGP	mc5	MUPIROCIIN
WLGP	md2	FUSIDIC ACID
WLGP	me4	CLOTRIMAZOLE [SKIN]
WLGP	me7	MICONAZOLE NITRATE [SKIN]
WLGP	mej	TERBINAFINE HYDROCHLORIDE [2]
WLGP	mf1	ACICLOVIR [SKIN]
WLGP	mg5	MALATHION
WLGP	mg7	PHENOTHRIN
WLGP	mg8	PERMETHRIN
WLGP	mif	SODIUM CHLORIDE [SKIN]
WLGP	N05	Osteoarthritis and allied disorders
WLGP	N06	Other and unspecified arthropathies
WLGP	N09	Other and unspecified joint disorders
WLGP	N13	Other cervical disorders
WLGP	N14	Other and unspecified back disorders
WLGP	N21	Peripheral enthesopathies and allied syndromes
WLGP	N22	Other disorders of the synovium, tendon and bursa
WLGP	N23	Muscle, ligament and fascia disorders
WLGP	N24	Other soft tissue disorders
WLGP	N33	Other bone and cartilage disorders
WLGP	n45	DIPHThERIA VACCINES
WLGP	n47	INFLUENZA VACCINES
WLGP	n4h	TYPHOID VACCINE
WLGP	n4m	HEPATITIS A VACCINE
WLGP	oa1	LIDOCAINE HCL [ANAESTHESIA]
WLGP	oaz	LIDOCAINE [GENERIC ADDIT]
WLGP	p16	DRESSING PERFORATED FILM ABSORBENT STERILE
WLGP	p1a	STERILE DRESSING PACK
WLGP	p1n	POVIDONE-IODINE DRESSING
WLGP	p1w	NON-WOVEN FABRIC BACKED ADHESIVE DRESSING

WLGP	p43	RESERVOIR CHAMBER LARGE VOLUME
WLGP	p46	PEAK FLOW METERS
WLGP	p5j	PERMEABLE NON-WOVEN SURGICAL ADHESIVE TAPE
WLGP	ph7	LANCETS-STERILE SINGLE-USE
WLGP	ps2	STOCKINETTE ELASTIC TUBULAR 1
WLGP	puh	BLOOD GLUCOSE TESTING STRIPS
WLGP	R00	[D]General symptoms
WLGP	R02	[D]Symptoms affecting skin and other integumentary tissue
WLGP	R03	[D]Nutrition, metabolic and developmental symptoms
WLGP	R04	[D]Head and neck symptoms
WLGP	R05	[D]Cardiovascular system symptoms
WLGP	R06	[D]Respiratory system and chest symptoms
WLGP	R07	[D]Digestive system symptoms
WLGP	R09	[D]Other abdominal and pelvic symptoms
WLGP	S23	Fracture of radius and ulna
WLGP	S24	Fracture of carpal bone
WLGP	S25	Fracture of metacarpal bone
WLGP	S26	Fracture of one or more phalanges of hand
WLGP	S34	Fracture of ankle
WLGP	S35	Fracture of one or more tarsal and metatarsal bones
WLGP	S3z	Fracture of unspecified bones
WLGP	S52	Sprain of wrist and hand
WLGP	S55	Sprain of ankle and foot
WLGP	S57	Sprain of other parts of back
WLGP	S64	Intracranial injury NOS
WLGP	S8z	Open wound of head, neck and trunk NOS
WLGP	SD.	Superficial injury
WLGP	SK1	Other specified injury
WLGP	SL.	Poisoning
WLGP	SN5	Adverse effects NEC
WLGP	SP2	Other procedure complication NEC
WLGP	T1.	Motor vehicle traffic accidents (MVTA)
WLGP	TC.	Accidental falls

WLGP	TE6	Other injury caused by animals
WLGP	TK.	Suicide and selfinflicted injury
WLGP	U20	[X]Intentional self poisoning by and exposure to noxious substances
WLGP	U3.	[X]Assault
WLGP	ZV2	[V]Encounter due to reproduction and development problems
WLGP	ZV4	[V]Persons with a condition influencing their health status
WLGP	ZV5	[V]Specified procedures and aftercare
WLGP	ZV6	[V]Other reasons for encounter
WLGP	ZV7	[V]Well persons examination, investigation and screening
WLGP	7E00	Excision of cervix uteri
WLGP	122	No relevant family history
WLGP	124	FH: Neoplasm - *
WLGP	136	Alcohol consumption
WLGP	138	Exercise grading
WLGP	151	Menstrual data
WLGP	152	Parity status
WLGP	158	H/O: abnormal uterine bleeding
WLGP	165	Temperature symptoms
WLGP	168	Tiredness symptom
WLGP	171	Cough
WLGP	173	Breathlessness
WLGP	181	Palpitations
WLGP	182	Chest pain
WLGP	191	Tooth symptoms
WLGP	196	Type of GIT pain
WLGP	198	Nausea
WLGP	199	Vomiting
WLGP	229	O/E - height
WLGP	235	O/E - rate of respiration
WLGP	242	O/E - pulse rate
WLGP	246	O/E - blood pressure reading
WLGP	271	O/E - gravid uterus size
WLGP	277	O/E - VE for pelvic assessment

WLGP	332	Tuberculin test - mantoux
WLGP	413	Laboratory test requested
WLGP	414	Sample sent to lab. for test
WLGP	423	Haemoglobin estimation
WLGP	424	Full blood count - FBC
WLGP	425	Haematocrit - PCV
WLGP	426	Red blood cell (RBC) count
WLGP	428	Mean corpusc. haemoglobin(MCH)
WLGP	429	Mean corpusc. Hb. conc. (MCHC)
WLGP	442	Thyroid hormone tests
WLGP	445	Serum pregnancy test (B-HCG)
WLGP	451	Renal function tests
WLGP	461	Urine exam. - general
WLGP	465	Urine pregnancy test
WLGP	466	Urine test for glucose
WLGP	467	Urine protein test
WLGP	511	Radiology - general
WLGP	525	Plain X-ray spine
WLGP	527	Plain X-ray pelvis
WLGP	529	Plain X-ray hand
WLGP	535	Standard chest X-ray
WLGP	537	Soft tissue X-ray breast
WLGP	567	Computerised axial tomography
WLGP	569	Nuclear magnetic resonance
WLGP	585	Other diagnostic ultrasound
WLGP	611	General contraceptive advice
WLGP	614	Oral contraceptive
WLGP	621	Patient currently pregnant
WLGP	633	Outcome of delivery
WLGP	635	Maturity of baby
WLGP	652	Typhoid vaccination
WLGP	653	Tuberculosis (BCG) vaccination
WLGP	662	Cardiac disease monitoring

WLGP	663	Respiratory disease monitoring
WLGP	679	Health education - subject
WLGP	681	Screening - general
WLGP	685	Cervical neoplasia screening
WLGP	7E02	Biopsy of cervix uteri
WLGP	892	Informed consent for procedure
WLGP	1151	No known allergies
WLGP	1225	No FH: Stroke/TIA
WLGP	1226	No FH: Ischaemic heart disease
WLGP	1227	No FH: Hypertension
WLGP	1228	No family history diabetes
WLGP	1252	FH: Diabetes mellitus
WLGP	1331	Single
WLGP	1361	Teetotaller
WLGP	1362	Trivial drinker - <1u/day
WLGP	1363	Light drinker - 1-2u/day
WLGP	1364	Moderate drinker - 3-6u/day
WLGP	1367	Stopped drinking alcohol
WLGP	1371	Never smoked tobacco
WLGP	1372	Trivial smoker - < 1 cig/day
WLGP	1373	Light smoker - 1-9 cigs/day
WLGP	1374	Moderate smoker - 10-19 cigs/d
WLGP	1375	Heavy smoker - 20-39 cigs/day
WLGP	1379	Ex-moderate smoker (10-19/day)
WLGP	1382	Avoids even trivial exercise
WLGP	1383	Enjoys light exercise
WLGP	1384	Enjoys moderate exercise
WLGP	1465	H/O: depression
WLGP	1513	Last menstrual period -1st day
WLGP	1514	Estimated date of confinement
WLGP	1519	Wishes to postpone menstruatn.
WLGP	1683	Tired all the time
WLGP	1717	Night cough present

WLGP	1718	Night cough absent
WLGP	1719	Chesty cough
WLGP	1737	Wheezing
WLGP	1739	Shortness of breath
WLGP	1955	Heartburn
WLGP	1969	Abdominal pain
WLGP	1972	Epigastric pain
WLGP	1977	Right iliac fossa pain
WLGP	1978	Left iliac fossa pain
WLGP	1982	Nausea present
WLGP	1992	Vomiting
WLGP	2126	Patient's condition improved
WLGP	2128	Patient's condition the same
WLGP	2227	O/E - rash present
WLGP	2315	Resp. system examined - NAD
WLGP	2431	O/E - pulse rhythm regular
WLGP	2464	O/E - BP reading normal
WLGP	2516	Abdomen examined - NAD
WLGP	3128	Fundoscopy
WLGP	3212	Standard ECG
WLGP	3386	Lung vital capacity
WLGP	3395	Peak exp. flow rate: PEFR/PFR
WLGP	3396	Forced vital capacity - FVC
WLGP	4131	Blood test requested
WLGP	4141	Stool sample sent to lab.
WLGP	4142	Blood sample -> Haematol Lab
WLGP	4143	Blood sample -> Biochem Lab
WLGP	4145	Blood sample -> Lab NOS
WLGP	4146	Urine sample sent to Lab
WLGP	4147	Swab sent to Lab
WLGP	4257	Packed cell volume
WLGP	4258	Haematocrit
WLGP	4266	Nucleated red blood cell count

WLGP	4426	Serum T4 level
WLGP	4427	Free T4 level
WLGP	4434	Follicle stim. hormone - F.S.H
WLGP	4463	Serum progesterone
WLGP	4465	Serum oestradiol level
WLGP	4473	Serum testosterone
WLGP	4474	Free androgen index
WLGP	4613	Urinalysis = no abnormality
WLGP	4615	MSU sent to lab.
WLGP	4618	Urine dipstick test
WLGP	4652	Urine pregnancy test negative
WLGP	4655	High sensitivity urine pregnancy test
WLGP	4661	Urine glucose test not done
WLGP	4662	Urine glucose test negative
WLGP	4671	Urine protein test not done
WLGP	4672	Urine protein test negative
WLGP	4682	Urine ketone test negative
WLGP	4692	Urine blood test = negative
WLGP	5254	Plain X-ray cervical spine
WLGP	5256	Plain X-ray lumbar spine
WLGP	5853	U-S heart scan
WLGP	5855	U-S abdominal scan
WLGP	5856	U-S pelvic scan
WLGP	5882	Spirometry
WLGP	6141	Oral contraceptive started
WLGP	6144	Oral contraceptive repeat
WLGP	6147	Combined oral contraceptive
WLGP	6148	Progestagen only oral contrac.
WLGP	6151	IUD fitted
WLGP	6152	IUD removed
WLGP	6154	IUD checked - no problems
WLGP	6219	Patient ? pregnant
WLGP	6331	Single live birth

WLGP	6521	First typhoid vaccination
WLGP	6523	Booster typhoid vaccination
WLGP	6541	First diphtheria vaccination
WLGP	6542	Second diphtheria vaccination
WLGP	6543	Third diphtheria vaccination
WLGP	6544	Booster diphtheria vaccination
WLGP	6551	First pertussis vaccination
WLGP	6552	Second pertussis vaccination
WLGP	6553	Third pertussis vaccination
WLGP	6561	First tetanus vaccination
WLGP	6562	Second tetanus vaccination
WLGP	6563	Third tetanus vaccination
WLGP	6564	Booster tetanus vaccination
WLGP	6571	Meningitis vaccination
WLGP	6572	Pneumococcal vaccination
WLGP	6581	First polio vaccination
WLGP	6582	Second polio vaccination
WLGP	6583	Third polio vaccination
WLGP	6584	Booster polio vaccination
WLGP	6636	Inhaler technique shown
WLGP	6637	Inhaler technique observed
WLGP	6775	Sterilisation counselling
WLGP	6776	Preg. termination counselling
WLGP	6777	Contraception counselling
WLGP	6781	Health education offered
WLGP	6791	Health ed. - smoking
WLGP	6792	Health ed. - alcohol
WLGP	6793	Health ed. - cervical cytology
WLGP	6795	Health ed. - breast exam.
WLGP	6798	Health ed. - exercise
WLGP	6799	Health ed. - diet
WLGP	6852	Ca cervix screen - offered
WLGP	6853	Ca cervix screen - not wanted

WLGP	6857	Ca cervix screen -not attended
WLGP	6859	Ca cervix - screen done
WLGP	6862	Breast neoplasm screen
WLGP	6896	Depression screening using questions
WLGP	7305	Clearance of external auditory canal
WLGP	7313	Drainage of middle ear
WLGP	7530	Excision of tonsil
WLGP	7700	Emergency excision of appendix
WLGP	7701	Other excision of appendix
WLGP	7810	Excision of gall bladder
WLGP	8923	Consent given for minor surgery procedure
WLGP	44E3	Total bilirubin
WLGP	7E04	Abdominal excision of uterus
WLGP	7E08	Other evacuation of contents of uterus
WLGP	7E09	Intrauterine contraceptive device procedure
WLGP	65E9	PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given
WLGP	2E27	O/E - tympanic temperature
WLGP	2E31	O/E - temperature normal
WLGP	0...	Occupations
WLGP	1...	History / symptoms
WLGP	12..	Family history
WLGP	12C.	FH: Cardiovascular disease
WLGP	12C1	FH: Hypertension
WLGP	12C2	FH: Ischaemic heart dis. <60
WLGP	12C3	FH: Ischaemic heart dis. >60
WLGP	12C4	FH: CVA/stroke
WLGP	12C5	FH: Myocardial infarction
WLGP	12D2	FH: Asthma
WLGP	133F	Marital state unknown
WLGP	136J	Social drinker
WLGP	137G	Trying to give up smoking
WLGP	137L	Current non-smoker
WLGP	137P	Cigarette smoker

WLGP	137R	Current smoker
WLGP	137S	Ex smoker
WLGP	138Z	Exercise grading NOS
WLGP	13A.	Diet - patient initiated
WLGP	13AZ	Patient initiated diet NOS
WLGP	13H7	Unwanted pregnancy
WLGP	13Hc	Bereavement
WLGP	13HT	Home problems
WLGP	13IB	Child in care
WLGP	13IM	Child on protection register
WLGP	13J.	Employment milestones
WLGP	13J7	Unemployed
WLGP	13JM	Problems at work
WLGP	14..	Past medical history
WLGP	141B	H/O: viral illness
WLGP	146B	H/O: deliberate self harm
WLGP	14a.	History of road traffic accident
WLGP	14B4	H/O: asthma
WLGP	14F1	H/O: eczema
WLGP	14G3	H/O: significant knee disorder
WLGP	14G9	H/O: fracture
WLGP	14L.	H/O: drug allergy
WLGP	14L1	H/O: penicillin allergy
WLGP	14M.	H/O: non-drug allergy
WLGP	14Q.	H/O: regular medication
WLGP	15..	Gynaecological history
WLGP	15D.	Dyspareunia
WLGP	16..	General symptoms
WLGP	16C.	Backache symptom
WLGP	16C2	Backache
WLGP	16C5	C/O - low back pain
WLGP	16C6	Back pain without radiation NOS
WLGP	16E.	Feels unwell

WLGP	173B	Nocturnal cough / wheeze
WLGP	173I	MRC Breathlessness Scale: grade 2
WLGP	182B	Rib pain
WLGP	197C	Lower abdominal pain
WLGP	19B.	Flatulence/wind
WLGP	19C.	Constipation
WLGP	19F.	Diarrhoea symptoms
WLGP	19FZ	Diarrhoea symptom NOS
WLGP	19G.	Diarrhoea and vomiting
WLGP	1A..	Genitourinary symptoms
WLGP	1A1.	Micturition frequency
WLGP	1A22	Enuresis
WLGP	1A53	Lumbar ache - renal
WLGP	1A55	Dysuria
WLGP	1A59	C/O pelvic pain
WLGP	1A7.	Vaginal discharge symptom
WLGP	1A8.	Breast lump symptom
WLGP	1A22	Fertility problem
WLGP	1B13	Anxiousness
WLGP	1B17	Depressed
WLGP	1B1B	Cannot sleep - insomnia
WLGP	1B1G	Headache
WLGP	1B1L	Stress related problem
WLGP	1B1U	Symptoms of depression
WLGP	1B1X	Behavioural problem
WLGP	1B5.	Incoordination symptom
WLGP	1B6.	Disturbance of consciousness
WLGP	1B8.	Eye symptoms
WLGP	1BA5	Frontal headache
WLGP	1BD1	Suicidal ideation
WLGP	1BO.	Mood swings
WLGP	1BT.	Depressed mood
WLGP	1C..	Ear/nose/throat symptoms

WLGP	1C12	Hearing difficulty
WLGP	1C14	Blocked ear
WLGP	1C3.	Earache symptoms
WLGP	1C6.	Nose bleed symptom
WLGP	1C8.	Nasal symptoms OS
WLGP	1C9.	Sore throat symptom
WLGP	1D11	C/O: a swelling
WLGP	1D13	C/O: a pain
WLGP	1D14	C/O: a rash
WLGP	1D15	C/O: itching
WLGP	1FA.	Diet good
WLGP	1J..	Suspected condition
WLGP	1J4.	Suspected UTI
WLGP	1M..	Pain
WLGP	1M10	Knee pain
WLGP	1M11	Foot pain
WLGP	2...	Examination / Signs
WLGP	212G	Asthma resolved
WLGP	22A.	O/E - weight
WLGP	22K.	Body Mass Index
WLGP	22K4	Body mass index index 25-29 - overweight
WLGP	22K5	Body mass index 30+ - obesity
WLGP	22K8	Body mass index 20-24 - normal
WLGP	22N0	Waist circumference
WLGP	23..	Examn. of respiratory system
WLGP	24..	Exam. of cardiovascular system
WLGP	26..	Exam. of genitourinary system
WLGP	26B.	O/E - general breast exam.
WLGP	2B6.	O/E - visual acuity R-eye
WLGP	2B7.	O/E - visual acuity L-eye
WLGP	2D..	Ear, nose + throat examination
WLGP	2D7.	O/E - painful ear
WLGP	2D82	O/E - wax in auditory canal

WLGP	2E3.	O/E - level of fever
WLGP	2F13	O/E - dry skin
WLGP	2FD.	O/E - skin cyst
WLGP	2G5E	O/E - Right diabetic foot at low risk
WLGP	2G5I	O/E - Left diabetic foot at low risk
WLGP	2I11	O/E - a lump
WLGP	32..	Electrocardiography
WLGP	339A	Peak flow rate before bronchodilation
WLGP	339B	Peak flow rate after bronchodilation
WLGP	339M	FEV1/FVC ratio
WLGP	339O	Forced expired volume in 1 second
WLGP	339R	FEV1/FVC percent
WLGP	339S	Percent predicted FEV1
WLGP	388f	Patient health questionnaire (PHQ-9) score
WLGP	388P	HAD scale: depression score
WLGP	38DP	QRISK2 cardiovascular disease 10 year risk score
WLGP	38G5	Biopsychosocial assessment
WLGP	4...	Laboratory procedures
WLGP	41..	Laboratory procedures -general
WLGP	41B1	Blood test due
WLGP	41C.	Patient informed - test result
WLGP	41C2	Test result to pat.by 'phone
WLGP	41C3	Test result to pat.personally
WLGP	41D0	Blood sample taken
WLGP	42..	Haematology
WLGP	421B	Blood film microscopy
WLGP	42A.	Mean corpuscular volume (MCV)
WLGP	42B.	Plasma viscosity
WLGP	42B6	Erythrocyte sedimentation rate
WLGP	42d1	Transferrin saturation index
WLGP	42g.	Haematology test
WLGP	42H.	Total white cell count
WLGP	42h0	Clotting screening test

WLGP	42J.	Neutrophil count
WLGP	42jG	APTT
WLGP	42K.	Eosinophil count
WLGP	42L.	Basophil count
WLGP	42M.	Lymphocyte count
WLGP	42N.	Monocyte count
WLGP	42P.	Platelet count
WLGP	42Q5	Prothrombin time
WLGP	42QE	International normalised ratio
WLGP	42Qn	Fibrinogen level
WLGP	42R4	Serum ferritin
WLGP	42R7	Serum iron level
WLGP	42T.	Serum vitamin B12
WLGP	42U5	Serum folate
WLGP	42W4	HbA1c level (DCCT aligned)
		Haemoglobin A1c level - International Federation of Clinical Chemistry and Laboratory Medicine standardised
WLGP	42W5	
WLGP	42YD	B12/folate level
WLGP	42Z5	Mean platelet volume
WLGP	42Z7	Red blood cell distribution width
WLGP	43A.	Infectious mononucleosis test
WLGP	43aC	Anti-tissue transglutaminase level
WLGP	43ad	Tissue transglutaminase IgA level
WLGP	43F.	Rheumatoid factor
WLGP	43G1	Anti-nuclear factor
WLGP	43Gd	Thyroid peroxidase antibody level
WLGP	43J3	IgG
WLGP	43J4	IgM
WLGP	43J5	IgA
WLGP	43U.	Chlamydia antigen test
WLGP	43U3	Chlamydia trachomatis antigen test
WLGP	43W9	Helicobacter pylori IgG antibody level
WLGP	43WA	Helicobacter pylori antibody level

WLGP	43Z2	Prostate specific antigen
WLGP	442A	TSH - thyroid stim. hormone
WLGP	442J	Thyroid function test
WLGP	442V	Serum free T4 level
WLGP	442W	Serum TSH level
WLGP	443e	Serum LH level
WLGP	443h	Serum FSH level
WLGP	443j	Serum prolactin level
WLGP	44a6	CA125 level
WLGP	44CB	Serum transferrin
WLGP	44CC	Plasma C reactive protein
WLGP	44CD	Serum sex hormone binding globulin level
WLGP	44CN	Serum amylase level
WLGP	44CS	Serum C reactive protein level
WLGP	44D.	Liver function tests - general
WLGP	44D6	Liver function test
WLGP	44E.	Serum bilirubin level
WLGP	44EC	Serum total bilirubin level
WLGP	44F.	Serum alkaline phosphatase
WLGP	44f.	Serum glucose level
WLGP	44f0	Serum random glucose level
WLGP	44f1	Serum fasting glucose level
WLGP	44F3	Total alkaline phosphatase
WLGP	44G.	Liver enzymes
WLGP	44g.	Plasma glucose level
WLGP	44g0	Plasma random glucose level
WLGP	44g1	Plasma fasting glucose level
WLGP	44G3	ALT/SGPT serum level
WLGP	44G4	Gamma - G.T. level
WLGP	44G9	Serum gamma-glutamyl transferase level
WLGP	44GB	Serum alanine aminotransferase level
WLGP	44h0	Blood potassium level
WLGP	44HB	AST serum level

WLGP	44HG	Serum creatine kinase level
WLGP	44I.	Serum electrolytes
WLGP	44I4	Serum potassium
WLGP	44I5	Serum sodium
WLGP	44I7	Serum bicarbonate
WLGP	44I8	Serum calcium
WLGP	44I9	Serum inorganic phosphate
WLGP	44IC	Corrected serum calcium level
WLGP	44J.	Blood urea/renal function
WLGP	44J3	Serum creatinine
WLGP	44J5	Renal profile
WLGP	44J9	Serum urea level
WLGP	44JB	Urea and electrolytes
WLGP	44K5	Serum urate level
WLGP	44IF	Serum cholesterol/HDL ratio
WLGP	44IL	Serum LDL/HDL ratio
WLGP	44M3	Serum total protein
WLGP	44M4	Serum albumin
WLGP	44M5	Serum globulin
WLGP	44MV	Serum protein profile
WLGP	44O.	Serum lipids
WLGP	44O5	Fasting blood lipids
WLGP	44p.	Biochemical test
WLGP	44P.	Serum cholesterol
WLGP	44P5	Serum HDL cholesterol level
WLGP	44P6	Serum LDL cholesterol level
WLGP	44PA	HDL : LDL ratio
WLGP	44PF	Total cholesterol:HDL ratio
WLGP	44PL	Non HDL cholesterol level
WLGP	44Q.	Serum triglycerides
WLGP	44q4	Urine opiates screening test
WLGP	44qF	Urine amphetamine screening test
WLGP	44T1	Random blood sugar

WLGP	44TJ	Blood glucose level
WLGP	44TK	Fasting blood glucose level
WLGP	44U.	Blood glucose result
WLGP	44YA	Blood oxygen saturation
WLGP	44Z2	Bone profile
WLGP	44Z3	Serum total HCG level
		Glomerular filtration rate calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation
WLGP	451E	Glomerular filtration rate
WLGP	451F	Urine examination
WLGP	46..	Urine creatinine
WLGP	46M7	Urine protein
WLGP	46N.	Urine albumin
WLGP	46N4	Urine benzodiazepine
WLGP	46Q8	Urine methadone
WLGP	46QB	Urine cocaine metabolite screen
WLGP	46QH	Urine albumin:creatinine ratio
WLGP	46TC	Urine culture
WLGP	46U.	Urine microalbumin
WLGP	46W.	Urine nitrite negative
WLGP	46X1	Stool culture
WLGP	47D3	Microscopy, culture and sensitivities
WLGP	4116	Urinary microscopy, culture and sensitivities
WLGP	4119	Enteric microscopy, culture and sensitivities
WLGP	411A	Mycology microscopy, culture and sensitivities
WLGP	411B	Genital microscopy, culture and sensitivities
WLGP	411C	Respiratory microscopy, culture and sensitivities
WLGP	411E	Wound microscopy, culture and sensitivities
WLGP	411F	Wound exudate sample
WLGP	412D	Microbiology
WLGP	4J..	Sample culture
WLGP	4J17	Viral studies
WLGP	4J3A	Urine sample for organism
WLGP	4JJ.	

WLGP	4JJ1	MSU sent for C/S
WLGP	4JK2	High vaginal swab taken
WLGP	4JK9	Endocervical chlamydia swab
WLGP	4K..	General pathology
WLGP	4K1.	Histology
WLGP	4K1D	Histology laboratory test
WLGP	4K2.	Cervical smear result
WLGP	4K21	Cervical smear:inadequate spec
WLGP	4K22	Cervical smear: negative
WLGP	4K23	Cerv.smear: mild dyskaryosis
WLGP	4K24	Cerv.smear: severe dyskaryosis
WLGP	4K28	Cerv.smear: mod.dyskaryosis
WLGP	4K29	Cerv.smear: borderline changes
WLGP	4K31	Cervical smear-no inflammation
WLGP	4K54	Cytology laboratory test
WLGP	4K55	Cervical cytology test
WLGP	4Q72	Calcium level
WLGP	5...	Radiology/physics in medicine
WLGP	52..	Plain radiography
WLGP	52A.	Plain X-ray hip/leg
WLGP	52A7	Plain X-ray knee
WLGP	52B.	Plain X-ray foot
WLGP	58D.	Ultrasound scan
WLGP	61..	Contraception
WLGP	614D	Oral contraceptive prescribed
WLGP	614E	Oral contraceptive advice
WLGP	61A.	Post-coital contraception
WLGP	61B.	Depot contraceptive
WLGP	61B1	Depot contraceptive given
WLGP	61M.	Emergency contraception
WLGP	62..	Patient pregnant
WLGP	62B.	Delivery booking place
WLGP	62G.	Antenatal ultrasound scan

WLGP	62N.	Antenatal examinations
WLGP	62N1	A/N booking examination
WLGP	62R.	Postnatal visits
WLGP	62S.	Maternal P/N 6 week exam.
WLGP	63..	Birth details
WLGP	64..	Child health care
WLGP	64B.	Child exam. - birth
WLGP	64D.	Child 6 week exam.
WLGP	64E.	Child 8-9 month examination
WLGP	64M1	Child exam.: vision
WLGP	64M3	Child exam.: squint
WLGP	64M5	Child exam.: hearing
WLGP	65..	Infectious dis:prevent/control
WLGP	657A	1st haemophilus B vaccination
WLGP	657B	2nd haemophilus B vaccination
WLGP	657C	3rd haemophilus B vaccination
WLGP	657D	Booster (single) haemophilus B vaccination
WLGP	657E	First meningitis C vaccination
WLGP	657F	Second meningitis C vaccination
WLGP	657G	Third meningitis C vaccination
WLGP	657I	Single meningitis C vaccination
WLGP	657J	Meningitis ACW & Y vaccination
WLGP	657S	Booster meningitis C vaccination
WLGP	65a0	First diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
WLGP	65A1	Measles vaccination
WLGP	65a1	Second diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
WLGP	65a2	Third diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
WLGP	65B.	Rubella vaccination
WLGP	65E.	Influenza vaccination
WLGP	65ED	Seasonal influenza vaccination

WLGP	65F1	1st hepatitis B vaccination
WLGP	65F2	2nd hepatitis B vaccination
WLGP	65F3	3rd hepatitis B vaccination
WLGP	65F5	Mumps vaccination
WLGP	65FA	1st hepatitis A vaccination
WLGP	65FD	Booster hepatitis A vaccin.
WLGP	65FF	1st hepatitis A junior vaccination
WLGP	65FS	First human papillomavirus vaccination
WLGP	65FT	Second human papillomavirus vaccination
WLGP	65FV	Third human papillomavirus vaccination
WLGP	65H.	Triple - DTP - vaccination
WLGP	65H1	First triple vaccination - DTP
WLGP	65H2	Second triple vaccination-DTP
WLGP	65H3	Third triple vaccination - DTP
WLGP	65I1	First DTP (triple)+polio vacc.
WLGP	65I2	Second DTP (triple)+polio vacc
WLGP	65I3	Third DTP (triple)+polio vacc.
WLGP	65I9	Booster diphtheria, tetanus, acellular pertussis and inactivated polio vaccination
WLGP	65J4	Boost double -DT- vaccination
WLGP	65K4	Booster DT(double)+polio vacc.
WLGP	65K6	First low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65K7	Second low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65K8	Third low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65K9	First booster low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65KA	Second booster low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65M1	Measles/mumps/rubella vaccin.
WLGP	65M2	Measles/rubella vaccination
WLGP	65MA	Measles mumps and rubella booster vaccination
WLGP	65ML	First hepatitis A and typhoid vaccination
WLGP	661M	Clinical management plan agreed
WLGP	663e	Asthma restricts exercise
WLGP	663H	Inhaler technique - good
WLGP	663N	Asthma disturbing sleep

WLGP	663n	Asthma treatment compliance satisfactory
WLGP	663O	Asthma not disturbing sleep
WLGP	663P	Asthma limiting activities
WLGP	663q	Asthma daytime symptoms
WLGP	663Q	Asthma not limiting activities
WLGP	663s	Asthma never causes daytime symptoms
WLGP	663U	Asthma management plan given
WLGP	663v	Asthma causes daytime symptoms most days
WLGP	66AS	Diabetic annual review
WLGP	66At	Diabetic dietary review
WLGP	66CB	Ideal weight
WLGP	66R.	Repeat prescription monitoring
WLGP	66R7	Rep.presc.treatment stopped
WLGP	66RZ	Rep.presc. monitoring NOS
WLGP	66YJ	Asthma annual review
WLGP	66YK	Asthma follow-up
WLGP	66Yp	Asthma review using Royal College of Physicians three questions
WLGP	67..	Counselling/health education
WLGP	677B	Advice about treatment given
WLGP	67E.	Foreign travel advice
WLGP	67H.	Lifestyle counselling
WLGP	67I.	Advice
WLGP	68..	Screening
WLGP	685A	Ca cervix screen-no result yet
WLGP	685B	Ca cervix screen normal
WLGP	685F	Cervical smear due
WLGP	685L	Cervical smear refused
WLGP	685R	Liquid based cervical cytology screening
WLGP	68A7	Diabetic retinopathy screening
WLGP	68N.	Immunisation status screen
WLGP	68N5	Full consent for immunisation
WLGP	68NE	No consent - influenza imm.
WLGP	68NV	Influenza vacc consent given

WLGP	68P.	Adult screening
WLGP	68R.	New patient screen
WLGP	68R2	New patient screen done
WLGP	69D2	Adult health exam.
WLGP	6A..	Patient reviewed
WLGP	6A1.	Patient reviewed at hospital
WLGP	6A6.	Mental health review
WLGP	745H	Smoking cessation therapy
WLGP	761F	Diagnostic fiberoptic endoscopic examination of upper gastrointestinal tract
WLGP	7B2A	Diagnostic cystoscopy
WLGP	7D1C	Exploration of vagina
WLGP	7E0E	Diagnostic endoscopic examination of uterus
WLGP	7E1C	Endoscopic bilateral occlusion of fallopian tubes
WLGP	7E2A	Other examination of female genital tract
WLGP	7F12	Elective caesarean delivery
WLGP	7F13	Other caesarean delivery
WLGP	7F19	Normal delivery
WLGP	7G03	Other excision of skin
WLGP	7G22	Removal of repair material from skin
WLGP	7G2A	Introduction of therapeutic substance into subcutaneous tissue
WLGP	7G2H	Other operations on subcutaneous tissue
WLGP	7H29	Diagnostic endoscopic examination of peritoneum
WLGP	7K1L	Other closed reduction of fracture of bone
WLGP	7L17	Blood withdrawal
WLGP	7L18	Intramuscular injection
WLGP	81H.	Dressing of wound
WLGP	85D.	Injection given
WLGP	8A44	Pulse oximetry monitoring
WLGP	8B1.	Emergency treatment
WLGP	8B21	Drug prescription
WLGP	8B2D	Hospital prescription
WLGP	8B2J	Prescription by supplementary prescriber
WLGP	8B3.	Drug therapy

WLGP	8B31	Drug administration
WLGP	8B35	Drug Rx stopped-medical advice
WLGP	8B39	Drugs not taken/completed
WLGP	8B3A	Drug dosage altered
WLGP	8B3H	Medication requested
WLGP	8B3h	Medication review without patient
WLGP	8B3j	Asthma medication review
WLGP	8B3N	Prescription not collected
WLGP	8B3R	Drug therapy discontinued
WLGP	8B3S	Medication review
WLGP	8B3V	Medication review done
WLGP	8B3x	Medication review with patient
WLGP	8B3y	Medication review of medical notes
WLGP	8B4.	Previous treatment continue
WLGP	8BIC	Medication review done by pharmacist
WLGP	8C1B	Nursing care blood sample taken
WLGP	8C9.	Reassurance given
WLGP	8CA.	Patient given advice
WLGP	8CA4	Patient advised re diet
WLGP	8CAK	Patient given telephone advice out of hours
WLGP	8CAL	Smoking cessation advice
WLGP	8CAw	Advice about long acting reversible contraception
WLGP	8CAZ	Patient given advice NOS
WLGP	8CB.	Had a chat to patient
WLGP	8CEG	Long acting reversible contraception leaflet given
WLGP	8E..	Physiotherapy/remedial therapy
WLGP	8GA0	Crisis intervention
WLGP	8H..	Referral for further care
WLGP	8H2.	Emergency hospital admission
WLGP	8H21	Admit medical emergency unsp.
WLGP	8H3Z	Other hospital admission NOS
WLGP	8H4.	Referral to physician
WLGP	8H41	General medical referral

WLGP	8H42	Referral to paediatrician
WLGP	8H43	Dermatological referral
WLGP	8H44	Cardiological referral
WLGP	8H46	Neurological referral
WLGP	8H48	Gastroenterological referral
WLGP	8H49	Psychiatric referral
WLGP	8H4B	Referred to rheumatologist
WLGP	8H5.	Referral to surgeon
WLGP	8H51	General surgical referral
WLGP	8H53	ENT referral
WLGP	8H54	Orthopaedic referral
WLGP	8H58	Gynaecological referral
WLGP	8H5B	Referred to urologist
WLGP	8H7.	Other referral
WLGP	8H76	Refer to dietician
WLGP	8H77	Refer to physiotherapist
WLGP	8H78	Refer to counsellor
WLGP	8H7B	Refer to community psych.nurse
WLGP	8H7N	Refer for colposcopy
WLGP	8H7O	Refer to Radiology department
WLGP	8H7W	Refer to TOP counselling
WLGP	8H7X	Refer to podiatry
WLGP	8H8.	Follow-up arranged
WLGP	8H9.	Planned telephone contact
WLGP	8HA.	No follow-up arranged
WLGP	8Hc0	Referral to community mental health team
WLGP	8Hc2	Referral to primary care mental health team
WLGP	8Hd.	Admission to hospital
WLGP	8HE.	Discharged from hospital
WLGP	8HE1	Discharged from outpatients
WLGP	8HE5	Removed from waiting list
WLGP	8HHR	Referral to child and adolescent psychiatry service
WLGP	8HHV	Referral for termination of pregnancy

WLGP	8HJA	Trauma self-referral
WLGP	8HJJ	Self-referral to accident and emergency department
WLGP	8HQ1	Refer for X-Ray
WLGP	8HQ2	Refer for ultrasound investign
WLGP	8HTI	Referral to breast clinic
WLGP	8I23	Immunisation contraindicated
WLGP	8IAj	Smoking cessation advice declined
WLGP	8IEM	Smoking cessation drug therapy declined
WLGP	8M6.	Requests pregnancy termination
WLGP	9H91	Depression medication review
WLGP	9H92	Depression interim review
WLGP	A07y	Gastrointestinal tract infection due to specified organism NEC
WLGP	a23A	GAVISCON ADVANCE peppermint sugar free suspension
WLGP	a23v	GAVISCON ADVANCE sugar free suspension
WLGP	a23y	GAVISCON peppermint liquid 500mL
WLGP	a24t	PEPTAC liquid
WLGP	a24z	PEPTAC peppermint liquid
WLGP	a471	*BUSCOPAN 10mg tablets
WLGP	a47y	HYOSCINE BUTYLBROMIDE 10mg tablets
WLGP	a4ex	MEBEVERINE HYDROCHLORIDE 135mg tablets
WLGP	a4f3	PEPPERMINT OIL BP 0.2mL e/c capsules
WLGP	A52.	Chickenpox - varicella
WLGP	A53.	Herpes zoster
WLGP	A54.	Herpes simplex
WLGP	A542	Herpetic gingivostomatitis
WLGP	a62w	RANITIDINE 150mg tablets
WLGP	a6b1	OMEPRAZOLE 20mg e/c capsules
WLGP	a6b7	OMEPRAZOLE 10mg e/c capsules
WLGP	a6c2	LANSOPRAZOLE 30mg capsules
WLGP	a6c3	LANSOPRAZOLE 15mg capsules
WLGP	A780	Molluscum contagiosum
WLGP	A781	Viral warts
WLGP	A79z	Viral infection NOS

WLGP	a83y	LOPERAMIDE HYDROCHLORIDE 2mg capsules
WLGP	AB0.	Dermatophytosis including tinea or ringworm
WLGP	AB01	Dermatophytosis of nail
WLGP	AB04	Dermatophytosis of foot
WLGP	AB10	Pityriasis versicolor
WLGP	AB2.	Candidiasis
WLGP	AB20	Candidiasis of mouth and oesophagus
WLGP	AB21	Candidal vulvovaginitis
WLGP	ac71	SENNA 7.5mg tablets
WLGP	AC74	Enterobiasis - threadworm
WLGP	AD20	Pediculus capitis - head lice
WLGP	AD30	Scabies
WLGP	ae11	LACTULOSE 3.35g/5mL solution
WLGP	ae46	MOVICOL oral powder
WLGP	ae4c	LAXIDO ORANGE oral powder sachets
WLGP	ah18	ANUSOL cream
WLGP	aj15	ANUSOL-HC ointment 30g
WLGP	aj1t	XYLOPROCT ointment 20g
WLGP	aw11	ORLISTAT 120mg capsules
WLGP	b211	BENDROFLUMETHIAZIDE 2.5mg tablets
WLGP	B76.	Benign neoplasm of skin
WLGP	bd11	PROPRANOLOL 10mg tablets
WLGP	bd12	PROPRANOLOL 40mg tablets
WLGP	bi62	RAMIPRIL 2.5mg capsules
WLGP	bi63	RAMIPRIL 5mg capsules
WLGP	blb1	AMLODIPINE 5mg tablets
WLGP	bu23	ASPIRIN 75mg dispersible tablets
WLGP	bw34	TRANEXAMIC ACID 500mg tablets
WLGP	bxd2	SIMVASTATIN 20mg tablets
WLGP	bxd5	SIMVASTATIN 40mg tablets
WLGP	bxi2	ATORVASTATIN 20mg tablets
WLGP	C04.	Acquired hypothyroidism
WLGP	C10F	Type 2 diabetes mellitus

WLGP	c13J	SALBUTAMOL 100micrograms CFC-free inhaler
WLGP	c13T	VENTOLIN 100micrograms Evohaler
WLGP	c13U	SALBUTAMOL 100micrograms CFC-free breath-actuated aerosol inhaler
WLGP	c13v	SALBUTAMOL 100microgram inhaler
WLGP	C380	Obesity
WLGP	c61z	BECLOMETASONE DIPROPIONATE 100micrograms inhaler
WLGP	c66d	CLENIL MODULITE 100micrograms CFC-free inhaler
WLGP	c841	CHLORPHENAMINE MALEATE 4mg tablets
WLGP	c843	PIRITON 4mg tablets
WLGP	c84y	CHLORPHENAMINE MALEATE 2mg/5mL syrup
WLGP	c8iw	PROMETHAZINE 25mg tablets
WLGP	c8n1	CETIRIZINE 10mg tablets
WLGP	c8o1	LORATADINE 10mg tablets
WLGP	c8o3	LORATADINE 5mg/5mL syrup
WLGP	c8p1	FEXOFENADINE HYDROCHLORIDE 120mg tablets
WLGP	c8p3	FEXOFENADINE HYDROCHLORIDE 180mg tablets
WLGP	c8rz	DESLORATADINE 5mg tablets
WLGP	ch14	SIMPLE linctus
WLGP	ch15	SIMPLE paediatric linctus
WLGP	ci1d	GALPSEUD 30mg/5mL linctus
WLGP	ci1w	PSEUDOEPHEDRINE HCL 60mg tablets
WLGP	D00.	Iron deficiency anaemias
WLGP	d1a9	TEMAZEPAM 10mg tablets
WLGP	d1d1	ZOPICLONE 7.5mg tablets
WLGP	d1d3	ZOPICLONE 3.75mg tablets
WLGP	d213	DIAZEPAM 2mg tablets
WLGP	d214	DIAZEPAM 5mg tablets
WLGP	d215	DIAZEPAM 10mg tablets
WLGP	d711	AMITRIPTYLINE 10mg tablets
WLGP	d712	AMITRIPTYLINE 25mg tablets
WLGP	d75y	DOSULEPIN HYDROCHLORIDE 25mg capsules
WLGP	d75z	DOSULEPIN HYDROCHLORIDE 75mg tablets
WLGP	d79z	LOFEPRAMINE 70mg tablets

WLGP	d7ex	TRAZODONE HYDROCHLORIDE 50mg capsules
WLGP	da41	FLUOXETINE 20mg capsules
WLGP	da51	SERTRALINE 50mg tablets
WLGP	da52	SERTRALINE 100mg tablets
WLGP	da61	PAROXETINE 20mg tablets
WLGP	da71	VENLAFAXINE 37.5mg tablets
WLGP	da72	VENLAFAXINE 75mg tablets
WLGP	da77	VENLAFAXINE 75mg m/r capsules
WLGP	da91	CITALOPRAM 20mg tablets
WLGP	da93	CITALOPRAM 10mg tablets
WLGP	da95	CITALOPRAM 40mg tablets
WLGP	daB1	MIRTAZAPINE 30mg tablets
WLGP	daB5	MIRTAZAPINE 15mg oro-dispersible tablets
WLGP	daBy	MIRTAZAPINE 45mg tablets
WLGP	daBz	MIRTAZAPINE 15mg tablets
WLGP	daC1	ESCITALOPRAM 10mg tablets
WLGP	dh1z	BETAHISTINE HYDROCHLORIDE 8mg tablets
WLGP	dh4y	CYCLIZINE 50mg tablets
WLGP	dh7x	DOMPERIDONE 10mg tablets
WLGP	dhb1	METOCLOPRAMIDE 10mg tablets
WLGP	dhed	PROCHLORPERAZINE 3mg bucc.tabs
WLGP	dher	PROCHLORPERAZINE 5mg tablets
WLGP	di21	PARACETAMOL 500mg tablets
WLGP	di22	PARACETAMOL 500mg soluble tabs
WLGP	di24	PARACETAMOL 250mg/5mL mixture
WLGP	di2n	PARACETAMOL 120mg/5mL oral suspension
WLGP	di2q	PARACETAMOL 500mg capsules
WLGP	di2s	PARACETAMOL 120mg/5mL sugar free suspension
WLGP	di2u	PARACETAMOL 250mg/5mL sugar free suspension
WLGP	di2x	CALPOL PAEDIATRIC 120mg/5mL suspension
WLGP	di2y	CALPOL PAEDIATRIC 120mg/5mL sugar free suspension
WLGP	dia2	CO-CODAMOL 8mg/500mg tablets
WLGP	dia6	CO-DYDRAMOL tablets

WLGP	dia7	*CO-PROXAMOL tablets
WLGP	dian	PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg tablets
WLGP	diap	CO-CODAMOL 8mg/500mg effervescent tablets
WLGP	diaq	CO-CODAMOL 8mg/500mg capsules
WLGP	diaU	PARACETAMOL+CODEINE PHOSPHATE 500mg/15mg tablets
WLGP	dibD	PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg capsules
WLGP	dj81	DIHYDROCODEINE 30mg tablets
WLGP	dji2	TRAMADOL HCL 50mg capsules
WLGP	dl5A	SUMATRIPTAN 50mg tablets
WLGP	dnj1	GABAPENTIN 100mg capsules
WLGP	dnj2	GABAPENTIN 300mg capsules
WLGP	dnpx	PREGABALIN 75mg capsules
WLGP	du3A	NICOTINE 21mg/24hours patches
WLGP	du3m	NIQUITIN CQ 21mg/24hours patches
WLGP	du3s	NIQUITIN CQ 21mg/24hours clear patches
WLGP	du8x	VARENICLINE 500micrograms+1mg tablets
WLGP	du8z	VARENICLINE 1mg tablets
WLGP	E112	Single major depressive episode
WLGP	E113	Recurrent major depressive episode
WLGP	e153	PHENOXYMETHYLPENICILLIN 250mg tablets
WLGP	e155	PHENOXYMETHYLPENICILLIN 125mg/5mL syrup
WLGP	e157	PHENOXYMETHYLPENICILLIN 250mg/5mL syrup
WLGP	E200	Anxiety states
WLGP	E204	Neurotic depression reactive type
WLGP	E205	Neurasthenia - nervous debility
WLGP	e221	FLUCLOXACILLIN 250mg capsules
WLGP	e222	FLUCLOXACILLIN 500mg capsules
WLGP	E227	Psychosexual dysfunction
WLGP	e22j	FLUCLOXACILLIN 125mg/5mL syrup
WLGP	e22v	FLUCLOXACILLIN 125mg/5mL oral suspension
WLGP	E23.	Alcohol dependence syndrome
WLGP	E24.	Drug dependence
WLGP	E250	Nondependent alcohol abuse

WLGP	E274	Non-organic sleep disorders
WLGP	E278	Psychalgia
WLGP	E2B.	Depressive disorder NEC
WLGP	e311	AMOXICILLIN 250mg capsules
WLGP	e312	AMOXICILLIN 500mg capsules
WLGP	e316	AMOXIL 500mg capsules
WLGP	e31h	AUGMENTIN 375mg tablets
WLGP	e31t	CO-AMOXICLAV 375mg tablets
WLGP	e31U	CO-AMOXICLAV 625mg tablets
WLGP	e31z	CO-AMOXICLAV 250/62 in 5mL suspension
WLGP	e3zk	AMOXICILLIN 125mg/5mL sugar free suspension
WLGP	e3zm	AMOXICILLIN 125mg/5mL syrup
WLGP	e3zn	AMOXICILLIN 250mg/5mL syrup
WLGP	e3zu	AMOXICILLIN 250mg/5mL sugar free suspension
WLGP	e691	CEFALEXIN 250mg capsules
WLGP	e692	CEFALEXIN 500mg capsules
WLGP	e693	CEFALEXIN 250mg tablets
WLGP	e694	CEFALEXIN 500mg tablets
WLGP	e758	DOXYCYCLINE 100mg capsules
WLGP	e76z	LYMECYCLINE 408mg capsules
WLGP	e782	OXYTETRACYCLINE 250mg tablets
WLGP	e911	ERYTHROMYCIN 250mg e/c tablets
WLGP	e91u	ERYTHROMYCIN 125mg/5mL suspension
WLGP	e91v	ERYTHROMYCIN 250mg/5mL suspension
WLGP	e921	CLARITHROMYCIN 250mg tablets
WLGP	e927	CLARITHROMYCIN 500mg tablets
WLGP	ecc1	TRIMETHOPRIM 100mg tablets
WLGP	ecc2	TRIMETHOPRIM 200mg tablets
WLGP	ecc4	TRIMETHOPRIM 50mg/5mL sugar free suspension
WLGP	ef11	METRONIDAZOLE 200mg tablets
WLGP	ef12	METRONIDAZOLE 400mg tablets
WLGP	eg11	NITROFURANTOIN 50mg tablets
WLGP	eg1w	NITROFURANTOIN 100mg m/r capsules

WLGP	eg1y	NITROFURANTOIN 50mg capsules
WLGP	eg6w	CIPROFLOXACIN 500mg tablets
WLGP	eg6x	CIPROFLOXACIN 250mg tablets
WLGP	eh71	NYSTATIN 100,000units/mL suspension
WLGP	eh73	NYSTAN 100,000units/mL suspension
WLGP	eh81	FLUCONAZOLE 50mg capsules
WLGP	eh82	FLUCONAZOLE 150mg capsules
WLGP	eha1	TERBINAFINE 250mg tablets
WLGP	ei15	ACICLOVIR 200mg tablets
WLGP	ei1o	ACICLOVIR 800mg tablets
WLGP	EMIS	NA
WLGP	eq1y	MEBENDAZOLE 100mg tablets
WLGP	eq1z	MEBENDAZOLE 100mg/5mL suspension
WLGP	Eu32	[X]Depressive episode
WLGP	Eu43	[X]Reaction to severe stress, and adjustment disorders
WLGP	F26.	Migraine
WLGP	f41y	METFORMIN HYDROCHLORIDE 500mg tablets
WLGP	F4C0	Acute conjunctivitis
WLGP	F4D0	Blepharitis
WLGP	F4D1	Hordeolum and other deep inflammation of eyelid
WLGP	F501	Infective otitis externa
WLGP	F502	Other otitis externa
WLGP	F504	Impacted cerumen (wax in ear)
WLGP	F51.	Nonsuppurative otitis media + eustachian tube disorders
WLGP	F510	Acute non suppurative otitis media
WLGP	F52.	Suppurative and unspecified otitis media
WLGP	F52z	Otitis media NOS
WLGP	F561	Other and unspecified peripheral vertigo
WLGP	F587	Otalgia
WLGP	F59.	Hearing loss
WLGP	f921	LEVOTHYROXINE SODIUM 25micrograms tablets
WLGP	f922	LEVOTHYROXINE SODIUM 50micrograms tablets
WLGP	fe62	PREDNISOLONE 5mg tablets

WLGP	fe6i	PREDNISOLONE 5mg e/c tablets
WLGP	fg51	NORETHISTERONE 5mg tablets
WLGP	G2..	Hypertensive disease
WLGP	G20.	Essential hypertension
WLGP	g427	CANESTEN-1 500mg vaginal tablets
WLGP	g429	CLOTTRIMAZOLE 1% cream
WLGP	g42A	CANESTEN COMBI pessary+cream
WLGP	g42r	CLOTTRIMAZOLE 500mg+2% pessary+cream
WLGP	g42v	CLOTTRIMAZOLE 2% vaginal cream
WLGP	g42x	CLOTTRIMAZOLE 200mg vaginal tablets
WLGP	g42y	CLOTTRIMAZOLE 500mg vaginal tablets
WLGP	g42z	CLOTTRIMAZOLE 10% cream
WLGP	g811	MARVELON tablets
WLGP	g832	LOGYNON tablets
WLGP	g834	MICROGYNON-30 tablets
WLGP	g837	OVRANETTE tablets
WLGP	g838	*SCHERING-PC4 tablets
WLGP	g83D	MICROGYNON 30 ED tablets
WLGP	g83G	RIGEVIDON tablets
WLGP	G84.	Haemorrhoids
WLGP	g891	CILEST tablets
WLGP	g8A1	YASMIN tablets
WLGP	ga27	MIRENA 52mg intrauterine system
WLGP	ga29	*LEVONELLE-2 tablets
WLGP	ga2B	LEVONORGESTREL 1.5mg tablets
WLGP	ga2D	LEVONELLE 1500micrograms tablets
WLGP	ga36	DEPO-PROVERA 150mg/1mL prefilled syringe
WLGP	ga53	NORIDAY tablets 84CP
WLGP	ga8B	CERAZETTE 75micrograms tablets
WLGP	ga8C	CERELLE 75micrograms tablets
WLGP	gdew	DULOXETINE 60mg gastro-resistant capsules
WLGP	gdex	DULOXETINE 30mg gastro-resistant capsules
WLGP	H00.	Acute nasopharyngitis

WLGP	H01.	Acute sinusitis
WLGP	H02.	Acute pharyngitis
WLGP	H03.	Acute tonsillitis
WLGP	H037	Recurrent acute tonsillitis
WLGP	H040	Acute laryngitis
WLGP	H05z	Upper respiratory infection NOS
WLGP	H060	Acute bronchitis
WLGP	H06z	Acute bronchitis or bronchiolitis NOS
WLGP	H120	Chronic rhinitis
WLGP	H17.	Allergic rhinitis
WLGP	H170	Allergic rhinitis due to pollens
WLGP	H27z	Influenza NOS
WLGP	H33.	Asthma
WLGP	H333	Acute exacerbation of asthma
WLGP	hc21	DEPO-PROVERA 450mg/3mL injection
WLGP	i11t	FERROUS FUMARATE 210mg tablets
WLGP	i151	FERROUS SULFATE 200mg tablets
WLGP	i16d	PREGADAY tablets
WLGP	i332	FOLIC ACID 5mg tablets
WLGP	i334	FOLIC ACID 400micrograms tablets
WLGP	i81j	DIORALYTE blackcurrant oral powder
WLGP	in45	THIAMINE HYDROCHLORIDE 100mg tablets
WLGP	in72	VITAMIN-B-CO STRONG tablets
WLGP	J025	Periapical abscess without a sinus
WLGP	J082	Oral aphthae
WLGP	J101	Oesophagitis
WLGP	J10y	Other oesophageal disorders
WLGP	j112	ASPIRIN 300mg dispersible tablets
WLGP	J15.	Gastritis and duodenitis
WLGP	J16y	Other specified stomach function disorders
WLGP	j22e	DICLOFENAC 50mg e/c tablets
WLGP	j281	IBUPROFEN 200mg tablets
WLGP	j282	IBUPROFEN 400mg tablets

WLGP	j283	IBUPROFEN 600mg tablets
WLGP	j28w	IBUPROFEN 100mg/5mL syrup
WLGP	j28Y	IBUPROFEN 100mg/5mL sugar free syrup
WLGP	j2b1	MEFENAMIC ACID 250mg capsules
WLGP	j2bx	MEFENAMIC ACID 500mg tablets
WLGP	j2c1	NAPROXEN 250mg tablets
WLGP	j2c2	NAPROXEN 500mg tablets
WLGP	j2cl	NAPROXEN 500mg e/c tablets
WLGP	J43.	Other non-infective inflammatory gastroenteritis and colitis
WLGP	J520	Constipation - functional
WLGP	J521	Irritable colon - Irritable bowel syndrome
WLGP	J573	Haemorrhage of rectum and anus
WLGP	ja18	ALGESAL 10% cream
WLGP	ja1U	IBUPROFEN 5% gel
WLGP	ja2S	CAPSAICIN 0.025% cream
WLGP	ja2z	IBUPROFEN 10% gel
WLGP	K15.	Cystitis
WLGP	K190	Urinary tract infection, site not specified
WLGP	K28y	Other male genital organ diseases OS
WLGP	K310	Inflammatory breast disease
WLGP	K317	Breast signs and symptoms
WLGP	k321	CHLORAMPHENICOL 0.5% eye drops
WLGP	k32w	CHLORAMPHENICOL 1% eye ointment
WLGP	k3g1	FUSIDIC ACID 1% eye drops
WLGP	k3g2	*FUCITHALMIC 1% eye drops 5g
WLGP	K421	Vaginitis and vulvovaginitis
WLGP	K583	Dysmenorrhoea
WLGP	K59.	Menstruation disorders
WLGP	K590	Absence of menstruation
WLGP	K592	Excessive or frequent menstruation
WLGP	K594	Irregular menstrual cycle
WLGP	K596	Metrorrhagia
WLGP	K59y	Other menstruation disorders

WLGP	k69y	SODIUM CROMOGLICATE 2% eye drops
WLGP	L04.	Spontaneous abortion
WLGP	L13.	Excessive pregnancy vomiting
WLGP	L20.	Normal delivery in a completely normal case
WLGP	I322	CLIOQUINOL+FLUMETASONE PIV 1%/0.02% ear drops
WLGP	I323	LOCORTEN-VIOFORM ear drops 10mL
WLGP	I355	GENTISONE HC ear drops 10mL
WLGP	I35z	GENTAMICIN+HYDROCORTISONE ACETATE 0.3%/1% ear drops
WLGP	L398	Caesarean delivery
WLGP	I415	SOFRADEX EYE/EAR drops 10mL
WLGP	I41b	OTOMIZE ear spray 5mL
WLGP	I713	SODIUM BICARBONATE ear drops
WLGP	I715	CERUMOL ear drops 11mL
WLGP	I71m	OLIVE OIL ear drops 10mL
WLGP	I812	BECONASE AQUEOUS 50microgram nasal spray
WLGP	I81z	BECLOMETASONE 50micrograms aqueous nasal spray
WLGP	I886	AVAMYS 27.5micrograms nasal spray
WLGP	I8Dz	MOMETASONE FUROATE MONOHYDRATE 0.05% aqueous nasal spray
WLGP	Ia15	NASEPTIN cream 15g
WLGP	Ib11	DIFFLAM 0.15% oral rinse 300mL
WLGP	Ib12	DIFFLAM 0.15% mouth and throat spray
WLGP	Ib1y	BENZYDAMINE HYDROCHLORIDE 0.15% oral rinse
WLGP	Ib1z	BENZYDAMINE HYDROCHLORIDE 0.15% mouth and throat spray
WLGP	Ic42	DAKTARIN oral gel 80g
WLGP	M0..	Skin and subcutaneous tissue infections
WLGP	M01z	Boil NOS
WLGP	M020	Cellulitis and abscess of finger
WLGP	M03z	Cellulitis and abscess NOS
WLGP	M05.	Impetigo
WLGP	M07z	Local infection skin/subcut tissue NOS
WLGP	M0z.	Skin and subcut tissue infection NOS
WLGP	M101	Seborrhoeic dermatitis
WLGP	m111	AQUEOUS cream

WLGP	M111	Atopic dermatitis/eczema
WLGP	m115	DIPROBASE cream 50g
WLGP	m11a	DIPROBASE dispenser cream 500g
WLGP	M12.	Contact dermatitis and other eczemas
WLGP	m122	EMULSIFYING ointment
WLGP	m12c	DIPROBASE ointment 50g
WLGP	M12z	Contact dermatitis NOS
WLGP	M153	Rosacea
WLGP	M161	Other psoriasis
WLGP	m210	DOUBLEBASE gel 500g
WLGP	m21R	E45 cream 500g pump
WLGP	M21z	Skin atrophy/hypertrophy NOS
WLGP	m22G	HYDROMOL ointment 125g
WLGP	M230	Ingrowing nail
WLGP	m23o	SUDOCREM cream 30g
WLGP	M240	Alopecia
WLGP	M244	Folliculitis
WLGP	m25k	OILATUM EMOLLIENT bath additive 500mL
WLGP	M261	Other acne
WLGP	M262	Sebaceous cyst - wen
WLGP	m272	DERMOL 500 lotion
WLGP	M28.	Urticaria
WLGP	M2yz	Other skin and subcutaneous tissue disease NOS
WLGP	m313	CALAMINE lotion
WLGP	m412	HYDROCORTISONE 1% cream 30g
WLGP	m414	HYDROCORTISONE 1% cream 100g
WLGP	m419	*HYDROCORTISONE 0.5% cream 50g
WLGP	m42D	HYDROCORTISONE 1% ointment 50g
WLGP	m453	CANESTEN-HC cream 30g
WLGP	m454	DAKTACORT cream 30g
WLGP	m458	FUCIDIN-H cream 30g
WLGP	m45A	FUCIDIN-H cream 60g
WLGP	m45s	TIMODINE cream 30g

WLGP	m45v	DAKTACORT ointment 30g
WLGP	m45V	HYDROCORTISONE ACETATE+FUSIDIC ACID 1%/2% cream
WLGP	m45Y	HYDROCORTISONE+MICONAZOLE NITRATE 1%/2% cream
WLGP	m45Z	HYDROCORTISONE+CLOTRIMAZOLE 1%/1% cream
WLGP	m483	BETNOVATE 0.1% cream 100g
WLGP	m48o	BETAMETHASONE 0.1% scalp application
WLGP	m48q	BETAMETHASONE 0.1% cream
WLGP	m48r	BETAMETHASONE 0.1% ointment
WLGP	m49d	FUCIBET cream 30g
WLGP	m49v	BETAMETHASONE+FUCIDIC ACID 0.1%/2% cream
WLGP	m4b1	EUMOVATE 0.05% cream 30g
WLGP	m4b7	EUMOVATE 0.05% cream 15g
WLGP	m4by	CLOBETASONE 0.05% cream
WLGP	m673	ZINERYT lotion 30mL
WLGP	m676	ERYTHROMYCIN+ZINC ACETATE 40mg/12mg/mL topical solution
WLGP	m677	ZINERYT lotion 90mL
WLGP	m68C	DUAC ONCE DAILY gel 50g
WLGP	m816	SALACTOL 16.7% paint 10mL
WLGP	m818	SALATAC 12% gel 8g
WLGP	mb1v	KETOCONAZOLE 20mg/mL shampoo
WLGP	mb1z	CAPASAL shampoo 250mL
WLGP	mc5y	MUPIROCIN 2% cream
WLGP	md21	FUCIDIN 2% cream 15g
WLGP	md2v	FUSIDIC ACID 2% cream
WLGP	me41	CANESTEN 1% cream 20g
WLGP	me4w	CLOTRIMAZOLE 1% cream
WLGP	me71	MICONAZOLE 2% cream
WLGP	me78	DAKTARIN 2% cream 30g
WLGP	mejz	TERBINAFINE HYDROCHLORIDE 1% cream
WLGP	mf11	ZOVIRAX 5% cream 2g
WLGP	mf1z	ACICLOVIR 5% cream
WLGP	mg5x	MALATHION 0.5% liquid
WLGP	mg77	*FULL MARKS liquid 200mL

WLGP	mg7C	*FULL MARKS 0.2% lotion 50mL
WLGP	mg81	PERMETHRIN 1% scalp application
WLGP	mg82	LYCLEAR 1% cream rinse 59mL
WLGP	mg83	PERMETHRIN 5% cream 30g
WLGP	mg84	LYCLEAR 5% cream 30g
WLGP	N094	Pain in joint - arthralgia
WLGP	N131	Cervicalgia - pain in neck
WLGP	N142	Pain in lumbar spine
WLGP	N143	Sciatica
WLGP	N145	Backache, unspecified
WLGP	N213	Enthesopathy of the elbow region
WLGP	N217	Enthesopathy of the ankle and tarsus
WLGP	N224	Ganglion and cyst of synovium, tendon and bursa
WLGP	N241	Myalgia and myositis unspecified
WLGP	N245	Pain in limb
WLGP	N247	Other musculoskeletal limb symptoms
WLGP	n45n	REVAXIS suspension for injection 0.5mL prefilled syringe
WLGP	n4h2	TYPHIM VI VACCINE 25microgram/0.5mL prefilled syringe
WLGP	p161	MELOLIN 5x5cm dressing
WLGP	p1n1	INADINE 5cmx5cm dressing
WLGP	p436	VOLUMATIC spacer device
WLGP	p43F	AEROCHAMBER spacer device
WLGP	p46E	STANDARD RANGE EN13826 peak flow meter
WLGP	p5j8	MICROPORE 2.5cmx5m tape
WLGP	R002	[D]Syncope and collapse
WLGP	R003	[D]Convulsions
WLGP	R004	[D]Dizziness and giddiness
WLGP	R005	[D]Sleep disturbances
WLGP	R006	[D]Pyrexia of unknown origin
WLGP	R00z	[D]Other general symptoms
WLGP	R021	[D]Rash and other nonspecific skin eruption
WLGP	R022	[D]Local superficial swelling, mass or lump
WLGP	R040	[D]Headache

WLGP	R056	[D]Lymph node enlargement
WLGP	R060	[D]Respiratory abnormalities
WLGP	R062	[D]Cough
WLGP	R065	[D]Chest pain
WLGP	R090	[D]Abdominal pain
WLGP	S234	Closed fracture of radius and ulna, lower end
WLGP	S242	Fracture at wrist and hand level
WLGP	S25.	Fracture of metacarpal bone
WLGP	S26.	Fracture of one or more phalanges of hand
WLGP	S3z.	Fracture of unspecified bones
WLGP	S550	Ankle sprain
WLGP	S570	Neck sprain
WLGP	S646	Head injury
WLGP	S8z.	Open wound of head, neck and trunk NOS
WLGP	SD..	Superficial injury
WLGP	SK13	Other elbow, forearm and wrist injuries
WLGP	SK17	Other knee, leg, ankle and foot injuries
WLGP	SL..	Poisoning
WLGP	SN53	Allergy, unspecified
WLGP	SP25	Postoperative infection
WLGP	T1..	Motor vehicle traffic accidents (MVTA)
WLGP	TC..	Accidental falls
WLGP	TE60	Dog bite
WLGP	TK..	Suicide and selfinflicted injury
WLGP	U3..	[X]Assault
WLGP	ZV25	[V]Contraceptive management
WLGP	ZV27	[V]Outcome of delivery
WLGP	ZV40	[V]Mental and behavioural problems
WLGP	ZV58	[V]Other and unspecified aftercare
WLGP	ZV68	[V]Administrative encounters
WLGP	ZV6D	[V]Person consulting for counselling or advice
WLGP	ZV76	[V]Screening for malignant neoplasm
WLGP	663e0	Asthma sometimes restricts exercise

WLGP	1151	No known allergies
WLGP	1225	No FH: Stroke/TIA
WLGP	1226	No FH: Ischaemic heart disease
WLGP	1227	No FH: Hypertension
WLGP	1228	No family history diabetes
WLGP	1252	FH: Diabetes mellitus
WLGP	1331	Single
WLGP	1361	Teetotaler
WLGP	1362	Trivial drinker - <1u/day
WLGP	1363	Light drinker - 1-2u/day
WLGP	1364	Moderate drinker - 3-6u/day
WLGP	1367	Stopped drinking alcohol
WLGP	1371	Never smoked tobacco
WLGP	1372	Trivial smoker - < 1 cig/day
WLGP	1373	Light smoker - 1-9 cigs/day
WLGP	1374	Moderate smoker - 10-19 cigs/d
WLGP	1375	Heavy smoker - 20-39 cigs/day
WLGP	1379	Ex-moderate smoker (10-19/day)
WLGP	1382	Avoids even trivial exercise
WLGP	1383	Enjoys light exercise
WLGP	1384	Enjoys moderate exercise
WLGP	1465	H/O: depression
WLGP	1513	Last menstrual period -1st day
WLGP	1514	Estimated date of confinement
WLGP	1519	Wishes to postpone menstruatn.
WLGP	1683	Tired all the time
WLGP	1717	Night cough present
WLGP	1718	Night cough absent
WLGP	1719	Chesty cough
WLGP	1737	Wheezing
WLGP	1739	Shortness of breath
WLGP	1955	Heartburn
WLGP	1969	Abdominal pain

WLGP	1972	Epigastric pain
WLGP	1977	Right iliac fossa pain
WLGP	1978	Left iliac fossa pain
WLGP	1982	Nausea present
WLGP	1992	Vomiting
WLGP	2126	Patient's condition improved
WLGP	2128	Patient's condition the same
WLGP	2227	O/E - rash present
WLGP	2315	Resp. system examined - NAD
WLGP	2431	O/E - pulse rhythm regular
WLGP	2464	O/E - BP reading normal
WLGP	2516	Abdomen examined - NAD
WLGP	3212	Standard ECG
WLGP	3386	Lung vital capacity
WLGP	3395	Peak exp. flow rate: PEFR/PFR
WLGP	3396	Forced vital capacity - FVC
WLGP	4131	Blood test requested
WLGP	4141	Stool sample sent to lab.
WLGP	4142	Blood sample -> Haematol Lab
WLGP	4143	Blood sample -> Biochem Lab
WLGP	4145	Blood sample -> Lab NOS
WLGP	4146	Urine sample sent to Lab
WLGP	4147	Swab sent to Lab
WLGP	4257	Packed cell volume
WLGP	4258	Haematocrit
WLGP	4266	Nucleated red blood cell count
WLGP	4426	Serum T4 level
WLGP	4427	Free T4 level
WLGP	4434	Follicle stim. hormone - F.S.H
WLGP	4463	Serum progesterone
WLGP	4465	Serum oestradiol level
WLGP	4473	Serum testosterone
WLGP	4474	Free androgen index

WLGP	4613	Urinalysis = no abnormality
WLGP	4615	MSU sent to lab.
WLGP	4618	Urine dipstick test
WLGP	4652	Urine pregnancy test negative
WLGP	4655	High sensitivity urine pregnancy test
WLGP	4661	Urine glucose test not done
WLGP	4662	Urine glucose test negative
WLGP	4671	Urine protein test not done
WLGP	4672	Urine protein test negative
WLGP	4682	Urine ketone test negative
WLGP	4692	Urine blood test = negative
WLGP	5254	Plain X-ray cervical spine
WLGP	5256	Plain X-ray lumbar spine
WLGP	5853	U-S heart scan
WLGP	5855	U-S abdominal scan
WLGP	5856	U-S pelvic scan
WLGP	5882	Spirometry
WLGP	6141	Oral contraceptive started
WLGP	6144	Oral contraceptive repeat
WLGP	6147	Combined oral contraceptive
WLGP	6148	Progestagen only oral contrac.
WLGP	6151	IUD fitted
WLGP	6152	IUD removed
WLGP	6154	IUD checked - no problems
WLGP	6219	Patient ? pregnant
WLGP	6331	Single live birth
WLGP	6521	First typhoid vaccination
WLGP	6523	Booster typhoid vaccination
WLGP	6541	First diphtheria vaccination
WLGP	6542	Second diphtheria vaccination
WLGP	6543	Third diphtheria vaccination
WLGP	6544	Booster diphtheria vaccination
WLGP	6551	First pertussis vaccination

WLGP	6552	Second pertussis vaccination
WLGP	6553	Third pertussis vaccination
WLGP	6561	First tetanus vaccination
WLGP	6562	Second tetanus vaccination
WLGP	6563	Third tetanus vaccination
WLGP	6564	Booster tetanus vaccination
WLGP	6571	Meningitis vaccination
WLGP	6572	Pneumococcal vaccination
WLGP	6581	First polio vaccination
WLGP	6582	Second polio vaccination
WLGP	6583	Third polio vaccination
WLGP	6584	Booster polio vaccination
WLGP	6636	Inhaler technique shown
WLGP	6637	Inhaler technique observed
WLGP	6775	Sterilisation counselling
WLGP	6776	Preg. termination counselling
WLGP	6777	Contraception counselling
WLGP	6781	Health education offered
WLGP	6791	Health ed. - smoking
WLGP	6792	Health ed. - alcohol
WLGP	6793	Health ed. - cervical cytology
WLGP	6795	Health ed. - breast exam.
WLGP	6798	Health ed. - exercise
WLGP	6799	Health ed. - diet
WLGP	6852	Ca cervix screen - offered
WLGP	6853	Ca cervix screen - not wanted
WLGP	6857	Ca cervix screen -not attended
WLGP	6859	Ca cervix - screen done
WLGP	6862	Breast neoplasm screen
WLGP	6896	Depression screening using questions
WLGP	7530	Excision of tonsil
WLGP	7700	Emergency excision of appendix
WLGP	8923	Consent given for minor surgery procedure

WLGP	21262	Asthma resolved
WLGP	7E004	Large loop excision transformation zone
WLGP	73050	Irrigation of external auditory canal for removal of wax
WLGP	7E094	Introduction of Mirena coil
WLGP	0....	Occupations
WLGP	1....	History / symptoms
WLGP	12...	Family history
WLGP	122..	No relevant family history
WLGP	124..	FH: Neoplasm - *
WLGP	12C..	FH: Cardiovascular disease
WLGP	12C1.	FH: Hypertension
WLGP	12C2.	FH: Ischaemic heart dis. <60
WLGP	12C3.	FH: Ischaemic heart dis. >60
WLGP	12C4.	FH: CVA/stroke
WLGP	12C5.	FH: Myocardial infarction
WLGP	12D2.	FH: Asthma
WLGP	133F.	Marital state unknown
WLGP	136..	Alcohol consumption
WLGP	136J.	Social drinker
WLGP	137G.	Trying to give up smoking
WLGP	137L.	Current non-smoker
WLGP	137P.	Cigarette smoker
WLGP	137R.	Current smoker
WLGP	137S.	Ex smoker
WLGP	138..	Exercise grading
WLGP	138Z.	Exercise grading NOS
WLGP	13A..	Diet - patient initiated
WLGP	13AZ.	Patient initiated diet NOS
WLGP	13H7.	Unwanted pregnancy
WLGP	13Hc.	Bereavement
WLGP	13HT1	Stress at home
WLGP	13IM.	Child on protection register
WLGP	13J..	Employment milestones

WLGP	13J7.	Unemployed
WLGP	13JM.	Problems at work
WLGP	14...	Past medical history
WLGP	141B.	H/O: viral illness
WLGP	146B.	H/O: deliberate self harm
WLGP	14a..	History of road traffic accident
WLGP	14B4.	H/O: asthma
WLGP	14F1.	H/O: eczema
WLGP	14G3.	H/O: significant knee disorder
WLGP	14G9.	H/O: fracture
WLGP	14L..	H/O: drug allergy
WLGP	14L1.	H/O: penicillin allergy
WLGP	14M..	H/O: non-drug allergy
WLGP	14Q..	H/O: regular medication
WLGP	15...	Gynaecological history
WLGP	151..	Menstrual data
WLGP	152..	Parity status
WLGP	158..	H/O: abnormal uterine bleeding
WLGP	15D..	Dyspareunia
WLGP	16...	General symptoms
WLGP	165..	Temperature symptoms
WLGP	168..	Tiredness symptom
WLGP	16C..	Backache symptom
WLGP	16C2.	Backache
WLGP	16C5.	C/O - low back pain
WLGP	16C6.	Back pain without radiation NOS
WLGP	16E..	Feels unwell
WLGP	171..	Cough
WLGP	173..	Breathlessness
WLGP	173B.	Nocturnal cough / wheeze
WLGP	173I.	MRC Breathlessness Scale: grade 2
WLGP	181..	Palpitations
WLGP	182..	Chest pain

WLGP	182B.	Rib pain
WLGP	191..	Tooth symptoms
WLGP	196..	Type of GIT pain
WLGP	197C.	Lower abdominal pain
WLGP	198..	Nausea
WLGP	199..	Vomiting
WLGP	19B..	Flatulence/wind
WLGP	19C..	Constipation
WLGP	19F..	Diarrhoea symptoms
WLGP	19FZ.	Diarrhoea symptom NOS
WLGP	19G..	Diarrhoea and vomiting
WLGP	1A...	Genitourinary symptoms
WLGP	1A1..	Micturition frequency
WLGP	1A53.	Lumbar ache - renal
WLGP	1A55.	Dysuria
WLGP	1A59.	C/O pelvic pain
WLGP	1A7..	Vaginal discharge symptom
WLGP	1A8..	Breast lump symptom
WLGP	1AZ2.	Fertility problem
WLGP	1B13.	Anxiousness
WLGP	1B17.	Depressed
WLGP	1B1B.	Cannot sleep - insomnia
WLGP	1B1G.	Headache
WLGP	1B1L.	Stress related problem
WLGP	1B1U.	Symptoms of depression
WLGP	1B1X.	Behavioural problem
WLGP	1B5..	Incoordination symptom
WLGP	1B6..	Disturbance of consciousness
WLGP	1B8..	Eye symptoms
WLGP	1BA5.	Frontal headache
WLGP	1BD1.	Suicidal ideation
WLGP	1BO..	Mood swings
WLGP	1BT..	Depressed mood

WLGP	1C...	Ear/nose/throat symptoms
WLGP	1C12.	Hearing difficulty
WLGP	1C14.	Blocked ear
WLGP	1C3..	Earache symptoms
WLGP	1C6..	Nose bleed symptom
WLGP	1C8..	Nasal symptoms OS
WLGP	1C9..	Sore throat symptom
WLGP	1D11.	C/O: a swelling
WLGP	1D13.	C/O: a pain
WLGP	1D14.	C/O: a rash
WLGP	1D15.	C/O: itching
WLGP	1FA..	Diet good
WLGP	1J...	Suspected condition
WLGP	1J4..	Suspected UTI
WLGP	1M...	Pain
WLGP	1M10.	Knee pain
WLGP	1M11.	Foot pain
WLGP	2....	Examination / Signs
WLGP	212G.	Asthma resolved
WLGP	229..	O/E - height
WLGP	22A..	O/E - weight
WLGP	22K..	Body Mass Index
WLGP	22K4.	Body mass index index 25-29 - overweight
WLGP	22K5.	Body mass index 30+ - obesity
WLGP	22K8.	Body mass index 20-24 - normal
WLGP	22N0.	Waist circumference
WLGP	23...	Examn. of respiratory system
WLGP	235..	O/E - rate of respiration
WLGP	24...	Exam. of cardiovascular system
WLGP	242..	O/E - pulse rate
WLGP	246..	O/E - blood pressure reading
WLGP	26...	Exam. of genitourinary system
WLGP	26B..	O/E - general breast exam.

WLGP	271..	O/E - gravid uterus size
WLGP	277..	O/E - VE for pelvic assessment
WLGP	2B6..	O/E - visual acuity R-eye
WLGP	2B7..	O/E - visual acuity L-eye
WLGP	2D...	Ear, nose + throat examination
WLGP	2D7..	O/E - painful ear
WLGP	2D82.	O/E - wax in auditory canal
WLGP	2E27.	O/E - tympanic temperature
WLGP	2E3..	O/E - level of fever
WLGP	2E31.	O/E - temperature normal
WLGP	2F13.	O/E - dry skin
WLGP	2FD..	O/E - skin cyst
WLGP	2G5E.	O/E - Right diabetic foot at low risk
WLGP	2G5I.	O/E - Left diabetic foot at low risk
WLGP	2I11.	O/E - a lump
WLGP	32...	Electrocardiography
WLGP	332..	Tuberculin test - mantoux
WLGP	339A.	Peak flow rate before bronchodilation
WLGP	339B.	Peak flow rate after bronchodilation
WLGP	339M.	FEV1/FVC ratio
WLGP	339O.	Forced expired volume in 1 second
WLGP	339R.	FEV1/FVC percent
WLGP	339S.	Percent predicted FEV1
WLGP	388f.	Patient health questionnaire (PHQ-9) score
WLGP	388P.	HAD scale: depression score
WLGP	38DP.	QRISK2 cardiovascular disease 10 year risk score
WLGP	38G5.	Biopsychosocial assessment
WLGP	4....	Laboratory procedures
WLGP	41...	Laboratory procedures -general
WLGP	413..	Laboratory test requested
WLGP	414..	Sample sent to lab. for test
WLGP	41B1.	Blood test due
WLGP	41C..	Patient informed - test result

WLGP	41C2.	Test result to pat.by 'phone
WLGP	41C3.	Test result to pat.personally
WLGP	41D0.	Blood sample taken
WLGP	42...	Haematology
WLGP	421B.	Blood film microscopy
WLGP	423..	Haemoglobin estimation
WLGP	424..	Full blood count - FBC
WLGP	425..	Haematocrit - PCV
WLGP	426..	Red blood cell (RBC) count
WLGP	428..	Mean corpusc. haemoglobin(MCH)
WLGP	429..	Mean corpusc. Hb. conc. (MCHC)
WLGP	42A..	Mean corpuscular volume (MCV)
WLGP	42B..	Plasma viscosity
WLGP	42B6.	Erythrocyte sedimentation rate
WLGP	42d1.	Transferrin saturation index
WLGP	42g..	Haematology test
WLGP	42H..	Total white cell count
WLGP	42h0.	Clotting screening test
WLGP	42J..	Neutrophil count
WLGP	42jG.	APTT
WLGP	42K..	Eosinophil count
WLGP	42L..	Basophil count
WLGP	42M..	Lymphocyte count
WLGP	42N..	Monocyte count
WLGP	42P..	Platelet count
WLGP	42Q5.	Prothrombin time
WLGP	42QE.	International normalised ratio
WLGP	42Qn.	Fibrinogen level
WLGP	42R4.	Serum ferritin
WLGP	42R7.	Serum iron level
WLGP	42T..	Serum vitamin B12
WLGP	42U5.	Serum folate
WLGP	42W4.	HbA1c level (DCCT aligned)

WLGP	42W5.	Haemoglobin A1c level - International Federation of Clinical Chemistry and Laboratory Medicine standardised
WLGP	42YD.	B12/folate level
WLGP	42Z5.	Mean platelet volume
WLGP	42Z7.	Red blood cell distribution width
WLGP	43A..	Infectious mononucleosis test
WLGP	43aC.	Anti-tissue transglutaminase level
WLGP	43ad.	Tissue transglutaminase IgA level
WLGP	43F..	Rheumatoid factor
WLGP	43J3.	IgG
WLGP	43J4.	IgM
WLGP	43J5.	IgA
WLGP	43U..	Chlamydia antigen test
WLGP	43U3.	Chlamydia trachomatis antigen test
WLGP	43W9.	Helicobacter pylori IgG antibody level
WLGP	43WA.	Helicobacter pylori antibody level
WLGP	442..	Thyroid hormone tests
WLGP	442A.	TSH - thyroid stim. hormone
WLGP	442J.	Thyroid function test
WLGP	442V.	Serum free T4 level
WLGP	442W.	Serum TSH level
WLGP	443e.	Serum LH level
WLGP	443h.	Serum FSH level
WLGP	443j.	Serum prolactin level
WLGP	445..	Serum pregnancy test (B-HCG)
WLGP	44a60	Serum CA 125 (cancer antigen 125) level
WLGP	44CB.	Serum transferrin
WLGP	44CC.	Plasma C reactive protein
WLGP	44CD.	Serum sex hormone binding globulin level
WLGP	44CN.	Serum amylase level
WLGP	44CS.	Serum C reactive protein level
WLGP	44D..	Liver function tests - general
WLGP	44D6.	Liver function test

WLGP	44E..	Serum bilirubin level
WLGP	44E3.	Total bilirubin
WLGP	44EC.	Serum total bilirubin level
WLGP	44F..	Serum alkaline phosphatase
WLGP	44f..	Serum glucose level
WLGP	44f0.	Serum random glucose level
WLGP	44f1.	Serum fasting glucose level
WLGP	44F3.	Total alkaline phosphatase
WLGP	44G..	Liver enzymes
WLGP	44g..	Plasma glucose level
WLGP	44g0.	Plasma random glucose level
WLGP	44g1.	Plasma fasting glucose level
WLGP	44G3.	ALT/SGPT serum level
WLGP	44G4.	Gamma - G.T. level
WLGP	44G9.	Serum gamma-glutamyl transferase level
WLGP	44GB.	Serum alanine aminotransferase level
WLGP	44h0.	Blood potassium level
WLGP	44HB.	AST serum level
WLGP	44HG.	Serum creatine kinase level
WLGP	44I..	Serum electrolytes
WLGP	44I4.	Serum potassium
WLGP	44I5.	Serum sodium
WLGP	44I7.	Serum bicarbonate
WLGP	44I8.	Serum calcium
WLGP	44I9.	Serum inorganic phosphate
WLGP	44IC.	Corrected serum calcium level
WLGP	44J..	Blood urea/renal function
WLGP	44J3.	Serum creatinine
WLGP	44J5.	Renal profile
WLGP	44J9.	Serum urea level
WLGP	44JB.	Urea and electrolytes
WLGP	44K5.	Serum urate level
WLGP	44IF.	Serum cholesterol/HDL ratio

WLGP	44IL.	Serum LDL/HDL ratio
WLGP	44M3.	Serum total protein
WLGP	44M4.	Serum albumin
WLGP	44M5.	Serum globulin
WLGP	44MV.	Serum protein profile
WLGP	44O..	Serum lipids
WLGP	44O5.	Fasting blood lipids
WLGP	44p..	Biochemical test
WLGP	44P..	Serum cholesterol
WLGP	44P5.	Serum HDL cholesterol level
WLGP	44P6.	Serum LDL cholesterol level
WLGP	44PA.	HDL : LDL ratio
WLGP	44PF.	Total cholesterol:HDL ratio
WLGP	44PL.	Non HDL cholesterol level
WLGP	44Q..	Serum triglycerides
WLGP	44q4.	Urine opiates screening test
WLGP	44qF.	Urine amphetamine screening test
WLGP	44T1.	Random blood sugar
WLGP	44TJ.	Blood glucose level
WLGP	44TK.	Fasting blood glucose level
WLGP	44U..	Blood glucose result
WLGP	44YA.	Blood oxygen saturation
WLGP	44YA0	Oxygen saturation at periphery
WLGP	44Z2.	Bone profile
WLGP	44Z3.	Serum total HCG level
WLGP	451..	Renal function tests
		Glomerular filtration rate calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation
WLGP	451E.	
WLGP	451F.	Glomerular filtration rate
WLGP	46...	Urine examination
WLGP	461..	Urine exam. - general
WLGP	465..	Urine pregnancy test
WLGP	466..	Urine test for glucose

WLGP	467..	Urine protein test
WLGP	46M7.	Urine creatinine
WLGP	46N..	Urine protein
WLGP	46N4.	Urine albumin
WLGP	46Q8.	Urine benzodiazepine
WLGP	46QB.	Urine methadone
WLGP	46QH.	Urine cocaine metabolite screen
WLGP	46TC.	Urine albumin:creatinine ratio
WLGP	46U..	Urine culture
WLGP	46W..	Urine microalbumin
WLGP	46X1.	Urine nitrite negative
WLGP	47D3.	Stool culture
WLGP	4I16.	Microscopy, culture and sensitivities
WLGP	4I19.	Urinary microscopy, culture and sensitivities
WLGP	4I1A.	Enteric microscopy, culture and sensitivities
WLGP	4I1B.	Mycology microscopy, culture and sensitivities
WLGP	4I1C.	Genital microscopy, culture and sensitivities
WLGP	4I1E.	Respiratory microscopy, culture and sensitivities
WLGP	4I1F.	Wound microscopy, culture and sensitivities
WLGP	4I2D.	Wound exudate sample
WLGP	4J...	Microbiology
WLGP	4J17.	Sample culture
WLGP	4J3A.	Viral studies
WLGP	4J..	Urine sample for organism
WLGP	4J1.	MSU sent for C/S
WLGP	4JK2.	High vaginal swab taken
WLGP	4JK9.	Endocervical chlamydia swab
WLGP	4K...	General pathology
WLGP	4K1..	Histology
WLGP	4K1D.	Histology laboratory test
WLGP	4K2..	Cervical smear result
WLGP	4K21.	Cervical smear:inadequate spec
WLGP	4K22.	Cervical smear: negative

WLGP	4K23.	Cerv.smear: mild dyskaryosis
WLGP	4K24.	Cerv.smear: severe dyskaryosis
WLGP	4K28.	Cerv.smear: mod.dyskaryosis
WLGP	4K29.	Cerv.smear: borderline changes
WLGP	4K31.	Cervical smear-no inflammation
WLGP	4K54.	Cytology laboratory test
WLGP	4K55.	Cervical cytology test
WLGP	4Q72.	Calcium level
WLGP	4Q721	Calcium adjusted level
WLGP	5....	Radiology/physics in medicine
WLGP	511..	Radiology - general
WLGP	52...	Plain radiography
WLGP	525..	Plain X-ray spine
WLGP	527..	Plain X-ray pelvis
WLGP	529..	Plain X-ray hand
WLGP	52A..	Plain X-ray hip/leg
WLGP	52A7.	Plain X-ray knee
WLGP	52B..	Plain X-ray foot
WLGP	535..	Standard chest X-ray
WLGP	537..	Soft tissue X-ray breast
WLGP	567..	Computerised axial tomography
WLGP	569..	Nuclear magnetic resonance
WLGP	585..	Other diagnostic ultrasound
WLGP	58D..	Ultrasound scan
WLGP	61...	Contraception
WLGP	611..	General contraceptive advice
WLGP	614..	Oral contraceptive
WLGP	614D.	Oral contraceptive prescribed
WLGP	614E.	Oral contraceptive advice
WLGP	61A..	Post-coital contraception
WLGP	61B..	Depot contraceptive
WLGP	61B1.	Depot contraceptive given
WLGP	61M..	Emergency contraception

WLGP	62...	Patient pregnant
WLGP	621..	Patient currently pregnant
WLGP	62B..	Delivery booking place
WLGP	62G..	Antenatal ultrasound scan
WLGP	62N..	Antenatal examinations
WLGP	62N1.	A/N booking examination
WLGP	62R..	Postnatal visits
WLGP	62S..	Maternal P/N 6 week exam.
WLGP	63...	Birth details
WLGP	633..	Outcome of delivery
WLGP	635..	Maturity of baby
WLGP	64...	Child health care
WLGP	64B..	Child exam. - birth
WLGP	64D..	Child 6 week exam.
WLGP	64E..	Child 8-9 month examination
WLGP	64M1.	Child exam.: vision
WLGP	64M3.	Child exam.: squint
WLGP	64M5.	Child exam.: hearing
WLGP	65...	Infectious dis:prevent/control
WLGP	652..	Typhoid vaccination
WLGP	653..	Tuberculosis (BCG) vaccination
WLGP	657A.	1st haemophilus B vaccination
WLGP	657B.	2nd haemophilus B vaccination
WLGP	657C.	3rd haemophilus B vaccination
WLGP	657D.	Booster (single) haemophilus B vaccination
WLGP	657E.	First meningitis C vaccination
WLGP	657F.	Second meningitis C vaccination
WLGP	657G.	Third meningitis C vaccination
WLGP	657I.	Single meningitis C vaccination
WLGP	657J.	Meningitis ACW & Y vaccination
WLGP	657S.	Booster meningitis C vaccination
WLGP	65a0.	First diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination

WLGP	65A1.	Measles vaccination
WLGP	65a1.	Second diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
WLGP	65a2.	Third diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
WLGP	65B..	Rubella vaccination
WLGP	65E..	Influenza vaccination
WLGP	65E9.	PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given
WLGP	65ED.	Seasonal influenza vaccination
WLGP	65F1.	1st hepatitis B vaccination
WLGP	65F2.	2nd hepatitis B vaccination
WLGP	65F3.	3rd hepatitis B vaccination
WLGP	65F5.	Mumps vaccination
WLGP	65FA.	1st hepatitis A vaccination
WLGP	65FD.	Booster hepatitis A vaccin.
WLGP	65FF.	1st hepatitis A junior vaccination
WLGP	65FS.	First human papillomavirus vaccination
WLGP	65FT.	Second human papillomavirus vaccination
WLGP	65FV.	Third human papillomavirus vaccination
WLGP	65H..	Triple - DTP - vaccination
WLGP	65H1.	First triple vaccination - DTP
WLGP	65H2.	Second triple vaccination-DTP
WLGP	65H3.	Third triple vaccination - DTP
WLGP	65I1.	First DTP (triple)+polio vacc.
WLGP	65I2.	Second DTP (triple)+polio vacc
WLGP	65I3.	Third DTP (triple)+polio vacc.
WLGP	65I9.	Booster diphtheria, tetanus, acellular pertussis and inactivated polio vaccination
WLGP	65J4.	Boost double -DT- vaccination
WLGP	65K4.	Booster DT(double)+polio vacc.
WLGP	65K6.	First low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65K7.	Second low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65K8.	Third low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65K9.	First booster low dose diphtheria, tetanus and inactivated polio vaccination

WLGP	65KA.	Second booster low dose diphtheria, tetanus and inactivated polio vaccination
WLGP	65M1.	Measles/mumps/rubella vaccn.
WLGP	65M2.	Measles/rubella vaccination
WLGP	65MA.	Measles mumps and rubella booster vaccination
WLGP	65ML.	First hepatitis A and typhoid vaccination
WLGP	661M.	Clinical management plan agreed
WLGP	662..	Cardiac disease monitoring
WLGP	663..	Respiratory disease monitoring
WLGP	663H.	Inhaler technique - good
WLGP	663N.	Asthma disturbing sleep
WLGP	663n.	Asthma treatment compliance satisfactory
WLGP	663O.	Asthma not disturbing sleep
WLGP	663P.	Asthma limiting activities
WLGP	663q.	Asthma daytime symptoms
WLGP	663Q.	Asthma not limiting activities
WLGP	663s.	Asthma never causes daytime symptoms
WLGP	663U.	Asthma management plan given
WLGP	663v.	Asthma causes daytime symptoms most days
WLGP	66AS.	Diabetic annual review
WLGP	66CB.	Ideal weight
WLGP	66R..	Repeat prescription monitoring
WLGP	66R7.	Rep.presc.treatment stopped
WLGP	66RZ.	Rep.presc. monitoring NOS
WLGP	66YJ.	Asthma annual review
WLGP	66YK.	Asthma follow-up
WLGP	66Yp.	Asthma review using Royal College of Physicians three questions
WLGP	67...	Counselling/health education
WLGP	677B.	Advice about treatment given
WLGP	679..	Health education - subject
WLGP	67E..	Foreign travel advice
WLGP	67H..	Lifestyle counselling
WLGP	67I..	Advice
WLGP	68...	Screening

WLGP	681..	Screening - general
WLGP	685..	Cervical neoplasia screening
WLGP	685A.	Ca cervix screen-no result yet
WLGP	685B.	Ca cervix screen normal
WLGP	685F.	Cervical smear due
WLGP	685L.	Cervical smear refused
WLGP	685R.	Liquid based cervical cytology screening
WLGP	68A7.	Diabetic retinopathy screening
WLGP	68N..	Immunisation status screen
WLGP	68N5.	Full consent for immunisation
WLGP	68NV.	Influenza vacc consent given
WLGP	68NV0	Consent given for seasonal influenza vaccination
WLGP	68P..	Adult screening
WLGP	68R..	New patient screen
WLGP	68R2.	New patient screen done
WLGP	69D2.	Adult health exam.
WLGP	6A...	Patient reviewed
WLGP	6A1..	Patient reviewed at hospital
WLGP	6A6..	Mental health review
WLGP	745H.	Smoking cessation therapy
WLGP	761Fz	Diagnostic fiberoptic endoscopic examination of upper gastrointestinal tract NOS
WLGP	7701z	Other excision of appendix NOS
WLGP	7D1C2	Colposcopy NEC
WLGP	7E0Ez	Diagnostic endoscopic examination of uterus NOS
WLGP	7E1C.	Endoscopic bilateral occlusion of fallopian tubes
WLGP	7E2A2	Papanicolaou smear NEC
WLGP	7F19.	Normal delivery
WLGP	7G22.	Removal of repair material from skin
WLGP	7H29.	Diagnostic endoscopic examination of peritoneum
WLGP	7L17.	Blood withdrawal
WLGP	7L172	Blood withdrawal for testing
WLGP	7L18.	Intramuscular injection
WLGP	81H..	Dressing of wound

WLGP	85D..	Injection given
WLGP	892..	Informed consent for procedure
WLGP	8A44.	Pulse oximetry monitoring
WLGP	8B1..	Emergency treatment
WLGP	8B21.	Drug prescription
WLGP	8B2D.	Hospital prescription
WLGP	8B2J.	Prescription by supplementary prescriber
WLGP	8B3..	Drug therapy
WLGP	8B311	Medication given
WLGP	8B313	Medication commenced
WLGP	8B314	Medication review
WLGP	8B316	Medication changed
WLGP	8B3A1	Medication increased
WLGP	8B3A2	Medication decreased
WLGP	8B3H.	Medication requested
WLGP	8B3h.	Medication review without patient
WLGP	8B3j.	Asthma medication review
WLGP	8B3N.	Prescription not collected
WLGP	8B3R.	Drug therapy discontinued
WLGP	8B3S.	Medication review
WLGP	8B3V.	Medication review done
WLGP	8B3x.	Medication review with patient
WLGP	8B3y.	Medication review of medical notes
WLGP	8B4..	Previous treatment continue
WLGP	8BIC.	Medication review done by pharmacist
WLGP	8C1B.	Nursing care blood sample taken
WLGP	8C9..	Reassurance given
WLGP	8CA..	Patient given advice
WLGP	8CA4.	Patient advised re diet
WLGP	8CAK.	Patient given telephone advice out of hours
WLGP	8CAL.	Smoking cessation advice
WLGP	8CAw.	Advice about long acting reversible contraception
WLGP	8CAZ.	Patient given advice NOS

WLGP	8CB..	Had a chat to patient
WLGP	8CEG.	Long acting reversible contraception leaflet given
WLGP	8E...	Physiotherapy/remedial therapy
WLGP	8GA0.	Crisis intervention
WLGP	8H...	Referral for further care
WLGP	8H2..	Emergency hospital admission
WLGP	8H21.	Admit medical emergency unsp.
WLGP	8H3Z.	Other hospital admission NOS
WLGP	8H4..	Referral to physician
WLGP	8H41.	General medical referral
WLGP	8H42.	Referral to paediatrician
WLGP	8H43.	Dermatological referral
WLGP	8H44.	Cardiological referral
WLGP	8H46.	Neurological referral
WLGP	8H48.	Gastroenterological referral
WLGP	8H49.	Psychiatric referral
WLGP	8H4B.	Referred to rheumatologist
WLGP	8H5..	Referral to surgeon
WLGP	8H51.	General surgical referral
WLGP	8H53.	ENT referral
WLGP	8H54.	Orthopaedic referral
WLGP	8H58.	Gynaecological referral
WLGP	8H5B.	Referred to urologist
WLGP	8H7..	Other referral
WLGP	8H76.	Refer to dietician
WLGP	8H77.	Refer to physiotherapist
WLGP	8H78.	Refer to counsellor
WLGP	8H7B.	Refer to community psych.nurse
WLGP	8H7N.	Refer for colposcopy
WLGP	8H7O.	Refer to Radiology department
WLGP	8H7W.	Refer to TOP counselling
WLGP	8H7X.	Refer to podiatry
WLGP	8H8..	Follow-up arranged

WLGP	8H9..	Planned telephone contact
WLGP	8HA..	No follow-up arranged
WLGP	8Hc0.	Referral to community mental health team
WLGP	8Hc2.	Referral to primary care mental health team
WLGP	8Hd..	Admission to hospital
WLGP	8HE..	Discharged from hospital
WLGP	8HE1.	Discharged from outpatients
WLGP	8HE5.	Removed from waiting list
WLGP	8HHR.	Referral to child and adolescent psychiatry service
WLGP	8HHV.	Referral for termination of pregnancy
WLGP	8HJA.	Trauma self-referral
WLGP	8HJJ.	Self-referral to accident and emergency department
WLGP	8HQ1.	Refer for X-Ray
WLGP	8HQ2.	Refer for ultrasound investign
WLGP	8HTI.	Referral to breast clinic
WLGP	8I23.	Immunisation contraindicated
WLGP	8IAj.	Smoking cessation advice declined
WLGP	8IEM.	Smoking cessation drug therapy declined
WLGP	8M6..	Requests pregnancy termination
WLGP	9H91.	Depression medication review
WLGP	9H92.	Depression interim review
WLGP	A07y0	Viral gastroenteritis
WLGP	a23A.	GAVISCON ADVANCE peppermint sugar free suspension
WLGP	a23v.	GAVISCON ADVANCE sugar free suspension
WLGP	a23y.	GAVISCON peppermint liquid 500mL
WLGP	a24t.	PEPTAC liquid
WLGP	a24z.	PEPTAC peppermint liquid
WLGP	a471.	*BUSCOPAN 10mg tablets
WLGP	a47y.	HYOSCINE BUTYLBROMIDE 10mg tablets
WLGP	a4ex.	MEBEVERINE HYDROCHLORIDE 135mg tablets
WLGP	a4f3.	PEPPERMINT OIL BP 0.2mL e/c capsules
WLGP	A52..	Chickenpox - varicella
WLGP	A53..	Herpes zoster

WLGP	A54..	Herpes simplex
WLGP	A542.	Herpetic gingivostomatitis
WLGP	a62w.	RANITIDINE 150mg tablets
WLGP	a6b1.	OMEPRAZOLE 20mg e/c capsules
WLGP	a6b7.	OMEPRAZOLE 10mg e/c capsules
WLGP	a6c2.	LANSOPRAZOLE 30mg capsules
WLGP	a6c3.	LANSOPRAZOLE 15mg capsules
WLGP	A780.	Molluscum contagiosum
WLGP	A781.	Viral warts
WLGP	A7811	Verruca plantaris
WLGP	A7814	Plain wart
WLGP	A79z.	Viral infection NOS
WLGP	a83y.	LOPERAMIDE HYDROCHLORIDE 2mg capsules
WLGP	AB0..	Dermatophytosis including tinea or ringworm
WLGP	AB01.	Dermatophytosis of nail
WLGP	AB04.	Dermatophytosis of foot
WLGP	AB10.	Pityriasis versicolor
WLGP	AB2..	Candidiasis
WLGP	AB21.	Candidal vulvovaginitis
WLGP	AB211	Candidiasis of vagina
WLGP	ac71.	SENNA 7.5mg tablets
WLGP	AC74.	Enterobiasis - threadworm
WLGP	AD20.	Pediculus capitis - head lice
WLGP	AD30.	Scabies
WLGP	ae11.	LACTULOSE 3.35g/5mL solution
WLGP	ae46.	MOVICOL oral powder
WLGP	ae4c.	LAXIDO ORANGE oral powder sachets
WLGP	ah18.	ANUSOL cream
WLGP	aj15.	ANUSOL-HC ointment 30g
WLGP	aj1t.	XYLOPROCT ointment 20g
WLGP	aw11.	ORLISTAT 120mg capsules
WLGP	b211.	BENDROFLUMETHIAZIDE 2.5mg tablets
WLGP	B76..	Benign neoplasm of skin

WLGP	bd11.	PROPRANOLOL 10mg tablets
WLGP	bd12.	PROPRANOLOL 40mg tablets
WLGP	bi62.	RAMIPRIL 2.5mg capsules
WLGP	bi63.	RAMIPRIL 5mg capsules
WLGP	blb1.	AMLODIPINE 5mg tablets
WLGP	bu23.	ASPIRIN 75mg dispersible tablets
WLGP	bw34.	TRANEXAMIC ACID 500mg tablets
WLGP	bxd2.	SIMVASTATIN 20mg tablets
WLGP	bxd5.	SIMVASTATIN 40mg tablets
WLGP	bxi2.	ATORVASTATIN 20mg tablets
WLGP	C04..	Acquired hypothyroidism
WLGP	C10F.	Type 2 diabetes mellitus
WLGP	c13J.	SALBUTAMOL 100micrograms CFC-free inhaler
WLGP	c13T.	VENTOLIN 100micrograms Evohaler
WLGP	c13U.	SALBUTAMOL 100micrograms CFC-free breath-actuated aerosol inhaler
WLGP	c13v.	SALBUTAMOL 100microgram inhaler
WLGP	C380.	Obesity
WLGP	c61z.	BECLOMETASONE DIPROPIONATE 100micrograms inhaler
WLGP	c66d.	CLENIL MODULITE 100micrograms CFC-free inhaler
WLGP	c841.	CHLORPHENAMINE MALEATE 4mg tablets
WLGP	c843.	PIRITON 4mg tablets
WLGP	c84y.	CHLORPHENAMINE MALEATE 2mg/5mL syrup
WLGP	c8iw.	PROMETHAZINE 25mg tablets
WLGP	c8n1.	CETIRIZINE 10mg tablets
WLGP	c8o1.	LORATADINE 10mg tablets
WLGP	c8o3.	LORATADINE 5mg/5mL syrup
WLGP	c8p1.	FEXOFENADINE HYDROCHLORIDE 120mg tablets
WLGP	c8p3.	FEXOFENADINE HYDROCHLORIDE 180mg tablets
WLGP	c8rz.	DESLORATADINE 5mg tablets
WLGP	ch14.	SIMPLE linctus
WLGP	ch15.	SIMPLE paediatric linctus
WLGP	ci1d.	GALPSEUD 30mg/5mL linctus
WLGP	ci1w.	PSEUDOEPHEDRINE HCL 60mg tablets

WLGP	D00..	Iron deficiency anaemias
WLGP	d1a9.	TEMAZEPAM 10mg tablets
WLGP	d1d1.	ZOPICLONE 7.5mg tablets
WLGP	d1d3.	ZOPICLONE 3.75mg tablets
WLGP	d213.	DIAZEPAM 2mg tablets
WLGP	d214.	DIAZEPAM 5mg tablets
WLGP	d215.	DIAZEPAM 10mg tablets
WLGP	d711.	AMITRIPTYLINE 10mg tablets
WLGP	d712.	AMITRIPTYLINE 25mg tablets
WLGP	d75y.	DOSULEPIN HYDROCHLORIDE 25mg capsules
WLGP	d75z.	DOSULEPIN HYDROCHLORIDE 75mg tablets
WLGP	d79z.	LOFEPRAMINE 70mg tablets
WLGP	d7ex.	TRAZODONE HYDROCHLORIDE 50mg capsules
WLGP	da41.	FLUOXETINE 20mg capsules
WLGP	da51.	SERTRALINE 50mg tablets
WLGP	da52.	SERTRALINE 100mg tablets
WLGP	da61.	PAROXETINE 20mg tablets
WLGP	da71.	VENLAFAXINE 37.5mg tablets
WLGP	da72.	VENLAFAXINE 75mg tablets
WLGP	da77.	VENLAFAXINE 75mg m/r capsules
WLGP	da91.	CITALOPRAM 20mg tablets
WLGP	da93.	CITALOPRAM 10mg tablets
WLGP	da95.	CITALOPRAM 40mg tablets
WLGP	daB1.	MIRTAZAPINE 30mg tablets
WLGP	daB5.	MIRTAZAPINE 15mg oro-dispersible tablets
WLGP	daBy.	MIRTAZAPINE 45mg tablets
WLGP	daBz.	MIRTAZAPINE 15mg tablets
WLGP	daC1.	ESCITALOPRAM 10mg tablets
WLGP	dh1z.	BETAHISTINE HYDROCHLORIDE 8mg tablets
WLGP	dh4y.	CYCLIZINE 50mg tablets
WLGP	dh7x.	DOMPERIDONE 10mg tablets
WLGP	dhb1.	METOCLOPRAMIDE 10mg tablets
WLGP	dhed.	PROCHLORPERAZINE 3mg bucc.tabs

WLGP	dher.	PROCHLORPERAZINE 5mg tablets
WLGP	di21.	PARACETAMOL 500mg tablets
WLGP	di22.	PARACETAMOL 500mg soluble tabs
WLGP	di24.	PARACETAMOL 250mg/5mL mixture
WLGP	di2n.	PARACETAMOL 120mg/5mL oral suspension
WLGP	di2q.	PARACETAMOL 500mg capsules
WLGP	di2s.	PARACETAMOL 120mg/5mL sugar free suspension
WLGP	di2u.	PARACETAMOL 250mg/5mL sugar free suspension
WLGP	di2x.	CALPOL PAEDIATRIC 120mg/5mL suspension
WLGP	di2y.	CALPOL PAEDIATRIC 120mg/5mL sugar free suspension
WLGP	dia2.	CO-CODAMOL 8mg/500mg tablets
WLGP	dia6.	CO-DYDRAMOL tablets
WLGP	dia7.	*CO-PROXAMOL tablets
WLGP	dian.	PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg tablets
WLGP	diap.	CO-CODAMOL 8mg/500mg effervescent tablets
WLGP	diaq.	CO-CODAMOL 8mg/500mg capsules
WLGP	diaU.	PARACETAMOL+CODEINE PHOSPHATE 500mg/15mg tablets
WLGP	dibD.	PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg capsules
WLGP	dj81.	DIHYDROCODEINE 30mg tablets
WLGP	dji2.	TRAMADOL HCL 50mg capsules
WLGP	dl5A.	SUMATRIPTAN 50mg tablets
WLGP	dnj1.	GABAPENTIN 100mg capsules
WLGP	dnj2.	GABAPENTIN 300mg capsules
WLGP	dnpx.	PREGABALIN 75mg capsules
WLGP	du3A.	NICOTINE 21mg/24hours patches
WLGP	du3m.	NIQUITIN CQ 21mg/24hours patches
WLGP	du3s.	NIQUITIN CQ 21mg/24hours clear patches
WLGP	du8x.	VARENICLINE 500micrograms+1mg tablets
WLGP	du8z.	VARENICLINE 1mg tablets
WLGP	E112.	Single major depressive episode
WLGP	E113.	Recurrent major depressive episode
WLGP	e153.	PHENOXYMETHYLPENICILLIN 250mg tablets
WLGP	e155.	PHENOXYMETHYLPENICILLIN 125mg/5mL syrup

WLGP	e157.	PHENOXYMETHYLPENICILLIN 250mg/5mL syrup
WLGP	E200.	Anxiety states
WLGP	E2001	Panic disorder
WLGP	E2003	Anxiety with depression
WLGP	E204.	Neurotic depression reactive type
WLGP	E205.	Neurasthenia - nervous debility
WLGP	e221.	FLUCLOXACILLIN 250mg capsules
WLGP	e222.	FLUCLOXACILLIN 500mg capsules
WLGP	e22j.	FLUCLOXACILLIN 125mg/5mL syrup
WLGP	e22v.	FLUCLOXACILLIN 125mg/5mL oral suspension
WLGP	E23..	Alcohol dependence syndrome
WLGP	E24..	Drug dependence
WLGP	E250.	Nondependent alcohol abuse
WLGP	E2781	Tension headache
WLGP	E2B..	Depressive disorder NEC
WLGP	e311.	AMOXICILLIN 250mg capsules
WLGP	e312.	AMOXICILLIN 500mg capsules
WLGP	e316.	AMOXIL 500mg capsules
WLGP	e31h.	AUGMENTIN 375mg tablets
WLGP	e31t.	CO-AMOXICLAV 375mg tablets
WLGP	e31U.	CO-AMOXICLAV 625mg tablets
WLGP	e31z.	CO-AMOXICLAV 250/62 in 5mL suspension
WLGP	e3zk.	AMOXICILLIN 125mg/5mL sugar free suspension
WLGP	e3zm.	AMOXICILLIN 125mg/5mL syrup
WLGP	e3zn.	AMOXICILLIN 250mg/5mL syrup
WLGP	e3zu.	AMOXICILLIN 250mg/5mL sugar free suspension
WLGP	e691.	CEFALEXIN 250mg capsules
WLGP	e692.	CEFALEXIN 500mg capsules
WLGP	e693.	CEFALEXIN 250mg tablets
WLGP	e694.	CEFALEXIN 500mg tablets
WLGP	e758.	DOXYCYCLINE 100mg capsules
WLGP	e76z.	LYMECYCLINE 408mg capsules
WLGP	e782.	OXYTETRACYCLINE 250mg tablets

WLGP	e911.	ERYTHROMYCIN 250mg e/c tablets
WLGP	e91u.	ERYTHROMYCIN 125mg/5mL suspension
WLGP	e91v.	ERYTHROMYCIN 250mg/5mL suspension
WLGP	e921.	CLARITHROMYCIN 250mg tablets
WLGP	e927.	CLARITHROMYCIN 500mg tablets
WLGP	ecc1.	TRIMETHOPRIM 100mg tablets
WLGP	ecc2.	TRIMETHOPRIM 200mg tablets
WLGP	ecc4.	TRIMETHOPRIM 50mg/5mL sugar free suspension
WLGP	ef11.	METRONIDAZOLE 200mg tablets
WLGP	ef12.	METRONIDAZOLE 400mg tablets
WLGP	eg11.	NITROFURANTOIN 50mg tablets
WLGP	eg1w.	NITROFURANTOIN 100mg m/r capsules
WLGP	eg1y.	NITROFURANTOIN 50mg capsules
WLGP	eg6w.	CIPROFLOXACIN 500mg tablets
WLGP	eg6x.	CIPROFLOXACIN 250mg tablets
WLGP	eh71.	NYSTATIN 100,000units/mL suspension
WLGP	eh73.	NYSTAN 100,000units/mL suspension
WLGP	eh81.	FLUCONAZOLE 50mg capsules
WLGP	eh82.	FLUCONAZOLE 150mg capsules
WLGP	eha1.	TERBINAFINE 250mg tablets
WLGP	ei15.	ACICLOVIR 200mg tablets
WLGP	ei1o.	ACICLOVIR 800mg tablets
WLGP	EMISA	NA
WLGP	eq1y.	MEBENDAZOLE 100mg tablets
WLGP	eq1z.	MEBENDAZOLE 100mg/5mL suspension
WLGP	Eu32.	[X]Depressive episode
WLGP	Eu32z	[X]Depressive episode, unspecified
WLGP	F26..	Migraine
WLGP	f41y.	METFORMIN HYDROCHLORIDE 500mg tablets
WLGP	F4C0.	Acute conjunctivitis
WLGP	F4D0.	Blepharitis
WLGP	F4D10	Hordeolum externum (stye)
WLGP	F501.	Infective otitis externa

WLGP	F502.	Other otitis externa
WLGP	F502z	Otitis externa NOS
WLGP	F504.	Impacted cerumen (wax in ear)
WLGP	F51..	Nonsuppurative otitis media + eustachian tube disorders
WLGP	F52..	Suppurative and unspecified otitis media
WLGP	F52z.	Otitis media NOS
WLGP	F5611	Benign paroxysmal positional vertigo or nystagmus
WLGP	F587.	Otalgia
WLGP	F59..	Hearing loss
WLGP	f921.	LEVOTHYROXINE SODIUM 25micrograms tablets
WLGP	f922.	LEVOTHYROXINE SODIUM 50micrograms tablets
WLGP	fe62.	PREDNISOLONE 5mg tablets
WLGP	fe6i.	PREDNISOLONE 5mg e/c tablets
WLGP	fg51.	NORETHISTERONE 5mg tablets
WLGP	G2...	Hypertensive disease
WLGP	G20..	Essential hypertension
WLGP	g427.	CANESTEN-1 500mg vaginal tablets
WLGP	g429.	CLOTRIMAZOLE 1% cream
WLGP	g42A.	CANESTEN COMBI pessary+cream
WLGP	g42r.	CLOTRIMAZOLE 500mg+2% pessary+cream
WLGP	g42v.	CLOTRIMAZOLE 2% vaginal cream
WLGP	g42x.	CLOTRIMAZOLE 200mg vaginal tablets
WLGP	g42y.	CLOTRIMAZOLE 500mg vaginal tablets
WLGP	g42z.	CLOTRIMAZOLE 10% cream
WLGP	g811.	MARVELON tablets
WLGP	g832.	LOGYNON tablets
WLGP	g834.	MICROGYNON-30 tablets
WLGP	g837.	OVRANETTE tablets
WLGP	g838.	*SCHERING-PC4 tablets
WLGP	g83D.	MICROGYNON 30 ED tablets
WLGP	g83G.	RIGEVIDON tablets
WLGP	G84..	Haemorrhoids
WLGP	g891.	CILEST tablets

WLGP	g8A1.	YASMIN tablets
WLGP	ga27.	MIRENA 52mg intrauterine system
WLGP	ga29.	*LEVONELLE-2 tablets
WLGP	ga2B.	LEVONORGESTREL 1.5mg tablets
WLGP	ga2D.	LEVONELLE 1500micrograms tablets
WLGP	ga36.	DEPO-PROVERA 150mg/1mL prefilled syringe
WLGP	ga53.	NORIDAY tablets 84CP
WLGP	ga8B.	CERAZETTE 75micrograms tablets
WLGP	ga8C.	CERELLE 75micrograms tablets
WLGP	gdew.	DULOXETINE 60mg gastro-resistant capsules
WLGP	gdex.	DULOXETINE 30mg gastro-resistant capsules
WLGP	H00..	Acute nasopharyngitis
WLGP	H01..	Acute sinusitis
WLGP	H02..	Acute pharyngitis
WLGP	H03..	Acute tonsillitis
WLGP	H037.	Recurrent acute tonsillitis
WLGP	H040.	Acute laryngitis
WLGP	H05z.	Upper respiratory infection NOS
WLGP	H060.	Acute bronchitis
WLGP	H06z0	Chest infection NOS
WLGP	H06z1	Lower resp tract infection
WLGP	H17..	Allergic rhinitis
WLGP	H170.	Allergic rhinitis due to pollens
WLGP	H27z.	Influenza NOS
WLGP	H33..	Asthma
WLGP	H333.	Acute exacerbation of asthma
WLGP	hc21.	DEPO-PROVERA 450mg/3mL injection
WLGP	i11t.	FERROUS FUMARATE 210mg tablets
WLGP	i151.	FERROUS SULFATE 200mg tablets
WLGP	i16d.	PREGADAY tablets
WLGP	i332.	FOLIC ACID 5mg tablets
WLGP	i334.	FOLIC ACID 400micrograms tablets
WLGP	i81j.	DIORALYTE blackcurrant oral powder

WLGP	in45.	THIAMINE HYDROCHLORIDE 100mg tablets
WLGP	in72.	VITAMIN-B-CO STRONG tablets
WLGP	J0250	Dental abscess
WLGP	J082.	Oral aphthae
WLGP	J10y4	Oesophageal reflux without mention of oesophagitis
WLGP	j112.	ASPIRIN 300mg dispersible tablets
WLGP	J15..	Gastritis and duodenitis
WLGP	J16y4	Dyspepsia
WLGP	j22e.	DICLOFENAC 50mg e/c tablets
WLGP	j281.	IBUPROFEN 200mg tablets
WLGP	j282.	IBUPROFEN 400mg tablets
WLGP	j283.	IBUPROFEN 600mg tablets
WLGP	j28w.	IBUPROFEN 100mg/5mL syrup
WLGP	j28Y.	IBUPROFEN 100mg/5mL sugar free syrup
WLGP	j2b1.	MEFENAMIC ACID 250mg capsules
WLGP	j2bx.	MEFENAMIC ACID 500mg tablets
WLGP	j2c1.	NAPROXEN 250mg tablets
WLGP	j2c2.	NAPROXEN 500mg tablets
WLGP	j2cl.	NAPROXEN 500mg e/c tablets
WLGP	J43..	Other non-infective inflammatory gastroenteritis and colitis
WLGP	J520z	Constipation NOS
WLGP	J521.	Irritable colon - Irritable bowel syndrome
WLGP	J573.	Haemorrhage of rectum and anus
WLGP	ja18.	ALGESAL 10% cream
WLGP	ja1U.	IBUPROFEN 5% gel
WLGP	ja2S.	CAPSAICIN 0.025% cream
WLGP	ja2z.	IBUPROFEN 10% gel
WLGP	K15..	Cystitis
WLGP	K190.	Urinary tract infection, site not specified
WLGP	K190z	Urinary tract infection, site not specified NOS
WLGP	K310.	Inflammatory breast disease
WLGP	K3170	Mastodynia - pain in breast
WLGP	k321.	CHLORAMPHENICOL 0.5% eye drops

WLGP	k32w.	CHLORAMPHENICOL 1% eye ointment
WLGP	k3g1.	FUSIDIC ACID 1% eye drops
WLGP	k3g2.	*FUCITHALMIC 1% eye drops 5g
WLGP	K4219	Bacterial vaginitis
WLGP	K583.	Dysmenorrhoea
WLGP	K59..	Menstruation disorders
WLGP	K590.	Absence of menstruation
WLGP	K5920	Menorrhagia
WLGP	K594.	Irregular menstrual cycle
WLGP	K596.	Metrorrhagia
WLGP	k69y.	SODIUM CROMOGLICATE 2% eye drops
WLGP	L04..	Spontaneous abortion
WLGP	L13..	Excessive pregnancy vomiting
WLGP	L20..	Normal delivery in a completely normal case
WLGP	I322.	CLIOQUINOL+FLUMETASONE PIV 1%/0.02% ear drops
WLGP	I323.	LOCORTEN-VIOFORM ear drops 10mL
WLGP	I355.	GENTISONE HC ear drops 10mL
WLGP	I35z.	GENTAMICIN+HYDROCORTISONE ACETATE 0.3%/1% ear drops
WLGP	I415.	SOFRADEX EYE/EAR drops 10mL
WLGP	I41b.	OTOMIZE ear spray 5mL
WLGP	I713.	SODIUM BICARBONATE ear drops
WLGP	I715.	CERUMOL ear drops 11mL
WLGP	I71m.	OLIVE OIL ear drops 10mL
WLGP	I812.	BECONASE AQUEOUS 50microgram nasal spray
WLGP	I81z.	BECLOMETASONE 50micrograms aqueous nasal spray
WLGP	I886.	AVAMYS 27.5micrograms nasal spray
WLGP	I8Dz.	MOMETASONE FUROATE MONOHYDRATE 0.05% aqueous nasal spray
WLGP	Ia15.	NASEPTIN cream 15g
WLGP	Ib11.	DIFFLAM 0.15% oral rinse 300mL
WLGP	Ib12.	DIFFLAM 0.15% mouth and throat spray
WLGP	Ib1y.	BENZYDAMINE HYDROCHLORIDE 0.15% oral rinse
WLGP	Ib1z.	BENZYDAMINE HYDROCHLORIDE 0.15% mouth and throat spray
WLGP	Ic42.	DAKTARIN oral gel 80g

WLGP	M0...	Skin and subcutaneous tissue infections
WLGP	M01z.	Boil NOS
WLGP	M03z0	Cellulitis NOS
WLGP	M03z1	Abscess NOS
WLGP	M05..	Impetigo
WLGP	M07z.	Local infection skin/subcut tissue NOS
WLGP	M0z..	Skin and subcut tissue infection NOS
WLGP	M101.	Seborrhoeic dermatitis
WLGP	m111.	AQUEOUS cream
WLGP	M111.	Atopic dermatitis/eczema
WLGP	m115.	DIPROBASE cream 50g
WLGP	m11a.	DIPROBASE dispenser cream 500g
WLGP	M12..	Contact dermatitis and other eczemas
WLGP	m122.	EMULSIFYING ointment
WLGP	m12c.	DIPROBASE ointment 50g
WLGP	M12z0	Dermatitis NOS
WLGP	M12z1	Eczema NOS
WLGP	M161z	Psoriasis NOS
WLGP	m210.	DOUBLEBASE gel 500g
WLGP	m21R.	E45 cream 500g pump
WLGP	M21z1	Skin tag
WLGP	m22G.	HYDROMOL ointment 125g
WLGP	M230.	Ingrowing nail
WLGP	M2300	Ingrowing great toe nail
WLGP	m23o.	SUDOCREM cream 30g
WLGP	M244.	Folliculitis
WLGP	m25k.	OILATUM EMOLLIENT bath additive 500mL
WLGP	M2610	Acne vulgaris
WLGP	M262.	Sebaceous cyst - wen
WLGP	m272.	DERMOL 500 lotion
WLGP	M28..	Urticaria
WLGP	M2yz.	Other skin and subcutaneous tissue disease NOS
WLGP	m313.	CALAMINE lotion

WLGP	m412.	HYDROCORTISONE 1% cream 30g
WLGP	m414.	HYDROCORTISONE 1% cream 100g
WLGP	m419.	*HYDROCORTISONE 0.5% cream 50g
WLGP	m42D.	HYDROCORTISONE 1% ointment 50g
WLGP	m453.	CANESTEN-HC cream 30g
WLGP	m454.	DAKTACORT cream 30g
WLGP	m458.	FUCIDIN-H cream 30g
WLGP	m45A.	FUCIDIN-H cream 60g
WLGP	m45s.	TIMODINE cream 30g
WLGP	m45v.	DAKTACORT ointment 30g
WLGP	m45V.	HYDROCORTISONE ACETATE+FUSIDIC ACID 1%/2% cream
WLGP	m45Y.	HYDROCORTISONE+MICONAZOLE NITRATE 1%/2% cream
WLGP	m45Z.	HYDROCORTISONE+CLOTRIMAZOLE 1%/1% cream
WLGP	m483.	BETNOVATE 0.1% cream 100g
WLGP	m48o.	BETAMETHASONE 0.1% scalp application
WLGP	m48q.	BETAMETHASONE 0.1% cream
WLGP	m48r.	BETAMETHASONE 0.1% ointment
WLGP	m49d.	FUCIBET cream 30g
WLGP	m49v.	BETAMETHASONE+FUCIDIC ACID 0.1%/2% cream
WLGP	m4b1.	EUMOVATE 0.05% cream 30g
WLGP	m4b7.	EUMOVATE 0.05% cream 15g
WLGP	m4by.	CLOBETASONE 0.05% cream
WLGP	m673.	ZINERYT lotion 30mL
WLGP	m676.	ERYTHROMYCIN+ZINC ACETATE 40mg/12mg/mL topical solution
WLGP	m677.	ZINERYT lotion 90mL
WLGP	m68C.	DUAC ONCE DAILY 5%/1% gel 50g
WLGP	m816.	SALACTOL 16.7% paint 10mL
WLGP	m818.	SALATAC 12% gel 8g
WLGP	mb1v.	KETOCONAZOLE 20mg/mL shampoo
WLGP	mb1z.	CAPASAL shampoo 250mL
WLGP	mc5y.	MUPIROCIN 2% cream
WLGP	md21.	FUCIDIN 2% cream 15g
WLGP	md2v.	FUSIDIC ACID 2% cream

WLGP	me41.	CANESTEN 1% cream 20g
WLGP	me4w.	CLOTRIMAZOLE 1% cream
WLGP	me71.	MICONAZOLE 2% cream
WLGP	me78.	DAKTARIN 2% cream 30g
WLGP	mejz.	TERBINAFINE HYDROCHLORIDE 1% cream
WLGP	mf11.	ZOVIRAX 5% cream 2g
WLGP	mf1z.	ACICLOVIR 5% cream
WLGP	mg5x.	MALATHION 0.5% liquid
WLGP	mg77.	*FULL MARKS liquid 200mL
WLGP	mg7C.	*FULL MARKS 0.2% lotion 50mL
WLGP	mg81.	PERMETHRIN 1% scalp application
WLGP	mg82.	LYCLEAR 1% cream rinse 59mL
WLGP	mg83.	PERMETHRIN 5% cream 30g
WLGP	mg84.	LYCLEAR 5% cream 30g
WLGP	N094.	Pain in joint - arthralgia
WLGP	N094K	Arthralgia of hip
WLGP	N131.	Cervicalgia - pain in neck
WLGP	N142.	Pain in lumbar spine
WLGP	N143.	Sciatica
WLGP	N145.	Backache, unspecified
WLGP	N2132	Lateral epicondylitis of the elbow
WLGP	N2410	Myalgia unspecified
WLGP	N245.	Pain in limb
WLGP	N2450	Hand pain
WLGP	N2452	Pain in leg
WLGP	N2453	Pain in arm
WLGP	n45n.	REVAXIS suspension for injection 0.5mL prefilled syringe
WLGP	n4h2.	TYPHIM VI VACCINE 25microgram/0.5mL prefilled syringe
WLGP	p161.	MELOLIN 5x5cm dressing
WLGP	p1n1.	INADINE 5cmx5cm dressing
WLGP	p436.	VOLUMATIC spacer device
WLGP	p43F.	AEROCHAMBER spacer device
WLGP	p46E.	STANDARD RANGE EN13826 peak flow meter

WLGP	p5j8.	MICROPORE 2.5cmx5m tape
WLGP	R0043	[D]Vertigo NOS
WLGP	R021.	[D]Rash and other nonspecific skin eruption
WLGP	R021z	[D]Rash and other nonspecific skin eruption NOS
WLGP	R0222	[D]Lump, localized and superficial
WLGP	R040.	[D]Headache
WLGP	R062.	[D]Cough
WLGP	R065A	[D]Musculoskeletal chest pain
WLGP	R090.	[D]Abdominal pain
WLGP	R090B	[D]Groin pain
WLGP	S25..	Fracture of metacarpal bone
WLGP	S26..	Fracture of one or more phalanges of hand
WLGP	S3z..	Fracture of unspecified bones
WLGP	S550.	Ankle sprain
WLGP	S5704	Whiplash injury
WLGP	S646.	Head injury
WLGP	S8z..	Open wound of head, neck and trunk NOS
WLGP	SD...	Superficial injury
WLGP	SK170	Other knee injury
WLGP	SK172	Other ankle injury
WLGP	SL...	Poisoning
WLGP	SP255	Postoperative wound infection, unspecified
WLGP	T1...	Motor vehicle traffic accidents (MVTA)
WLGP	TC...	Accidental falls
WLGP	TE60.	Dog bite
WLGP	TK...	Suicide and selfinflicted injury
WLGP	U3...	[X]Assault
WLGP	ZV27.	[V]Outcome of delivery
WLGP	ZV40.	[V]Mental and behavioural problems
WLGP	ZV583	[V]Attention to surgical dressings or sutures
WLGP	ZV68.	[V]Administrative encounters
WLGP	ZV680	[V]Issue of medical certificate
WLGP	ZV681	[V]Issue of repeat prescription

WLGP	ZV762	[V]Screening for malignant neoplasm of cervix
EDDS	Admission Count	Count of distinct Emergency Department admissions for the time period
EDDS + PEDW	Combined ED Admissions	Count of distinct Emergency Department and Emergency Hospital admissions for the time period
POLICE	PPN Count	Count of all the PPN submissions following the index submission
POLICE	Multiple Police Visits (PPNs)	Binary of yes/no for if they have multiple police visits to the victim after the index PPN submission
POLICE	SYSTEM_ID_PE	Unique identifier - for each PPN call
POLICE	EXTRACT_DT	Date of incident/ PPN call
POLICE	REFERRED_TO_MARAC_1	Referral to MARAC (if 14 or more YES on the DASH risk asesment)
POLICE	INJURY_1	Has the current incident resulted in an injury?
POLICE	INJURYDETAILS_1	Injury details (name of abusers(s))
POLICE	FIRSTINJURY_1	Please state whether this is the first injury?
POLICE	FRIGHTENED_2	Are you very frightened?
POLICE	FURTHERVIOLENCE_3	Is it furthur injury or violence? (name of abusers(s)) What are you afraid of? History of violence?
POLICE	ATTEMPTTOKILL_3	Has (...) ever attempted to kill you or someone else and you believed them?
POLICE	ATTEMPTTOKILLDETAILS_3	Attempt to kill details
POLICE	FURTHERVIOLENCEINJURY_3	Is it furthur injury or violence? (name of abusers(s))
POLICE	FURTHERVIOLENCEDETAILS_3	Further violence details
POLICE	AFRAIDOF_3	What are you afraid of?
POLICE	ISOLATED_4	Do you feel isolated from family/friends?
POLICE	FORCEDISOLATION_4	Does (name of abuser(s)) try to stop you from seeing friends/family/Dr or others?
POLICE	DEPRESSED_SUICIDAL_5	Are you feeling depressed or having suicidal thoughts
POLICE	SEPERATED_6	Have you separated or tried to separate from (name of abuser(s)..) within the past year?
POLICE	CHILDCONFLICT_7	Is there conflict over child contact?
POLICE	CHILDCONFLICTDETAILS_7	Child conflict details
POLICE	HARRASSED_8	Does (name of abuser(s)) constantly text, call, contact, follow, stalk or harass you?
POLICE	HARRASSEDHISTORY_8	Previous record of harassment?
POLICE	PROPERTYDAMAGE_8	Does (name of abuser(s)) damage furniture?
POLICE	UNANNOUNCEDVISIT_8	Uninvited visits to victim's home or workplace?
POLICE	FOLLOWINGYOU_8	Does (name of abuser(s)) constantly follow you?
POLICE	THIRDPARTYHARRASSMENT_8	Is there any other person that has threatened you or that you are afraid of?

POLICE	ENGAGEDOTHERS_8	Do you know if (...) has hurt anyone else? (inside or outside of the family)
POLICE	PREGNANT_9	Is anyone in the household pregnant? (may be the victim)
POLICE	PASTPREGNANT_9	(If no) Has anyone in the household had a child in last 18 months?
POLICE	OTHERCHILDREN_10	Are there any children or step-children either in the household or elsewhere?
POLICE	OTHERDEPENDANTS_10	Are there any other dependants either in the household or elsewhere?
POLICE	DEPENDANTSHARMED_11	Has (...) ever hurt the children/dependants?
POLICE	DEPENDANTSHARMEDDETAILS_11	Dependant harm details
POLICE	DEPENDANTSTHREATENED_12	Has (...) ever threatened to hurt or kill the children/dependants?
POLICE	ABUSEFREQUENCY_13	Is the abuse happening more often?
POLICE	ABUSEWORSE_14	Is the abuse getting worse?
POLICE	CONTROLLING_15	Does (...) try to control everything you do and/or are they excessively jealous?
POLICE	CONTROLLINGDETAILS_15	Control details
POLICE	WEAPONSUSED_16	Has (...) ever used weapons or objects to hurt you?
POLICE	THREATSTOKILL_17	Has (...) ever threatened to kill you or someone else and you believed them?
POLICE	ATTEMPTEDSTRANGLE_18	Has (...) ever attempted to strangle/choke/suffocate/drown you?
POLICE	ATTEMPTEDSTRANGLEDETAILS_18	Attempt to strangle/choke/suffocate/drown details
		Does (...) do or say things of a sexual nature that makes you feel bad or do physically to you or someone else.
POLICE	SEXUALHARM_19	Harm details
POLICE	SEXUALHARMDETAILS_19	Harm details
POLICE	THREATSFROMOTHERS_20	Is there any other person that has threatened you or that you are afraid of?
POLICE	THREATSFROMOTHERSDETAILS_20	Threat details
POLICE	HARMOTHERS_21	Do you know if (...) has hurt anyone else? (inside or outside of the family)
POLICE	HARMOTHERSDETAILS_21	harm other details
POLICE	ANIMALHARM_22	Has (...) ever mistreated an animal or family pet?
POLICE	FINANCIALISSUES_23	Are there any financial issues?
		Has (...) had problems in the past year with drugs (prescription or other), alcohol or mental health leading to problems in leading a normal life
POLICE	SUBSTANCEABUSE_24	Substance abuse details
POLICE	SUBSTANCEABUSEDDETAILS_24	Substance abuse details
POLICE	SUICIDE_25	Has (...) ever threatened or attempted suicide?
		Has (...) ever breached bail/an injunction and/or any agreement for when they can see you and/or the children?
POLICE	INJUNCTIONBREACHED_26	Type of injunction breach
POLICE	INJUNCTIONBREACHEDTYPE_26	Type of injunction breach
POLICE	INJUNCTIONBREACHEDDETAILS_26	Injunction breach details

POLICE	CRIMINALHISTORY_27	Do you know if (...) has ever been in trouble with the police or has a criminal history?
POLICE	OFFICERS_OBSERVATIONS	Free text for officers observations
POLICE	DV_RISK_ASSESSMENT_LEVEL	High, Medium, Standard or NULL category
POLICE	RISK_ASSESMENT_DETAILS	Free text on the risk assessment details
POLICE	REFERRED_TO_MARAC	Referral to MARAC (if 14 or more YES on the DASH risk asesment)
POLICE	SAFETYMEASURES	Free text for officers observations
PEDW+EDDS	Outcome	Whether the individual experienced the outcome